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Aegrotos sanate, leprosos purgate: 
Dono accepistis, dono date. 
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Abstract 
 
Options for treating Burkholderia cepacia complex (Bcc) and other multi-resistant Gram 
negative bacilli isolated from people with cystic fibrosis (CF) are limited. We assessed the 
in-vitro activity of tigecycline and eleven other antimicrobial agents against a collection of 
these organisms.  The collection comprised 128 isolates of CF-associated Gram negative 
bacilli (31 Burkholderia multivorans, 16 Burkholderia cenocepacia, 4 other members of the 
Burkholderia species, 47 Stenotrophomonas maltophilia, 20 Achromobacter xylosoxidans, 
and 10 other miscellaneous CF-associated Gram negative bacilli. Minimum inhibitory 
concentrations (MIC) of tigecycline and eleven other antimicrobials for each isolate were 
determined using E-test. Synergy between tigecycline and each of eight other antimicrobials 
was determined using an E-test overlay method.  The epidemiological spread of organisms 
indicated that the Leeds Teaching Hospitals NHS Trust (LTHT) infection control policies 
have had a measure of success and our work followed the pattern of many other CF units.  
Tigecycline showed poor in-vitro activity versus all members of the Bcc, with only 13% and 
3% of B. cenocepacia and B. multivorans susceptible, respectively. Conversely minocycline 
showed good activity against these species, with 94% and 91% of isolates being susceptible. 
Tigecycline showed good activity against A. xyloxidans and S. maltophilia with 85% and 
77% of isolates being susceptible, respectively. Tigecycline in combination with other 
agents mostly resulted in indifference.  Although the in-vitro activity of tigecycline is 
variable, we reviewed the potential and future clinical impact of this study and the likely 
issues for further study.  Whilst the relationship between synergy/MIC testing and clinical 
success remains unclear, there are a number of promising developments and ideas that may 
clarify this situation – further studies are warranted.    
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Chapter 1 
1.0  Introduction 
 
Cystic fibrosis (CF) is an autosomal recessive disease (Belkin et al, 2006), and is one of the 
most common of all lethal genetically inherited diseases with associated morbidity.  It 
affects around 1/2000–1/3000 live births in the Western world, though estimates vary 
(Walters & Mehta, 2007), and is particularly prevalent in the Caucasian population 
(O’Sullivan & Freedman, 2009).    
The disease occurs in approximately 1/3000 white Americans, 1/400-10,000 Latin 
Americans and 1/15,000-20,000 African Americans.  It is very unusual to encounter CF in 
either Africa or Asia – for example 1/350,000 in Japan are afflicted (O’Sullivan & 
Freedman, 2009).   The most common occurrence of CF appears to be in populations of 
northern European descent (1/3000 live births). 
CF is characterised by a significant reduction in lung function – obstructive lung disease and 
chronic endobronchial infection and colonisation, along with other non pulmonary 
symptoms.  It is a disease that has seen major developments over the last 10-20 years both in 
terms of therapy/research and life expectancy.  In 2006, the median life expectancy in the 
USA was 33 years (Belkin et al, 2006), whereas the predicted life expectancy in the UK has 
risen from 31 years, to 50 years (Dodge et al, 2007).  This rise is primarily caused by the 
development and use of intensive antimicrobial therapy over the past 20 years along with 
updated and thorough infection control practices (Millar et al, 2009, Saiman & Siegel, 
2004).   
It is estimated that approximately 90% of all CF patients die as a result of end stage 
obstructive lung disease – making CF one of the top three indications for lung 
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transplantation (Belkin et al, 2006).  Even with current transplantation criteria, however, 
approximately 30% of patients will die before lung transplantation is offered.   Lung 
transplantation is not always an option, and this is particularly the case with patients who 
have been colonised by resistant bacteria such as Burkholderia cepacia complex (Bcc) 
organisms (Liou et al, 2005).  CF patients are susceptible to infection and colonization by a 
number of organisms, the most common being Pseudomonas aeruginosa – which affects 
over 90% of patients at some point during their lives (Lyczak et al, 2002).  Other frequently 
isolated organisms include Stenotrophomonas maltophilia and Achromobacter xylosoxidans.  
Bcc are a major cause of mortality and morbidity via sepsis, rapid deterioration and 
necrotizing pneumonia – often leading to death by the so called “Cepacia syndrome” (Isles 
et al, 1984; Aaron et al, 2000).  
1.1 Pathophysiology of cystic fibrosis and the cystic fibrosis 
transmembrane regulator gene 
 
Chronic bacterial infection of the airways is generally associated with blockage/obstruction.  
In many patients, this can be caused by tumours or foreign bodies.  In CF patients, however, 
it is more usually the result of mucus plugs, adhesion and plaques.  Similar obstructions also 
contribute to other conditions such as chronic obstructive pulmonary disease (COPD).  
Observations from many studies, including murine models, suggest that mucus clearance is 
the dominant form of innate defence.  This is severely compromised in CF patients.  CF, 
when compared with conditions such as primary ciliary dyskinesia (PCD) results in more 
severe airway destruction and infection – indicating that mucus clearance may be more 
important than the action of the cilia (Randell & Boucher, 2006).   
In normal patients, the carefully co-ordinated system of epithelial water and ion transport, 
mucin secretion, and cilia action are responsible for airway clearance and maintenance.  
Water transport across the apical plasma membrane of airway epithelial cells is regulated by 
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chloride ion export through cystic fibrosis transmembrane regulator (CFTR) gene regulation 
– thus maintaining the airway surface liquid (ASL) status (Randell & Boucher, 2006).   
The close cell environment in the lungs has increasingly been recognised as one of the most 
important factors in airway clearance.  Two separate layers exist that together comprise the 
ASL.  The first is an overlying transported mucus layer.  Underneath this is a distinct close 
cell layer – the pericilliary layer (PCL).  Previous studies have found that the addition of 
liquid to this layer (usually brought about by medical conditions such as 
pseudohypoaldosteronism) can enhance the activity of cilia and thus the mucus clearance of 
the ASL (Randell & Boucher, 2006).  The mucus layer of the ASL consists of high-
molecular weight mucin dimers and trimers that interact with globular proteins.  It is thought 
that non-mucin proteins act as a cross link whilst also providing defence against pathogens 
and foreign bodies.  The near cell surface liquid of the PCL acts to preserve the architecture 
and movement of the cilia, whilst also allowing the movement of water and preventing 
foreign bodies such as microscopic particles from actually touching the cellular surfaces 
(Mall et al, 2004). 
CF is brought about by a mutation in the CFTR protein producing gene.  There are 
approximately 1500 CFTR mutations that have been identified, though the function of only 
a small number of these has been ascertained (O’Sullivan & Freedman, 2009) and CFTR is 
often classified as either absent, deficient or dysfunctional (David et al, 2009).   The 
mutations in the CFTR gene vary with geography – Phe508del, for example predominates in 
Northwest Europe, whereas Trp1282X dominates in Israel (O’Sullivan and Freedman, 
2009).  The CFTR gene has many regulatory roles including the inhibition of sodium 
transport, regulation of the outwardly rectifying chloride channel, regulation of ATP 
channels, regulation of intracellular vesicle transport, acidification of intracellular organelles 
and inhibition of endogenous calcium activated chloride channels, although its main role is 
to act as a chloride channel (O’Sullivan and Freedman, 2009).  It is these two main functions 
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of CFTR that contribute to the pathophysiology of the disease.  It is thought that the 
development of airway-surface liquid depletion is responsible for the collapse of cilliary 
function and the resultant loss of mucus clearance (Ratjen, 2009).  The actual process is 
thought to come about by the forcible interaction between cell surface mucins and the 
viscous, adhesive mucus layer.  The result of this PCL collapse, is the build up of mucus 
adhesion, the formation of plaques, and plugs of concentrated mucus (Mall et al, 2004). 
It would appear that the severity of the disease in many patients may be linked to the relative 
functionality of the CFTR protein and the effect of the mutations upon it.  Five classes have 
been identified, each of which may alter the presentation; for example, class I – three 
mutations in the CFTR gene are linked with pancreatic insufficiency.  It can be difficult to 
predict the pulmonary implications of each class due to the wide range of differing genetic 
backgrounds of patients.  Clinical presentation at CF clinics can and does vary greatly 
(David et al, 2009). 
1.1.1  Pathological mechanisms 
 
The airway epithelia regulate the properties of a thin layer of liquid – known as the ASL and 
it is this layer that is affected along with the cilia in CF patients.  The mechanisms that lead 
to the symptoms and pathology of CF are unclear and there has been much argument in the 
literature (Tarran et al, 2001). The two main hypotheses, however, relate to the salt 
concentration in the airway surface, or the volume of the ASL.    A number of different 
causative mechanisms have been suggested and these are summarised below. 
1.1.2 The “high salt hypothesis” 
 
 It is suggested that the deregulation of the chloride and sodium transport systems may lead 
to increased concentrations of these chemicals in the PCL (in a normal patient, the NaCl 
concentration is low at < 50 mM).  The high salt concentration and lack of regulation in CF 
patients may cause a reduction in the function of molecules that are naturally produced to 
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regulate or clear colonising bacteria – such as β-defensin 1.  This means that bacteria are 
able to colonise the lungs in the manner presented by many CF patients, as defensins have 
been demonstrated to operate inefficiently in salt concentrations > 100 mM (Goldman et al, 
1997).  
CFTR gene defect 
 
Defective ion transport 
 
Airway surface liquid depletion 
 
Defective mucociliary clearance 
 
Mucus obstruction 
 
        Inflammation 
Infection 
 Fig 1.1: Pathophysiology in CF lung disease (adapted from Ratjen, 2009) 
   
1.1.3  The “low volume hypothesis” 
 
 This postulates that the CFTR gene is unable to continue regulating the epithelial salt 
channels.  This results in excessive absorption of sodium and water - leading to dehydration 
of the lungs and associated airways – low ASL.  The water that should be present in the 
lungs acts both as a medium to enhance absorption of oxygen, but also as a lubricant.  This 
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loss of lubrication may result in the build up of mucus plaques on the epithelium resulting in 
small “hypoxic niches” that are able to provide a growth environment for colonising bacteria 
– particularly Pseudomonas aeruginosa   (O’Sullivan & Freedman, 2009).  It is also 
suggested that this lack of lubrication will allow the mucus to form a compressing layer on 
the cilia of the lungs (the PCL) – thus reducing their function.  This results in the patient 
being unable to clear mucus from the airway.  The loss of the chloride efflux system 
prevents the lungs from replacing and regulating this loss of water (Tarran et al, 2001).  
Whilst the host inflammatory response has also been suggested as a single reason for CF 
pathology, it has also been suggested that the low volume ASL may result in higher 
concentrations of inflammatory mediators.  This would induce an inflammatory process with 
“self reinforcing pathologic sequelae” (Belkin et al, 2006).  A study in 1998 by Hirotoshi et 
al, found that this reduction in ASL was the dominant factor in CF patients, and in this case, 
they were unable to find any evidence that the ASL was hypotonic or that salt concentrations 
differed significantly from those of normal patients.  It has been suggested, however, that the 
ion transport theory may be more consistent with the pathogenesis of “other organ-level 
phenotypes of CF” (Hirotoshi et al, 1998).  It remains unclear which of the effects presented 
here are dominant in the CF lung and as stated by Hirotoshi et al (1998), this may differ 
between patients and depend upon the level of CFTR inhibition.   
1.1.4 “The CFTR binding hypothesis” 
 
This suggests that where functional CFTR is present, any colonising bacteria would 
preferentially bind to it.  The result is a self limiting, short lived host immune response – 
clearing any colonisation.  In CF patients, this response is not present, and it is thought that 
an increase in asialo-GM1 in apical cell membranes allows increased binding of pathogens 
to the airway epithelium; these two factors together result in the rapid colonisation of the 
airways (O’Sullivan & Freedman, 2009). 
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1.1.5 Host inflammation 
 
It appears that the host inflammatory response is present regardless of the infective state of 
the patient (O’Sullivan & Freedman, 2009).  Mediators of inflammation such as TNFα, 
interleukin 6 and 8 and arachidonic acid metabolites have been found in CF patients.  
Additionally, a lack of anti-inflammatory substances such as decohexaenoic acid, lipoxin 
and interleukin 10 indicate that in these patients, the immune response is free to run 
unabated.   These pro-inflammatory markers have been found in children as young as four 
when bronchial alveolar lavages were tested (O’Sullivan & Freedman, 2009). 
The low volume hypothesis and high salt hypothesis are mutually exclusive in their 
properties in-vivo.  The suggestions implicating that in a high salt concentration environment 
model, the ASL should remain normal, whereas, in a low ASL environment, the NaCl 
concentration remains normal.  This makes it difficult to suggest a therapeutic strategy to 
treat the initiating events of CF (Tarran et al, 2001).   
1.2 Presenting symptoms of cystic fibrosis 
 
The clinical picture and presenting symptoms of CF vary greatly between patients whilst 
showing some overlap (O’Sullivan & Freedman, 2009).   
The earliest symptoms in neonates include any of a combination of meconium ileus 
(approximately 15%), protracted jaundice, abdominal or scrotal calcifications and intestinal 
atresia.  Meconium ileus is an obstructive bowel condition that affects both the small and 
large bowel.  Clubbing of fingers and toes is often seen along with vitamin D deficiency.  
The resulting osteoporosis generally begins in childhood but is not often detected until later 
in life.  Given the poor outlook and risk of malnutrition of CF patients, it is not surprising 
that, even in well nourished patients, bone formation is unable to keep up with bone 
resorption (O’Sullivan & Freedman, 2009). 
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Pancreatic insufficiency is seen in the infant/neonate and presents as abdominal bloating, 
failure to thrive and steatorrhoea.  Malnutrition resulting from these conditions was a major 
cause of death in the early years of CF medicine when the condition was new to medical 
science (Anderson, 1938).  Since 1938, pancreatic enzyme replacement therapy has been 
introduced, virtually ending these deaths.  This does remain an issue, however, and must be 
monitored with calorific intake and fat soluble vitamins being of uttermost importance 
(O’Sullivan & Freedman, 2009).     
Table 1.1: Signs and symptoms of cystic fibrosis (adapted from O’Sullivan & 
Freedman 2009) 
 
Pancreatic dysfunction is caused by the obstruction of the intrapancreatic ducts and the 
resulting autolysis of the pancreas – replacing pancreatic tissue with fat.  The resulting 
CFRD – CF-related diabetes mellitus, is a unique disease resulting from this damage.  It is 
generally related to glucagon deficiency, liver dysfunction, raised energy expenditure and 
poor glucose metabolism.  Decreased intestinal transit time and increased pulmonary 
workload (difficulty breathing) are also common.  CFRD is reported in approximately 30% 
General Family History of cystic fibrosis 
(any age) Salty tasting skin 
Clubbing of fingers and toes Hypochloraemic matabolic alkalosis 
Neonatal Meconium ileus Intestinal atresia 
Protracted jaundice 
Abdominal/scrotal calcifications 
Infancy S.aureus  pneumonia Chronic diarrhoea 
Cholestasis Failure to thrive 
Abdominal distention Infiltrates on chest radiographs 
Anasarca or hypoproteinaemia Idiopathic intracranial hyportension (Vit A deficiency) 
Steatorrhoea Haemolytic anaemia (Vit E deficiency) 
Childhood Rectal prolapse Chronic pansinusitis/nasal polyposis 
Liver disease distal intestinal obstruction syndrome 
idiopathic recurrent or chronic pancreatitis 
Adolescence Bronchiectasis Azoospermia (abscence of vas deferens) 
Adulthood Haemoptysis Idiopathic recurrent pancreatitis 
Delayed puberty Allergic bronchopulmonary aspergillosis 
Portal hypertension Chronic pansinusitis or nasal polyposis 
Productive cough 
Isolation of airway  Pseudomonas aeruginosa 
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of patients over the age of twenty five (O’Sullivan & Freedman, 2009).  Of the people who 
suffer with CFRD, females appear to have a higher mortality (O’Riordan et al, 2008).  
Because of the increased risk to patients with CFRD, regular screening is recommended (by 
way of an annual glucose tolerance test) to those patients over the age of ten years.  
Blockages of various types appear to affect CF patients throughout their lives.  In children, 
the obstruction of the intrahepatic bile ducts results in focal biliary cirrhosis.  This presents 
by the age of fifteen years and is only seen in approximately 5% of individuals (O’Sullivan 
and Freedman, 2009).   
In adults, men are almost always infertile.  This is the result of congenital bilateral absence 
of the vas deferens.  This is also the case for men who have only minor mutations of the 
CFTR gene and are otherwise asymptomatic.  The vas deferens appears to be very sensitive 
to changes in the CFTR gene.   
The most common symptoms of CF, however, relate to the pulmonary system.   
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Chapter 2 
2.0  Microbiology of cystic fibrosis 
 
Prior to antibiotic therapy and modern medicine, it was common for CF patients to die in 
infancy – most commonly from Staphylococcal infection (Govan & Deretic, 1996).  CF 
patients in the modern era, however, remain susceptible to infection and colonization by a 
number of organisms, the most common being Pseudomonas aeruginosa – originally called 
Bacillus pyocyaneus (Govan & Deretic, 1996) – which affects over 90% of patients at some 
point during their lives and is responsible for the vast proportion of mortality and morbidity 
in CF patients (Lyczak et al, 2002). Other frequently isolated organisms include 
Stenotrophomonas maltophilia and Burkholderia cepacia complex (Bcc) – the latter of 
which can lead to death by “Cepacia syndrome” (Isles et al, 1984; Aaron et al, 2000). Bcc 
has been responsible for many outbreaks in CF units around the world (Govan et al, 1993; 
Speert et al, 2002) and has been noted to increase the risk of death within one year of lung 
transplant by up to six times (Alexander et al, 2008).  It is notable, however, that the actual 
strain causing this complex has yet to be identified with any rigor although Burkholderia 
cenocepacia appears to be predominant.  To date, studies that have been carried out have 
only had very small numbers (LiPuma, 2005).  Whilst colonisation by pathogens such as 
Pseudomonas aeruginosa and Bcc often represent a negative development in the clinical 
progress of a patient, it has also been found that the antifungal properties of these organisms 
may, in fact, inhibit further colonisation by Candida and other fungal species (Govan & 
Deretic, 1996). 
Other organisms that have been found in the respiratory tract of CF patients include 
Haemophilus influenzae and Staphylococcus aureus (Geller, 2009) though, whilst often 
found, it is thought that both S. aureus and H. influenzae are not necessarily pathogens in CF 
patients (Lyczak et al, 2002). 
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Bacterial infection of the CF lung is almost entirely limited to the intraluminal mucus 
(Worlitzsch et al, 2002).  Mucinases produced by the bacteria allow them to set up small 
protected niche environments in the lung.  It has been found that they set up a complex 
micro-environment where oxygen diffusion is slow – creating anaerobic plaque formation.  
In addition, the easy biofilm formation may be enhanced by quorum factors and the lack of 
free motility (Belkin et al, 2006).  In the low ASL environment, the lack of water and 
considerably enhanced mesh structure of static mucus may result in a selective pressure that 
allows environmental organisms to thrive.  This may explain why soil organisms that are 
resistant to drought such as Burkholderia cepacia are able to predominate (Rogers et al, 
2004; Rogers et al, 2005).   
2.1  Burkholderia cepacia complex 
 
Burkholderia species have been the cause of much stigma within the CF community.  
Patients live in fear of contracting these organisms, and often become social pariahs within 
their own community once colonised.  Segregation and isolation of patients with these 
bacteria further enhance this problem which continues to blight the CF community and 
individual patients (Govan & Deretic, 1996).  It was noted in 1995 in the USA that the 
median survival for patients without Bcc species colonisation was thirty years.  For those 
patients that were, unfortunately, colonised with these organisms, the median survival rate 
dropped to just twenty one years (Aaron et al, 2000)  Whilst there is still disagreement about 
the validity of such a strategy, colonised patients are often cohorted and separated from 
other CF patients.  This can result in some disruption in their clinical management, but also 
further stigmatization (Govan & Deretic, 1996).   
The Burkholderia species were first described as phytopathogens that cause soft rot of onion 
bulbs by Burkholder (Burkholder, 1950); the Burkholderia cepacia complex represents a 
group of very similar species that are often isolated from CF patients.  The first described 
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cases where Burkholderia cepacia was isolated were in the late 1970s.  It is relatively 
unusual to isolate these otherwise benign organisms from healthy individuals (LiPuma, 
2005).  Originally described as “genomovars”, the specific differences found between each 
“genomovar” in further analysis prompted a new naming system whereby each 
“genomovar” was given a species specific name.  There are currently few known species, 
such as B. pseudomallei (causing the potentially fatal melioidosis) although it is thought 
likely that others will emerge (Inglis et al, 2004).  The number of members of the Bcc is 
constantly rising as novel species are identified – usually via RecA PCR; with B. ubonensis 
being one of the most recently proposed (LiPuma, 2005, Vanlaere et al, 2008).  In addition 
to these, there are a number of novel species that belong to a complex within the Bcc called 
the K taxon group.  These include B. contaminans sp nov and B .lata sp nov (Vanlaere et al, 
2009).  Examples of the Bcc group are given below: 
B. cepacia, B. multivorans, B. cenocepacia, B. stabilis, B. vienamiensis, B. dolosa, B. 
ambifaria, B. anthina, B. pyrrocinia, B. pseudomallei, B. ubonensis sp nov, B. latens sp nov, 
B. diffusa sp nov, B. arboris sp nov, B. seminalis sp nov, B .metallica sp nov. 
The identification of the Bcc is complicated further by the relative biochemical unreactivity.  
It is not often isolated in a routine laboratory, and is often misidentified.  Examples of this 
occurring can be found in most historical collections of Bcc isolates.  On further 
examination, it has been found that they can, with hindsight, be differentiated into the 
various species (LiPuma et al, 1990).  The possession of β-lactamases has recently been a 
method by which investigators have been able to differentiate species of the Bcc.  They 
demonstrated that whilst similar to each other, each chromosomally encoded β-lactamase 
differed in some way – and that they were species specific (PenA  [B. Multivorans] to PenL 
[B. thailandensis]).  From this, they were able to produce dendrograms and change the 
idenfification of a number of isolates from their collection (Poirel et al, 2009). 
12 
 
Isolation of Bcc species still remains tricky in the routine laboratory.  It has often been 
mistakenly identified as Pandorea, Ralstonia or Achromobacter species.  Another 
exacerbating problem is the relative rarity of isolation.  The result is that most commercially 
available identification kits such as the API system for biochemical analysis are inadequate 
(LiPuma, 2005).  The close genetic relatedness of the individual species also confound the 
issue further and make simple culture/biochemical techniques practically redundant.   
2.1.1 Burkholderia cepacia complex in cystic fibrosis 
 
A number of strains have been identified over time, as being particularly prevalent in CF 
and immunocompromised populations, and studies have found that the most frequently 
reported sites of isolation of Bcc has been the lower respiratory tract (approximately 31% of 
isolates), although other rare complications such as septicaemia (first reported in a 17 year 
old in 1980) do arise (Govan & Deretic, 1996).  The epidemic (ET12) strain is dominant in 
Eastern Canada and the UK.  This strain is unique to B. cenocepacia (Baldwin et al, 2008).  
PHDC an epidemic strain is seen in the mid-Atlantic region of the Eastern United States but 
has been seen in rare occasions in European patients – it was first detected in Italy in 2001 
(McDowell et al, 2004; LiPuma, 2005).  ET12 was thought to have arrived in the UK as a 
consequence of contact at a CF summer camp in Edinburgh in 1989.  Both the ET12 and 
PHDC strains are B. cenocepacia and it is clear that this species may be more transmissible 
between patients than other Bcc strains (Baldwin et al, 2008).  Studies have found that 
B.cenocepacia isolates found in patients often appear to be mutually exclusive from 
environmental strains and are often not genetically linked to environmentally isolated 
strains.  Patient to patient spread, therefore, is clearly the main vehicle through which 
patients are colonised with this organism.  B. multivorans, however, is regularly isolated in 
the environment and studies have demonstrated that colonisation of patients is likely to be 
through this route. The disparate distribution of isolates also suggests separate 
colonisation/infection events that affect each patient individually (LiPuma, 2005).  Patient to 
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patient spread is much less common with this species (Baldwin et al, 2008). Other species 
(such as B. dolosa SLC6) have been found to infect multiple patients though this is a less 
common event (Biddick et al, 2003).  Sporadic colonisation/infections have been found with 
other species such as B. gladioli though, again, this is uncommon and B. gladioli does not 
form part of the Bcc group.  Interestingly, it has been found that those species that are most 
frequently isolated from the environment, are the ones least found in CF and other patients 
(LiPuma, 2005). 
It appears that infection of CF patients generally occurs with a single strain – although 
transient co-infection has been documented (Bernhardt et al, 2003).  Indeed, there is also 
evidence that in some patients, infection with Bcc species may be transient in nature.  This is 
an area that needs to be studied further, however, as other, as yet unknown strains may be 
involved (LiPuma, 2005).  It has also been suggested that colonisation of patients by Bcc 
species may go unnoticed for as long as two years.  This appears to be anecdotal evidence, 
however, and may rely upon the quality of sputum sampling (LiPuma, 2005).   
The so called “cepacia syndrome” described in 1984 (Aaron et al, 2000) is a condition 
featuring necrotizing pneumonia, fever, bacteraemia, leukocytosis and a raised erythrocyte 
sedimentation rate (ESR).  It is thought that as many as 20% of colonised patients will 
succumb to this syndrome (Govan & Deretic, 1996).  The syndrome has largely been 
attributed to B. cenocepacia – albeit without sufficient rigor to conclusively rule out other 
species/strains.  It appears, however, that the ET12 strain predominates.  It has yet to be 
established whether other Bcc species have a role to play in this syndrome, and if not, what 
significance their role is in morbidity/mortality.  It has been established that other species 
have caused such outcomes – particularly B. multivorans and B. dolosa but it is clear that 
more work is required in this area – with larger numbers of strains/patients to assess patient 
outcome (LiPuma, 2005).  It has to be noted, with respect to the above, that in most patients 
that are colonised by Bcc, the outcome will be very similar to those who have been 
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colonised by Pseudomonas species (Govan & Deretic, 1996).  Historically, the most 
commonly found CF related Bcc isolates were of the B. cenocepacia group (formerly known 
as Genomovar III), and it is these that exclusively carry the ET12 transmissibility marker 
(McDowell et al, 2004). 
2.1.2 Epidemiology of Bcc in cystic fibrosis 
 
The reason for the rise of Bcc prevalence in CF populations has so far been difficult to 
explain with any certainty.  The increased prevalence first became apparent in the 1980s and 
was thought to be largely as a result of selective pressure by aggressive antimicrobial 
chemotherapy.  Nebulised colistin has been suggested as one of the prime suspects in this 
mechanism.  There has been little scientific evidence to back up these assumptions, 
however, and the social and economic lifestyles of an increasingly adult population of CF 
sufferers have yet to be factored into the equation with a full explanation remaining 
somewhat difficult to offer.   
The transmission of Bcc between patients, and in a nosocomial environment, has been 
difficult to prove.  Only with the advent of molecular methods such as pulsed field gel 
electrophoresis (PFGE) has this become possible.  It does appear that in most cases, 
chronically colonised patients will only harbour one strain throughout, though multiple 
morphotypes may appear (LiPuma et al, 1991).  In more recent years, occasional “swaps” of 
strains have been noted – for example a patient colonised with B. multivorans, may acquire a 
more virulent strain of B. cenocepacia (Saiman & Siegel, 2004). 
A number of case control studies have been carried out that suggest patient to patient 
transmission is a factor – particularly in the hospital environment.   A benchmark study by 
LiPuma et al (1990) was carried out at an education camp.  This study clearly demonstrated, 
using restriction fragment length polymorphism (RFLP) typing and contact tracing, that 
person to person spread was the primary method of acquisition (in this case).  It did not 
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indicate the actual method of transmission – whether by natural means or via a fomite 
pathway, though it was one of the first and most reliable studies that proved the, so far, 
circumstantial observations (Govan & Deretic, 1996).   
Whilst person to person contact has been demonstrated, Bcc has often proved difficult to 
isolate from environmental sources where CF patients have not previously been present.  It 
has been demonstrated, however, that Bcc can and does contaminate the environment 
around a colonised patient.  It seems highly likely, and a number of studies have confirmed 
this, that patient to environment transmission occurs.  This includes sources such as 
respiratory equipment (such as nebulisers), disinfectants and furniture – such as taps and 
sinks (Govan and Deretic, 1996).  Interestingly, it was found that transmission was often 
strain dependant.  Patients who were colonised by an epidemic strain (such as ET12), 
remained chronically colonised.  Where a patient possessed two strains, only the epidemic 
strain was passed to the close contact (Govan et al, 1993).   
Strain type, whilst associated with colonisation status did not appear to affect clinical 
outcome.  It was found in a study by Brown et al (1993) that whilst 50% of patients 
colonised by an epidemic strain eventually succumbed, a significant number of patients were 
stable for the period of the study.  Evidence was not found that correlated colonisation with 
poor pulmonary status.  However, it was found that poor pulmonary status was one of the 
risk factors for poor survivability once colonised (Brown et al, 1993; Govan and Deretic, 
1996).   
In recent years, the spread of colonisation appears to have moved from B. cenocepacia, to a 
greater incidence of B. multivorans.  The detection of unique strains – largely assumed to be 
from environmental sources has now become commonplace in many centres (Baldwin et al, 
2008, France et al, 2008) 
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2.1.3 Treatment and resistance 
 
Whilst it is not possible to completely eradicate Bcc from the lungs – particularly the lower 
respiratory tract, it has been demonstrated in a number of studies that the effect of 
antimicrobial chemotherapy has a beneficial effect in terms of reduction of bacterial density.  
This, in turn, reduces the host immune response and can lead to both a qualitative and 
quantitative reduction in bacterial virulence and virulence factor production (Aaron et al, 
2000).  It has also been demonstrated that the net benefit from antimicrobials only comes 
with combination therapy – opening the way for synergy investigations of the useful 
antibiotic groups (Aaron et al, 2000). 
Bcc species are very resistant to a broad spectrum of antibiotics including aminoglycosides 
and practically all of the available β-lactam antibiotics, and development of novel treatment 
therapies has been slow to evolve (Ciofu, 1996).  Indeed, resistance has been demonstrated 
even in patients who are not currently undergoing antimicrobial chemotherapy.  It has been 
found that even when susceptibility in-vitro appears to be promising, aggressive 
antimicrobial therapy often fails to yield good clinical improvement of the patient or 
quantitatively reduce the numbers of bacteria in cultures (Govan & Deretic, 1996).  It is 
thought that the environment of the CF lung may, in fact, induce resistance such as active 
efflux pump mechanisms. The Bcc are closely related to Pseudomonas aeruginosa, and as 
such demonstrate some homology in their resistance such as the multi drug efflux 
mechanisms (Zhang et al, 2001).  Numerous mechanisms of resistance have been 
noted/suggested, though a number of them are speculative.  One of the mechanisms confers 
resistance to chloramphenicol, quinolones and trimethoprim (Aaron et al, 2000). 
Meropenem has been shown to be effective against Bcc species, but resistance upon 
multiple treatments does develop (Ciofu, 1996).   Addition of a β-lactamase inhibitor with 
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carbapenems has been suggested but as yet, this has not been adopted.  One of the most 
interesting aspects of the Bcc resistance spectrum is that of the highly inducible 
chromosomal penA gene that encodes for a β-lactamase type enzyme.  This allows the 
bacterium to use penicillin antimicrobials as a substrate (Joris et al, 1993; Aaron et al, 
2000).  The alteration of penicillin binding proteins (PBPs) may also play a role (Aaron et 
al, 2000). 
It has been found that the Bcc outer membrane features far less permeability than many 
other organisms (up to ten times less permeable than E. coli).  It would appear that this has a 
wide ranging and broad spectrum effect not only on a wide range of antimicrobial agents, 
but also some disinfectants (Govan & Deretic, 1996).   
Quorum sensing may also play a role, where gene expression is dependent upon bacterial 
density.  Biofilm production and the actual cell wall structure also plays a role (LiPuma, 
2005), and there is some burgeoning research into this area.  It is thought that current 
susceptibility studies may not adequately predict the environment in which Bcc species (and, 
in fact other CF colonising organisms) exist.   
It is the multiple resistance of Bcc species that make laboratory susceptibilities difficult to 
interpret.  It is often the case that all or many of the single antibiotics tested are resistant in-
vitro and thus combination testing is becoming a popular, though still debated method of 
predicting clinical success (Aaron et al, 2000).  Additionally, where MICs are tested in-vitro 
and found to be sensitive, it has been demonstrated that clinical failure of an antimicrobial 
may still occur.  This brings the relevance of in-vitro testing into some question.  However, 
as stated previously, the in-vitro studies for this organism may still be relevant where 
empirical treatment is to be used (Ciofu et al, 1996; Petersen et al, 2006).   
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2.2 Stenotrophomonas maltophilia 
 
Often seen as an environmental organism, Stenotrophomonas maltophilia is an increasingly 
important nosocomial pathogen and is resistant to many of the commonly used antimicrobial 
agents (Gabriel et al, 2004).  It is found in a wide variety of environments and has been 
isolated from both soil and water habitats as well as animals.  It has been found in diverse 
areas such as Japanese oil fields and Antarctica (Denton & Kerr, 1998; Valdezate, 2004).  It 
has been found in a wide range of animals, both in faeces and in oral sites and has also been 
implicated in some animal diseases such as fleece rot in sheep (Denton & Kerr, 1998).  It 
has also been suggested as a potential biological control since it is known to produce 
maltophilin – an antifungal agent that inhibits Candida and Aspergillus spp (Jakobi et al, 
1996). Most of the species found in the genus Stenotrophomonas are environmental in 
nature and have been found in soil and agricultural settings (Yi et al, 2010).  These include 
S. ginsengisoli (Ginseng fields), S. koreensis (compost), S. dokdonensis (soil) and S. 
panacihumi (Ginseng field).   A study in 1999 by Berg and colleagues found that 
S.maltophilia isolates from environmental and clinical sources differed very little, with no 
clustering – suggesting that these two sources may not be mutually exclusive.  In the 
process, it was noted that PFGE was the most discriminatory test. 
Previously called Xanthomonas maltophilia and Pseudomonas maltophilia, 
Stenotrophomonas maltophilia is one of a small number of known organisms in its genus: 
Stenotrophomonas.  The genus was proposed by Palleroni & Bradbury (1993) and the type 
strain was first isolated from an oro-pharangeal swab of a patient with oral carcinoma 
(Denton & Kerr, 1998). S. maltophilia is a motile, Gram negative curving or straight rod 
shaped bacterium in the order of 0.5–1.5 µM long.  It is an obligate aerobe and grows 
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optimally at around 35
o
C in an aerobic environment.  Its colonial appearance on culture 
media is fairly typical of such “Pseudomonas like” organisms – flat, smooth and wet – often 
with a brown discoloured appearance (particularly in media with a high tyrosine content 
(Blazevic, 1976)).  Whilst considered to be generally unreactive biochemically, 
S.maltophilia can be identified by means of the commercially available API20NE system 
(Biomerieux).  Stenotrophomonas maltophilia is relatively easy to isolate and can be done 
so from a wide range of normally available media found in diagnostic laboratories.  
Common media such as Columbia blood, MacConkey and CLED agar will isolate this 
pathogen quite satisfactorily and the organism will grow overnight in temperatures ranging 
from 20-37
o
C in air.  S. maltophilia can also be isolated using blood culture systems, though 
the efficiency with which this is done is variable (Denton & Kerr, 1998).  
Molecular methods to identify S. maltophilia are available; for example single strand 
conformation polymorphism electrophoresis of polymerase chain reaction (PCR) amplified 
16s rRNA fragments.  In addition to this, differences in internal transcribed spacers have 
been described that are species specific (Tyler et al, 1995; Denton & Kerr, 1998). 
2.2.1 Antimicrobial testing 
 
Whilst S. maltophilia are noted to be phenotypically stable when sequenced, an issue that is 
encountered in the laboratory is that of variability/heterogeneity.  Indeed, this is a common 
factor with CF isolates.   Aaron (2007) found that CF organisms frequently exist as multiple 
morphotypes.  This reduces the accuracy and reproducibility of minimum inhibitory 
concentration (MIC), synergy and multiple combination bacterial testing (MCBT) methods 
and may render them useless or misleading to the clinician.  In one study covering 101 
sputum samples taken from patients, an average of four morphotypes of P. aeruginosa 
existed concurrently in each specimen with a mean of three different antibiograms from each 
morphotype.  With this number of morphotypes, it was common to see as many as twelve 
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different susceptibilities when testing from one specimen.  This is a commonly noted 
phenomenon with all of the species tested in this study.  This variation in observable results 
is noted to be particularly prominent in the quinolones and often makes optimisation of 
antimicrobial therapy difficult (Denton & Kerr, 1998).  Additionally, S. maltophilia is often 
isolated from mixed cultures, and this has stimulated some debate about its true role in CF 
pathology (Valdezate et al, 2004). 
Broth/agar dilution methods have been recommended by the Clinical Laboratory Standards 
Institute (CLSI), although a study by Yao et al (1995), found 94% agreement between E-
testing and the disc diffusion method.  A number of reasons have been cited for the 
seemingly random variation in susceptibility testing including Zn
2+
 concentration of the test 
media (affecting Imipenem).  Similar tests have been carried out to confirm these effects and 
have found that the same ion concentrations do not affect Meropenem.  Equally both Ca
2+
 
and Mg
2+
 ions do not appear to influence susceptibility testing (Hawkey et al, 1993; Denton 
& Kerr, 1998).  It is also well documented that the incubation temperature can affect the 
appearance of both aminoglycosides and polymyxin B – appearing to be more resistant 
when tested at 30
o
C.  Current British Society for Antimicrobial Chemotherapy (BSAC) 
recommendations are that all isolates of S. maltophilia are tested at 30
o
C to avoid false 
sensitivity reporting (Pappapetropolou et al, 1994; Wheat et al, 1985; Denton & Kerr, 1998).  
Another, more recent, variable that has been noted in the S. maltophilia species, is a novel 
small colony variant (SCV) that has resisted antimicrobial susceptibility testing and is 
difficult to grow consistently on standard media (Anderson et al, 2007).  It is possible that 
this and potential other SCVs may induce further variation within any testing schedule and 
that whilst doing this, they may not be detected by normal means.  These SCVs have been 
tested under non-standard conditions (chocolate agar with 48 h growth) with the result that 
they were found to have potential resistance to sulfamethoxazole-trimethoprim (unlike other 
S. maltophilia isolates).  However, they were found to have some potential susceptibility to 
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minocycline and levofloxacin (individually) – indicating the possibility of tigecycline 
sensitivity.   
2.2.2 Resistance mechanisms 
 
S. maltophilia demonstrates resistance to broad spectrum antibiotics – particularly the β-
lactams.  Whilst it was thought that two enzymes were responsible for this, further enzymes 
have been identified – mainly in the metallo β-lactamase or serine class. Of the two enzymes 
most studied, L1, a metallo β-lactamase differs from that of other species types and is found 
in virtually all wild type strains (Denton & Kerr, 1998).  Whilst this enzyme is dependent 
upon the zinc concentration, it can also be effective (though less so) in the presence of 
cobalt, cadmium or nickel ions.  It has been shown to hydrolyse penicillin antimicrobials but 
has no hydrolysing effect upon aztreonam.  It is also responsible for the effect commonly 
seen with the carbapenems (Denton & Kerr, 1998).  This enzyme is not affected by β-
lactamase inhibitors such as clavulanic acid, though other compounds have been shown to 
be effective in laboratory trials (Payne et al, 1997). L2 – the other enzyme that is found in 
S.maltophilia, is a TEM β-lactamase and in the serine class.  It is responsible for the 
hydrolysis of aztreonam and also demonstrates activity against cephalosporins.  It is 
inhibited by β-lactamase inhibitors such as clavulanic acid although is less susceptible to 
tazobactam or sulbactam inhibitors.  Oddities have been reported in the regulation of 
expression of these enzymes – where strains are able to produce large quantities without 
induction, but these appear to be isolated cases of mutation (Payne et al, 1997). 
In addition to enzymatic resistance mechanisms, it is thought that the poor penetration of 
penicillins and cephalosporins may enhance resistance.  It is not known how the number or 
state of porin channels affects this (Denton & Kerr, 1998).   
It is thought that aminoglycoside resistance is partly temperature related and also related to 
the O side chain of the lipopolysaccharides.  The lower growth temperature and subsequent 
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change in the phosphate content correlating with enhanced resistance (Denton & Kerr, 
1998). 
Cross resistance with quinolones and doxycycline has been reported and this is thought to be 
related to changes in the outer membrane proteins (Denton & Kerr, 1998; Giacometti et al, 
2000).  In addition to doxycycline, active transport (energy dependent efflux) resistance 
mechanisms to tetracyclines have also been reported.  This system is not active against 
aminoglycosides or β-lactam antimicrobials, but is effective against chloramphenicol and 
tetracyclines (Alonso & Martinez, 1997).  As with Pseudomonas aeruginosa and the Bcc 
species, efflux pumps have been described that confer multiple resistance.  Most of these are 
homologues of those described in Pseudomonas aeruginosa (Zhang et al, 2001).    
2.2.3 Treatment options 
 
As with other CF pathogens, the treatment of S. maltophilia infection is difficult.  Past 
evidence suggested that cotrimoxazole (trimethoprim-sulfamethoxazole) would have been 
the drug of choice, although resistance has been noted to rise and fall with increased and 
decreased use of this drug respectively (Denton & Kerr, 1998).  In light of the above 
evidence, it would be sensible to reject penicillins and most of the cephalosporins for 
empirical treatment.  Ceftazidime, however, has been found to be active against 
S.maltophilia although this is highly variable and not, therefore, reliable for empirical 
treatment (Denton & Kerr, 1998). 
A number of combination antibiotics have been tested against S. maltophilia, including 
ticarcillin clavulanate which demonstrated good activity.  Other combinations, however, did 
not yield good results.  These included amoxicillin clavulanate, ampicillin sulbactam and 
piperacillin-tazobactam (Denton & Kerr, 1998).  Likewise, aztreonam and imipenem, in 
combination with β-lactamase inhibitors fared poorly.  Where increased activity was noted, 
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it was found that plasma levels of clavulanic acid decrease sufficiently in-vivo to bring into 
doubt the usefulness of these combinations (Denton & Kerr, 1998).   
Minocycline and doxycycline have been demonstrated to exhibit good activity against 
S.maltophilia (Gabriel et al, 2004) – contrasting with that of the legacy compound, 
tetracycline (Tilton et al, 1978). 
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2.3 Achromobacter xylosoxidans 
 
Previously called Alcaligenes xylosoxidans, this organism is an unusual isolate from clinical 
material (Gabriel et al, 2004).  Achromobacter xylosoxidans is an aerobic Gram-negative, 
non-fermentative rod shaped bacillus (Siebor, 2006).  Oxidase positive and easily confused 
with Pseudomonas species, this organism was named by Yabuuchi & Ohyama (1971).  
Before being included in a single species type, this organism was recognised as a number of 
different biotypes – including: Alcaligenes faecalis (Moore & Picket (1960), and 
Alcaligenes denitrificans by De Ley et al (1970).  Upon further testing it became apparent 
that all of these biotypes were actually the same species (Igra-siegman, 1980).   
A. xylosoxidans is relatively easy to isolate – growing well on Columbia blood agar and 
MacConkey at 37
o
C overnight.  It produces glistening, smooth pinpoint colonies.  
A.xylosoxidans is able to be tested using the standard methods of other Gram negative 
bacteria.  Where confusion exists as to the identification of this organism, the peritrichous 
flagella type may be identified, thus distinguishing A.xylosoxidans from Pseudomonas 
species (Igra-siegman et al, 1980).  A. xylosoxidans can be identified in the routine 
laboratory, however, by the use of the API20NE identification system – and this has been 
found to be sufficiently accurate for routine use (Saiman et al, 2001).   
2.3.1 Treatment options 
 
As with other organisms found in CF, breakpoints are not routinely published by either 
BSAC, or CLSI and these can only, therefore, be extrapolated from other similar organisms 
or research publications. 
A. xylosoxidans has been found to be resistant to most commonly used aminoglycosides and 
penicillins such as ampicillin and it has been suggested that its emergence as a CF pathogen 
may, along with S. maltophilia, be as a result of aggressive selection pressure caused by 
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antimicrobial chemotherapies (Cystic Fibrosis Medicine, 2008).  Some sensitivity to 
chloramphenicol, tetracycline and colistin has also been described.  Cotrimoxazole and 
Polymyxin B show good activity against A. xylosoxidans.  A study carried out by Saiman et 
al (2001) found that A. xylosoxidans isolates were mostly resistant (97%) to conventional 
concentrations of tobramycin and colistin, though at the concentrations used in aerosol 
treatment, they were more susceptible (56% susceptibility).  Upon testing, the organisms 
averaged 50% susceptibility to minocycline, imipenem, meropenem and 
piperacillin/tazobactam.  Other agents (ciprofloxacin, tobramycin, cotrimoxazole, and 
chlorampenicol) did not fare well, with most of the isolates being resistant at normal 
therapeutic concentrations.   Significantly, for this study, minocycline was found to be active 
against 51% of isolates tested in a study by Saiman et al (2001).  None of the isolates tested, 
however, were CF related and this may have some bearing upon resistance mechanisms 
present.      
2.3.2 Clinical relevance 
 
The clinical relevance of A. xylosoxidans is, as yet, not fully understood (Saiman et al, 
2001).  Reports appear to suggest that colonisation by this organism does not necessarily 
lead to a decline in respiratory function (De Baets et al, 2007), though the presence of serum 
specific precipitating antibodies does appear to be linked with a decline in respiratory 
function (Ronne Hansen et al, 2006).  Most authors, however, agree that increased antibiotic 
intervention is necessary (Ronne Hansen et al, 2006; De Baets et al, 2007).   
2.4 Sequence of infection 
 
The assumption is that CF patients are born without any lung colonisation.  It is not 
uncommon, however, for over 30% of patients to have Pseudomonas aeruginosa isolated by 
their first birthday (Geller, 2009).  A study carried out in the United States found that of 
20,000 patients 29.8% of 2-5 year olds are colonised by Pseudomonas.  In the 26-30 year 
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old group, the percentage rises dramatically to 81.3% (Doring et al, 2000).  In the normal 
course of events, Pseudomonas will be isolated frequently – though not on every single 
culture, as transient colonisation develops.  These strains are most likely to be planktonic but 
non-mucoid in their nature. The hypersensitivity at colonisation results in an acute lung 
infection that may be treated at this stage – with the possible eradication of Pseudomonas 
(Doring et al, 2000).   
 If left untreated, however, this colonisation later develops with the appearance of mucoid 
strains that embed themselves into an exo-polysaccharide matrix – a biofilm (Geller, 2009).  
As this biofilm builds, a type III hypersensitivity develops and antibodies are produced 
against numerous but specific antigens.  The formation of immune complexes and the 
recruitment of neutrophils that decay appear to form areas of pus around the biofilms.  It is 
thought that this may contribute to the obstruction of the airway in CF patients (Doring et al, 
2000). Other bacteria are thought to be able to produce a similar effect in CF patients – even 
in the absence of Pseudomonas.  A decrease in forced expiratory volume (over 1 s) – FEV1 
has been demonstrated with other bacteria (Sharma et al, 1995).  With this in mind, 
however, it is a fact that many patients are able to continue for years without a significant 
decrease of FEV1 – even in the presence of Pseudomonas or other bacterial colonisation 
(Doring et al, 2000).  In most patients, however, mucoid Pseudomonas will result in a 
serious decline in FEV1.   As stated previously, it is thought that this decline is primarily 
due to the increase in sputum production/inflammation and the increased release of serine 
proteinases.  Other unrelated causes of exacerbations, however, cannot be ruled out (Doring 
et al, 2000).   
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2.5 Infection control  
 
Modified and stringent infection control practices have played an enormous part in the 
reduction of infection and colonisation.  The legislation and recommendations for infection 
control are legion and thorough (Saiman & Siegel, 2004).  Infection control practices follow 
similar lines to those of other hospital areas – hand hygiene, segregation and the observation 
of equipment precautions – such as the cleaning of nebuliser equipment.  The organisms 
isolated in CF patients are environmental in nature, and survive for prolonged periods on 
hard surfaces in the hospital and home environment.   
A number of studies have found that isolates in CF, which are effectively environmental 
organisms (Rogers et al, 2004; Valdezate et al, 2004; Rogers et al, 2005), are often 
unrelated and may originate from multiple, independent sites/sources (Denton et al, 1998; 
Denton & Kerr, 2002; Valdezate et al, 2004) – this is particularly true of S. maltophilia and 
B. multivorans isolates. Isolation of patients, it has been suggested, was not necessarily 
indicated as based upon the findings of these studies, it would appear that one of the most 
important factors in acquisition of colonising organisms is the environment from which they 
originate. There are many potential sources of infection/colonisation with S. maltophilia and 
other CF isolates.  One example where the spread of organisms was studied found that 
neubulizer use of antimicrobials such as tobramycin may have assisted the acquisition of 
S.maltophilia with 16% of patients receiving nebulised tobramycin and 22% receiving 
nebulised placebo acquiring new strains (Denton & Kerr, 2002).   However, whilst the 
segregation of patients to protect against acquisition of S. maltophilia is not necessarily 
indicated, the situation is very different for patients that are colonised with Bcc (Speert et al, 
2002).  Another study investigated the use of nebulisers but found mixed results.  Those 
patients who practiced good nebuliser hygiene and followed the recommended instructions 
for use were found to have minimal or no contamination from nebulisers (Hutchinson et al, 
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1996).  Interestingly, the number of contaminated nebulisers was noted to be high, but the 
transmission rates were relatively low – for example 7 out of 35 patients using a nebuliser 
were positive for either Bcc species or S. maltophilia.  The conclusions of the study were 
that most transmission of CF related organisms, must, therefore originate from other 
environmental sources.  This is further backed up by a more recent study by Valdezate et al 
(2004) where a large number of S. maltophilia isolates were investigated by the use of 
PFGE.  A high genetic diversity was found, despite all of the isolates being isolated at the 
same hospital.   
The acquisition of Bcc is for most patients, a great concern.  Aside from the obvious 
physical health implications, there are other concerns.  The psycho-social implications of 
infection control regulations within CF units and at other social gatherings where CF 
patients are likely to come into contact can be considerable.   
Burkholderia cepacia complex organisms are noted to be easily transmissible between 
patients on a unit (Speert et al, 2002) and so one may expect that isolates found in the same 
unit would be of similar relatedness – particularly strains of B. cenocepacia.   The study by 
Speert et al (2002) however, also demonstrated that it remains difficult to accurately predict 
the transmissibility of these organisms.  Their study found that B. cenocepacia (formerly 
Genomovar III) was the most transmissible strain type, and that the ET12 epidemic strain 
was the most “robust” marker of transmissibility.  B. multivorans in most studies have not 
been isolated in the same numbers, leading to many authors stating that it is a relatively 
uncommon CF pathogen when related to B. cenocepacia (Saiman & Siegel, 2004), though in 
recent years, there has been a reduction in the number of B. cenocepacia isolates – 
presumably as part of a concerted and rigorous infection control policy.  It has been 
demonstrated that B. multivorans is primarily contracted from environmental sources, unlike 
B. cenocepacia where patient-patient spread is the most common vehicle.  It is, therefore, 
more difficult to prevent the colonisation of patients by B. multivorans than B. cenocepacia.  
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Despite this change in relative distribution/prevalence, there have been noted cases where 
patients colonised with B. multivorans or other Bcc species, have “swapped” isolates.  This 
change of colonisation status from B. multivorans to the much more transmissible 
B.cenocepacia has resulted in a severe and rapid decline in respiratory function with 
catastrophic results for the patient (Saiman & Siegel, 2004).   
Recommendations have been made, that suggest it may be possible, and even prudent to 
cohort patients based upon transmissibility markers that are detected in their particular 
isolates of Bcc species.  However, it has been noted that some of these markers such as cblA 
and BCESM have been noted to reside upon unstable choromosomal regions – and this may 
render such practices unsafe (Mahenthiralingam et al, 1997; McDowell et al, 2004).   
Other organisms that have been noted in CF patients, present differing infection control 
risks.  The emergence of S. maltophilia and A. xylosoxidans (the latter being less common 
with prevalence rates reported around 10%) has increased the complexity of infection 
control procedures and antimicrobial chemotherapy, in that the routes of transmission, and 
indeed the clinical relevance, of these organisms may sometimes be in some doubt (Cystic 
Fibrosis Medicine, 2008).    
The Leeds Teaching Hospitals NHS Trust (LTHT) CF unit has followed the 
recommendations given by the CF Trust, and outlined in their document: “The Burkholderia 
cepacia complex – suggestions for prevention and infection control” (2004).  As stated 
earlier, the consequences of separation may be psychologically undesirable to patients, but it 
is considered necessary and as can be seen from the data presented in this, and past studies, 
it has been successful (CF Trust Guidelines, 2004).  Since the Bcc species (in addition to the 
more common Pseudomonas aeruginosa) are the most transmissible and potentially harmful 
strains, so it follows that infection control practices must seek to eliminate these organisms 
above all other social concerns.  
30 
 
Stringent infection control measures such as those applied in the LTHT have been 
demonstrated to significantly reduce the incidence of patient-patient spread of Bcc and other 
pathogens.  Likewise, these studies have also demonstrated that the emergence of 
environmental strains cannot easily be stemmed by such measures, as they remain largely 
outside the control of the hospital and clinician (Baldwin et al, 2008).  One result of good 
practice within CF units has been the reduction in B. cenocepacia colonisation rates.  
Conversely, and seemingly in line with our historical collection, the prevalence of 
B.multivorans has risen in the last decade – indicating again, that environmental factors may 
influence the rates of colonisation (Baldwin et al, 2008) – this was noted in Vancouver 
during a study carried out by Mahenthiralingam et al (1997) where little cross infection by 
B.multivorans was detected from a 17 year period.   It is thought that this rise in prevalence 
may be largely due to the fall in colonisation with B. cenocepacia isolates, rather than a 
direct rise in the number of B. multivorans.  The isolates that were collected by the 
microbiology department of LTHT would go some way to supporting this trend, with more 
distinct B. multivorans isolates being recorded over the 10 year period, than the more 
transmissible B. cenocepacia (Biddick et al, 2003).  It is clear that the distribution of species 
within the CF community is changing, and this may result from aggressive antimicrobial 
pressures, but is most likely to be due to thorough infection control practices (Reik et al, 
2005). 
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Chapter 3 
3.0 Antimicrobial chemotherapy   
 
The benefit of early prophylactic antibiotics has been questioned in the past – with some 
data suggesting that increased antibiotic use can be directly correlated with the rise in 
Pseudomonas colonisation and infection.  It is though that this may arise as a result of the 
suppression of the normal respiratory flora – thus paving the way for increased colonisation 
by Pseudomonas due to the lack of competition for resources. It has been demonstrated 
during in-vitro studies that combined therapies (such as oral ciprofloxacin with nebulised 
colistin), can potentially reduce the numbers of bacteria in the CF lung to almost 
undetectable limits though it would appear that the in-vivo situation may differ significantly.  
It is thought, however, that early therapy before colonisation may delay the onset of 
Pseudomonas infection (Valerius, 1991).  Intensive treatment has been demonstrated in 
some studies to reduce the onset of chronic Pseudomonas colonisation in over 80% of cases 
(Frederiksen et al, 1999).  Studies similar to this have been carried out using a range of 
different anti-Pseudomonal drugs such as ceftazidime and tobramycin.  It seems at present, 
however, that no rigorous (prospective) studies have been carried out where antibiotics are 
given to prevent Pseudomonas colonisation before colonisation is noted (Doring et al, 
2000).   
Another problem in treatment of CF patients is the mucoid Pseudomonas strain.  It has been 
proved virtually impossible to eradicate these strains when they colonise patients.  This is 
because it is difficult to achieve therapeutic concentrations of antibiotics that can penetrate 
the biofilm layer, and kill the organisms.  This may also be a problem with other colonising 
organisms such as those tested in this study.  In addition to the polysaccharide matrix in the 
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biofilm, the low ASL volume along with mucus plugging may also act to restrict antibiotic 
access (Doring et al, 2000).     
Antibiotics are thought to penetrate the bronchial secretions via the blood.  This is a process 
of passive diffusion and differs with each antibiotic type (Doring et al, 2000).  Inhalation of 
antibiotics is a common form of treatment with CF patients – with tobramycin and/or 
colistin being the most commonly used.  This ensures high therapeutic doses at the site of 
infection.  Drugs given parenterally will necessarily require much higher doses – raising 
issues of toxicity and practicality where the patient is self administering at home (Doring et 
al, 2000). 
Much has been said of Pseudomonas in CF, but there are other pathogens associated with 
pulmonary infection and colonisation and the treatment of these bring a number of 
difficulties, such as pan-resistance and antibiotic access to biofilm layers.  These organisms 
include the Burkholderia cepacia complex and its associated species as well as S.maltophilia 
and A. xylosoxidans.   
 3.1 Amikacin and tobramycin 
 
Both of these antibiotics are aminoglycosides – bactericidal protein synthesis inhibitors.  
Derived from Actinomycetes, their polycationic aminoglycoside structures bind to the outer 
membrane of the bacterial cell.  They will also bind to the anionic phospholipids of 
mammalian cell membranes.  Aminoglycosides also bind to the proximal tubular cells – 
bringing about some of the toxicity of this class of antibiotic.  Transport across mammalian 
cell membranes is generally restricted because of the hydrophobicity of these antibiotics.    
Due to the cationic nature of these antibiotics, they bind to the negatively charged sites on 
the outer bacterial membrane.  This binding is sufficient to disrupt the membrane integrity 
and it is this process that may be one of the two main modes of action of this antibiotic 
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group.  These antibiotics also bind to the 30S ribosomal subunit causing an alteration in the 
codon-anticodon recognition mechanism.  This results in misreading of mRNA and the 
subsequent production of nonsense proteins.  They have also been found to bind to the 50s 
ribosomal subunit, although the effect of this is unclear (Craig & Stitzel, 2003).  They enter 
the cell via an oxygen dependent active transport system (that may be blocked when the 
patient is treated with chloramphenicol).  It is thought that there may be more than one mode 
of action, as protein synthesis inhibitors are usually not so rapid in their killing of the 
bacterial cells.  One phenomenon that has been noted with aminoglycosides is their synergy 
when used in combination with β-lactam antibiotics.  It is thought that this is because the 
administration of a β-lactam antibiotic will reverse the often seen effects of low oxygen 
tension and low pH.  These effects are often noted in bacterial abscesses.  If the 
aminoglycoside alone were to be administered, then penetration into the cells would be 
inhibited as the active transport is dependent on the latter conditions being optimal.  Prior 
administration of the β-lactam antibiotic will effectively prepare the ground for 
administration of the aminoglycoside – resulting in a synergistic effect (Craig and Stitzel, 
2003).   
Gentamicin is the most commonly used aminoglycoside – often in cases of sepsis.  
tobramycin, however, is the aminoglycoside of choice against Pseudomonas aeruginosa.  
tobramycin is widely used to treat CF patients.   
Aminoglycosides are not well absorbed – being given intravenously or intramuscularly.  
They are not absorbed in the GI tract, exhibit minimal binding to plasma proteins, and do 
not cross the blood brain barrier.  Accumulation can occur in renally impaired patients, as 
virtually the entire antibiotic is eliminated by glomerular filtration in the kidneys, resulting 
in renal toxicity.  Likewise, in the tissues, it is possible to reach toxic levels where the dose 
is continuous and not monitored carefully.   
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One advantage of the aminoglycosides is the long duration of their post antibiotic effect.  
Even after the levels of antibiotic fall below the sub-inhibitory level, re-growth of the 
bacterial pathogen is restricted.  It is thought that this may be due to the time taken for the 
bacterial cells to repair/replace the ribosome.  This means that aminoglycosides such as 
tobramycin can be given as a once daily dose – making administration much simpler for CF 
patients.  
3.1.1 Resistance mechanisms 
 
One of the main resistance mechanisms in the aminoglycosides is the plasmid mediated 
production of enzymes that are capable of phosphorylating, adenylating or acetylating the 
antibiotic – usually by attacking the first ring structure.  Pseudomonads resist the transport 
of aminoglycosides in to the cytosol and the presence of multiple active transport pumps in 
bacteria such as these cause significant issues.  
3.2 Ceftazidime 
 
Comprising a 7-aminocephalosporanic acid composed of a hydrothiazine ring fused to a β-
lactam ring, this third generation cephalosporin has the greatest activity against 
Pseudomonal pathogens of all of the cephalosporins (Craig & Stitzel, 2003).  Ceftazidime is 
a semi-synthetic antibiotic of the cephalosporin class.  These drugs are derived from a 
number of microorganisms such as Cephalosporium and Streptomyces.  They are grouped 
according the stability of their β-lactam ring structure; each group varying in their 
antimicrobial spectrum of activity.  As with other β-lactam antibiotics, the mode of action is 
primarily aimed at the cell wall synthesis of the bacterium.  β-lactam antibiotics closely 
resemble the terminal D-alanyl-D-analine part of the pentapeptides of the peptidoglycan 
(Craig & Stitzel, 2003).  The covalent bonding of these transpeptidases results in an acyl-
enzyme molecule that is stable and inactive.  The resultant structure prevents further enzyme 
functions but requires the β-lactam ring structure to remain intact during this process.  The 
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penicillin binding proteins (PBPs) are also involved in the assembly and maintenance of the 
peptidoglycan cell wall.  There are a number of these that may be inactivated by the β-
lactam antibiotic which results in a weaker cell wall that may deform the bacterium or cause 
lysis.   
Ceftazidime is available either intramuscularly or intravenously – giving good 
bioavailability.  It is one of the limited number of cephalosporins that reach therapeutic 
concentrations in cerebrospinal fluid.  In addition, the third generation cephalosporins are 
among the most useful in the treatment of pulmonary infections (Craig & Stitzel, 2003). 
Ceftazidime is excreted primarily via the kidneys and as such, the dosage may need to be 
adjusted in renally impaired patients.   
3.2.1 Resistance mechanisms 
 
Whilst β-lactamase enzymes can inactivate ceftazidime, they are much less efficient than the 
cephalosporinases – β-lactamases that are specific to this group of antibiotics.  It is these β-
lactamases that hydrolyse the β-lactam ring structure, rendering it useless.  These enzymes 
are derived from the PBPs and bind to the β-lactam antibiotics.  This then forms an acyl-
enzyme molecule that can be deacylated and ultimately hydrolysed (Craig & Stitzel, 2003).  
The genes for these β-lactamase enzymes are often highly inducible (where they are 
chromosomal) and mobile – being transported via plasmids and transposons.  
Pseudomonas and some other Gram negative organisms are able to actively pump out the 
antibiotic from the cell.  The multi drug efflux mechanisms are often associated with 
multiple resistance and are a major problem in CF patients that are colonised with strains 
such as Bcc.   
The other mechanism of interest with respect to Gram negative organisms is the reduction in 
access to PBPs.  Clearly, if the antibiotic is unable to bind with these proteins, then it will be 
36 
 
rendered ineffective and clinical failure will result.  Gram negative organisms, by virtue of 
their outer cell membrane, are able to reduce access to large molecules such as β-lactam 
antibiotics.  This can be done by mutating the porin channels and is often seen in 
Pseudomonas species.  
Ceftazidime, in common with other cephalospirins of the third generation may induce the 
production of ESBL enzymes in Pseudomonas and other environmental colonisers.  These 
are highly transferable resistance mechanisms and can result in further cross resistance – 
particularly in a ward environment (Craig & Stitzel, 2003). 
3.3 Piperacillin/tazobactam 
 
Piperacillin along with ticarcillin and mezlocillin are anti-Pseudomonal penicillins.  
Piperacillin is generally combined with tazobactam which acts as a β-lactamase inhibitor.  It 
is often used to treat CF related Pseudomonas aeruginosa and also pneumonias in patients 
that have been ventilated.  It can only be given parenterally and is formulated as a sodium 
salt which may cause problems where older patients have congestive heart failure.  As with 
the cephalosporins, piperacillin is primarily excreted through the renal system and thus 
would require some dosage adjustment in renally impaired patients.  Piperacillin, as a β-
lactam antibiotic is susceptible to many of the same mechanisms as other β-lactams. 
3.4 Meropenem  
 
A bacteriocidal β-lactam antibiotic from the carbapenem family, meropenem is similar to 
imipenem in its spectrum of action.  Meropenem is a stable antibiotic and does not, 
therefore, have to be combined with cilastatin for administration, unlike imipenem.   The 
carbapenems were developed as broad spectrum antibiotics that were capable of dealing 
with β-lactamase induced resistance.  One of the most notable side effects of this class of 
antibiotics is the neurotoxicity that can be induced by high plasma concentrations, though 
meropenem is less likely to induce seizures than imipenem.  Meropenem is active against 
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Pseudomonas and most Enterobacteriaceae, although resistant strains have emerged.  It has 
also been shown to have good activity against Burkholderia spp although resistance, once 
again has been noted (Ciofu et al, 1996).  Meropenem is clinically ineffective against 
organisms such as Stenotrophomonas maltophilia.   
Whilst meropenem is generally well tolerated, there are a number of possible side effects, 
including nausea, dizziness and “drug fever”.  It may, however, be useful in cases where β-
lactam drugs are not indicated due to hypersensitivity (Ciofu et al, 1996).   
3.5 Aztreonam 
 
This is a monobactam antibiotic – comprised of a monocyclic β-lactam ring and a 
substituent at the R-3 position.  Active against Pseudomonas, Neisseria spp and 
Haemophilus, it is notable for being active only against aerobic Gram negative rod bacteria 
as it has only a low affinity for penicillin binding proteins.  It is stable against β-lactamase 
enzymes – both chromosomal and plasmid mediated, though is susceptible to extended 
spectrum β-lactamases (ESBLs).   
 Aztreonam, as the only clinically available member of the monobactam group, is 
administered parenterally with a half life of 2 h and is broadly similar in its 
pharmacokinetics to comparable cephalosporins.  It also has the added benefit of being 
viable in patients with type I hypersensitivity causing penicillin allergy.  It is noted to be 
useful against P. aeruginosa (Shawar et al, 1999), though more variable where tested 
against Bcc species.  Activity against S. maltophilia and A. xylosoxidans is noted to be 
relatively poor (Denton, 2008).   
3.6 Ciprofloxacin 
 
This is the most frequently used of all fluoroquinolone antimicrobial agents and is classed as 
a second generation antibiotic.  It is active against the DNA gyrase topoisomerase II – an 
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enzyme that prevents supercoiling of DNA by strand cutting.  An additional target unique to 
the fluoroquinolones is the topoisomerase IV DNA gyrase – this is responsible for the 
separation of the daughter cell after replication (Craig & Stitzel, 2003).  Transcription and 
replication are inhibited by these actions, leading to a dual effect.  The initial effect of 
ciprofloxacin is bacteriostatic.  However, when the bacterial cell is unable to repair its DNA 
lesions, ciprofloxacin becomes bactericidal.  It is active against both Gram positive bacteria 
and negative bacilli (GNB) and has been widely used against Pseudomonas aeruginosa in 
CF patients – its effectiveness due largely to the piperazine moiety against which resistance 
is increasing (Craig & Stitzel, 2003).  It also has excellent activity against other Gram 
negative enterobacteriaceae and some environmental Gram negative organisms.  
Ciprofloxacin can be given orally, with a half life of approximately 3.3 h and has a limited 
number of side effects including GI tract upsets, hypersensitivity reactions (to theophylline 
in athsmatics) and, more rarely, CNS problems.  It is well absorbed and often concentrates 
in both tissues and phagocytes with concentrations in extravascular spaces often exceeding 
those of the serum.  Ciprofloxacin killing is concentration dependant, and as such it 
demonstrates a long post antibiotic effect (Craig & Stitzel, 2003).   
Ciprofloxacin is absorbed rapidly after oral administration.  It is excreted via the kidneys 
and may also be metabolized by hepatic conjugation and glucorinidation.  Patients with 
hepatic or renal insufficiency, therefore, may need altered dosing (Craig & Stitzel, 2003). 
Whilst the use of ciprofloxacin in pregnant women and children is not generally indicated, it 
is used in CF children that have been colonised by Pseudomonas.   
3.6.1 Resistance mechanisms 
 
One of the main resistance mutations occurs in the DNA gyrase A gene (gyrA).  Lower 
levels of resistance are associated with topoisomerase IV with the primary mutation site 
being gyrA.  Active efflux and the alteration of porin proteins also reduce the uptake of 
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Ciprofloxacin into the bacterial cell.  It would appear that this resistance is chromosomally 
mediated.   
Additionally, ciprofloxacin is noted to suffer from some variability when used against 
certain groups of organisms – primarily S. maltophilia.  It is unclear whether this variability 
occurs clinically and affects patient outcomes, though in-vitro testing can be difficult to 
interpret, further adding to the problems created by the heterogeneity of S. maltophilia in 
antimicrobial testing (Denton & Kerr, 1998).   
One of the main determinants of resistance to quinolones is the presence of multi drug efflux 
mechanisms.  These have been described across CF colonising species and are generally 
homologous and highly conserved.  Additionally, it has been suggested that some 
quinolones may actually provide a substrate for these mechanisms – particularly those that 
are active primarily against Gram positive species.  There has been suggestion that pump 
inhibitors may be of use, though this is still largely unproven (Zhang et al, 2001). 
3.7 Colistin  
 
Produced from Bacillus colistinus, colistin is a polymyxin antibiotic (polymyxin E).  It has a 
cationic property and interacts with the phospholipids of the cell membrane.  This causes 
disruption to the structure, giving a bactericidal action with Gram negative organisms such 
as Pseudomonas and the enterobacteriaceae.  It is not well absorbed from the GI tract and 
its use is limited by the severe neuro and nephro-toxicity reactions.  It is generally used as a 
topical preparation in the eyes, ears and in skin infections where appropriate and is not 
generally indicated for other conditions where third/fourth generation cephalosporins are 
available.  It may be used in clinical situations where treatment options are more limited – 
such as in CF patients.  Colistin was largely overtaken by the use of aminoglycosides due to 
its high toxicity.  It has since, however, become a widely used antimicrobial and has been 
demonstrated to be effective against organisms such as Pseudomonas in CF patients.  There 
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are two available forms of colistin (colistin sulphate – mainly used topically, and sodium 
colistin methanesulphonate – used parenterally).  Both forms of colistin are available for 
nebuliser administration, and as such are useful for home administration by CF patients.  
Colistin methanesulphonate is the less toxic variant and is, therefore, more widely used in 
nebuliser form as colistin sulphate has been noted to cause respiratory irritation.  The exact 
mechanisms of toxicity of colistin are not fully understood, but nephro-toxicity may be an 
issue with some patients, though this can often be reversed upon suspension of treatment (Li 
et al, 2005). 
Colistin kills very rapidly, by binding to the bacterial cell membrane.  It displaces divalent 
cations from negatively charged phosphate groups of membrane lipids with the result that 
the cell membrane is catastrophically damaged.   
3.7.1 Resistance to colistin 
 
One benefit of the mechanism of action of this antibiotic is that it does not depend upon or 
affect any metabolic process within the bacterial cell.  Since this is where most resistance 
mechanisms undergo rapid development, colistin has seen a slower rise in resistance rates 
than comparable aminoglycosides such as tobramycin (Li et al, 2005).  Data relating to 
acquired resistance is limited though it is clear that this occurs where colistin is used over a 
period of time to treat Pseudomonas infections/colonisation.  Some cross resistance has been 
noted between colistin and other polymyxin antibiotics.  Unusually, it has been noted that 
where strains of Pseudomonas become more resistant to colistin, they may become more 
susceptible to a small number of other antibiotics – notably chloramphenicol and the 
tetracyclines.  A number of multi-drug efflux systems have been noted – though these are 
not thought to be specifically related to colistin – resistance being almost a by product as 
colistin is not noted to penetrate the cell sufficiently.  Additionally, a number of outer 
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membrane proteins that are able to change the valency of lipopolysaccharides in the cell 
memebrane have been noted to inactivate colistin and other polymyxins (Li et al, 2005). 
3.7.2 Susceptibility testing 
 
It has been noted that the killing effect of the two different preparations of colistin differs, 
with colistin sulphate being the most potent, but less used agent overall.  There is some 
question over the in-vitro susceptibility where the sodium colistin methanesulphonate is to 
be used, as most susceptibility tests use the sulphate preparation.   
3.8 Minocycline  
 
The legacy derivative of tigecycline, minocycline is one of the tetracycline class of 
antibiotics.  Tetracyclines act by inhibiting protein synthesis at the 30s ribosomal sub unit, 
and as such are bacteriostatic agents.  They prevent the binding of aminoacyl transfer RNA 
to the receptor site.    Tetracyclines are taken up into the bacterium by the process of active 
transport, causing an accumulation of the drug inside the cell.  This is often the target of 
tetracycline resistance mechanisms.  Tetracyclines are broad spectrum and are active against 
both Gram positive and Gram negative bacteria.  Minocycline in particular is active against 
Neisseria meningitidis and is often used to eradicate nasal carriage of this organism.   
Minocycline is useful orally or parenterally and will be found in most of the fluid 
compartments of the body as it is one of the most lipid soluble of the tetracycline class.  
Additionally, both minocycline and doxycycline are the only two tetracyclines that feature 
improved absorption when administered after food.  Given the serum half life of 
Minocycline (16 h), it is considered to be the longest acting member of the tetracyclines.  It 
is the good distribution qualities of minocycline that render it useful against mixed 
infections of the pulmonary system.   
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Minocycline is primarily excreted via the faeces, and reaches high concentrations in the bile 
– up to five times that of the serum concentration.   
3.8.1 Resistance mechanisms 
 
Most resistance to tetracyclines is conferred via plasmids.  The development of energy 
dependent efflux mechanisms allow the bacteria to transport minocycline out of the cell – a 
mechanism which is sufficiently conserved to result in multi-resistance.  It is common to 
find that resistance to one tetracycline class antibiotic will also be found with other classes – 
often with the exception of minocycline.  It has been found that sub-inhibitory 
concentrations of the drug are able to induce resistance by the production of two specific 
proteins that block the uptake of tetracyclines through the cytoplasmic membrane. 
3.9 Temocillin  
 
Related to ticarcillin, temocillin is one of the β-lactamase stable antibiotics.  It is non-toxic 
and usually well tolerated but its lack of activity against Gram positive organisms has 
resulted in it being “forgotten” as a useful antimicrobial (Livermore & Tulkens, 2009).  It 
fails to induce β-lactamase production and should not, therefore, show antagonism when 
tested or used in combination with other antimicrobials.  The problem resulting from this 
stability (temocillin is able to prevent the activation of serine preventing haemolysis), is that 
its binding to PBPs is dramatically impaired.  The principal binding site for this 
antimicrobial is PBP 3 – and this may be one of the reasons for its lack of activity against 
Gram positive organisms (Livermore & Tulkens, 2009).  Temocillin however, is considered 
to be one of the most active antimicrobials when compared with meropenem, imipenem, 
piperacillin and ceftazidime and has been shown to be of benefit in pulmonary exacerbations 
of CF (Lekkas et al, 2006).  Cross-resistance is rarely seen with other β-lactam antibiotics, 
and temocillin can be administered twice daily – making it a convenient and useful 
antimicrobial (Lekkas et al, 2006).  Temocillin has been used for a number of years and has 
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been shown in that time to be useful against both Pseudomonas and Burkholderia species 
(Taylor et al, 1992, Lekkas et al, 2006).  Whilst Pseudomonas species do have a high MIC 
to temocillin – possibly related to their efficient efflux, reduced binding and poor 
penetration; Burkholderia spp have in some studies, also been shown to be more susceptible 
to temocillin than to other β-lactam antimicrobials.  MIC90s of 32 mg/L have been reported 
(Livermore and Tulkens 2009).  Temocillin is usually administered via a continuous 
infusion, and evidence suggests that high doses can be tolerated, and it is recommended as a 
specialist agent for patients with ventilator associated pneumonia, and where ESBL 
producing organisms are suspected.   
Temocillin is resistant to many of the extended spectrum β-lactamases such as TEM, SHV, 
and CTX-M enzymes as well as AmpC (Livermore and Tulkens, 2009).  It has been used in 
cases of colonisation of CF patients with B. cepacia and a clinical improvement was 
observed.  Even in cases where temocillin was resistant in-vitro, a clinical improvement was 
noted – indicating that temocillin may still be useful at high MIC values (Taylor et al, 1992).   
3.10 Tigecycline 
 
Tigecycline (formerly GAR-936) is the 9-t-butylglycylamido
 
derivative of minocycline, a 
new antimicrobial in the glycylcycline class and exhibits broad spectrum activity against 
extended β-lactamase producing organisms.  It was first licenced in 2005 by the US Food 
and Drug Administration.  Resistance to other tetracyclines usually occurs as a result of 
alterations to the tetracycline efflux pump or ribosomal protection.  Tigecycline has been 
developed to overcome these mechanisms and does so by evasion of the Tet (A-E) efflux 
pumps.  Tigecycline also attaches to the Tet (M) related ribosomes – possibly in a different 
orientation to previous tetracyclines – thus avoiding the resistance conferred by this 
mechanism, though it has been noted that tigecycline is likely to be susceptible to some 
multidrug efflux pumps such as those found in Pseudomonas species (Livermore, 2005).  It 
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has been shown to be effective against both Gram negative and positive organisms, and does 
not show toxicity to patients with renal impairment (Kasbekar, 2006).  Activity has been 
demonstrated against relevant isolates such as Stenotrophomonas maltophilia and 
Acinetobacter spp.  Tigecycline is able to bypass many resistance mechanisms including the 
multidrug efflux pump mechanism (Pankey, 2005a, Pankey, 2005b).  Studies have found, 
however, that this antibiotic agent shows only limited activity against Proteus spp and 
Pseudomonas aeruginosa (Milatovic, 2003).  Tigecycline is considered to be a useful 
alternative for use against CTX-M producing E.coli.  This is particularly useful as 
tigecycline is currently licenced for use in complex intra-abdominal infections as it shows 
excellent penetration into soft tissues. 
Tigecycline works by binding to the 30S ribosomal sub unit – thus blocking the entry of 
tRNA.  This mechanism, therefore, prevents protein synthesis by interrupting or halting the 
building of amino acids into peptide chains.  The affinity of tigecycline to the ribosomal 
subunit is increased by up to five times by the addition of an N,N,-dimethylglyclamido 
group at the nine position of the minocycline molecule (Greer, 2006).  It is not subject to 
efflux or ribosomal protection mechanisms and is active against organisms that, under other 
circumstances, would demonstrate tetracycline resistance determinants (Petersen et al, 
2006). 
3.10.1 Susceptibility testing 
 
Tigecycline is notable in that it shows some variation when tested upon different media.  
MICs have been found to be one dilution higher when tested on Mueller Hinton agar instead 
of isosensitest agar, though how this translates to clinical practice is as yet unclear.  
Likewise, stored broths or long term stored media may render the drug more prone to 
oxidative damage though this is not noted to affect either disc testing or E-testing 
(Livermore, 2005). 
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Chapter 4 
4.0 In-vitro synergy testing of organisms by E-test 
 
The recommendation made by Peterson & Shanholtzer (1992) with regard to antimicrobial 
testing in the laboratory was that it should be reproducible, standardized and clinically 
relevant – this is still particularly relevant and presents numerous problems for testing in CF.  
They recommended the use of serial dilution methods that match as closely as possible the 
likely concentrations achievable in-vivo.   
 
Fig 4.1 E-testing both alone (top left) and in combination (tob right and bottom) – 
note the combination elipse (see Chapter 5 for detailed method). 
This was not recommended for routine testing but for on-demand testing where the clinical 
need was apparent.  Additionally, it was suggested that these results should not be taken at 
face value, and that a clinical interpretation would have to be applied before patient 
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treatment commences.  One of the interesting points made was the idea of reproducible and 
standardised serial dilution tests carried out in the laboratory.  The E-testing method used in 
this study is the modern equivalent of this and can be seen in Fig 4.1 above.  
The E-test – or “epsilometer” is an agar diffusion method that uses a concentration gradient 
of a selected antimicrobial substance.  This is placed onto an agar plate inoculated with the 
target organism and is then incubated overnight.  The result is an elliptical zone that 
intersects at the minimum inhibitory concentration of the gradient – the MIC (Fig 4.1).   E-
tests are available for most antimicrobials and are a quick and useful method of MIC testing 
for the non-specialist routine laboratory (White et al, 1996).   
Synergy has, in the past, been determined by older established methods: checkerboard and 
time kill assays. 
The checkerboard assay uses serial twofold dilutions of two antibiotics of different classes.  
These dilutions span the entire range of antimicrobial MICs from susceptible to resistant.  
The calculation used to determine synergy is identical to that used for E-testing.  The time 
kill assay uses a similar method of broth dilutions but the concentrations differ slightly – 
reflecting ¼ to 2x the MIC for the test antibiotic when used with the particular bacterial 
species.  These are then incubated overnight and sub-cultured at 0 h and 24 h respectively.  
The resulting colony count is used to define synergy (which is defined as ≥ 100 fold 
decrease in colony count at 24 h when compared to the original inoculum).  Concordance of 
results has been demonstrated with the older methods and the E-tests and there are a number 
of studies where all three methods have been compared (Saiman, 2007).  One example is a 
study by White et al (1996) where comparisons were made, and the E-test/checkerboard 
method were found to have between 75% and > 90% concordance, with similar results 
recorded between the E-test method and the time-kill assay (Bonapace et al, 2000; Orhan et 
al, 2005; Balke et al, 2006) though there have been occasional instances where this has not 
occurred. Further studies have been carried out with specific organisms – of note, a large 
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study of S. maltophilia where 94% concordance with the traditional broth microdilution 
method was found over a range of 176 isolates and sixteen antibiotics (Yao et al, 1995).   
The E-test method, whilst relatively simple, remains a novel method for synergy testing and 
is not in general use within routine laboratories (Balke et al, 2006) and there is some 
disagreement whether this situation should change in the future (Saiman, 2007).  In a small 
number of studies, however, E-tests have been shown not to agree with previously used 
methods, though a number of possibilities exist that may cause these discrepant results.   The 
checkerboard method demonstrates inhibition of bacterial growth using a microtitre plate 
assay with synergy being calculated in a similar way to that of E-testing (Anonymous, 1996; 
Orhan et al, 2005; Pankey and Ashcraft, 2005).  The time-kill method, however, measures 
the quantitative extent of killing.  Both methods have some detractors and are time 
consuming (White et al, 1996).  Other limitations include the relative concentrations of a 
given antibiotic along with the quality/quantity of inocula.  If the concentration of the given 
antibiotic does not affect the growth curve, then it is difficult to determine whether any 
effect is additive or synergistic and this can only be determined by the use of a standardised 
equation that may be seen as being subjective (Moellering, 1979).  In addition, the drug 
concentration is fixed in the time-kill assay.  In-vivo, the concentration would steadily fall.  
Combined with the lack of standardised concentrations, this produces yet another limitation.  
Re-growth of organisms is a possibility where sub-inhibitory concentrations are selected.  
This, again, can skew the results in any type of broth culture (Pankey et al, 2005).  It is well 
documented that where a checkerboard assay is carried out, the results would need to be 
confirmed by time-kill assay (Petersen et al, 2006). The generally good agreement between 
E-test synergy and that seen using both checkerboard or time kill assays has lead a number 
of investigators to use the E-test method for determining synergy and antagonism.  It is true 
to say that the checkerboard and very time consuming time kill assays together do show both 
synergy and the trend for it over time (when combined) – giving a true reflection of the 
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extent of any synergy.  It was also suggested by Petersen et al (2006) that the checkerboard 
assay alone, may overestimate synergy where a bacteriostatic agent is tested in combination 
with a bactericidal agent.  
Table 4.1:  Benefits and disadvantages of various synergy test methods 
(adapted from Saiman, 2007) 
       
   
Benefits   Disadvantages 
 
Checkerboard  Easy, uses clinical Tests bacteriostatic activity 
 
Dilution   concentrations       
 
Multi 
Combination Tests Bactericidal May not reflect concentrations 
 
Bactericidal 
Testing activity   
in vivo, may not correlate 
clinically 
 
Time-Kill Tests bactericidal activity 
Time consuming, tests limited 
no 
 
    CLSI defined method of agents   
 
E-Testing Commercially available, can be Bacteriostatic concentrations 
 
    performed routinely     
 
E-testing, however, is not only less time consuming, it is also far more practical in the 
routine laboratory and warrants further use (Principe et al, 2009).  The advantages and 
disadvantages of each method used for synergy testing can be seen in Table 4.1 (adapted 
from Saiman, 2007) 
The E-test synergy method uses a concentration that is equal to the MIC for each drug.  This 
MIC matching demonstrates, clearly, any additive/synergistic effect – or, indeed, any 
antagonistic behaviour.  It also allows, on solid media, the scientist to view any resistant 
sub-populations.  This is not possible in the time-kill assay, as it uses a liquid culture system.  
Pankey et al (2005) found that by using the combination elipse effect of the E-testing 
method, the results were much easier and more practical to review visually.  This is true of 
low MIC synergy that may be more difficult to detect in the checkerboard assay.  Where 
organisms are sensitive to the antibiotic in a broth culture, then synergy cannot be detected.  
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The E-test method, using solid media, means that even in this situation, the user can view 
the differences in MIC (Principe et al, 2009).  
E-testing has been found to be practical, consistent and relatively cheap when compared to 
other tests.  It shows very good concordance with other methods and, whilst still a novel 
method for synergy testing, is likely to become the de-facto standard method for future work 
(Manno et al, 2003; Pankey et al, 2005; Petersen et al, 2006; Saiman 2007, Principe et al, 
2009)). 
4.1 Clinical relevance of synergy testing 
 
The rationale behind synergy testing is a complex one.  One of the non-clinical issues is the 
lack of drug development vs. the emergence of bacterial resistance.  The high cost of 
development of antimicrobials prohibits their development as pharmaceutical companies 
only reap a low rate of financial gain when compared with other products (Saiman, 2007).  
Clinically, it is generally undesirable to use more antibiotics than is absolutely necessary – 
not just for cost implications, but also to reduce toxicity to the patient (Eliopoulos & 
Eliopoulos, 1988).  However, it has been demonstrated in some cases that antimicrobials 
may have a positive clinical outcome even where they are noted to be resistant in-vitro 
(Denton & Kerr, 1998; Saiman, 2007).  For this reason, synergy testing and the resultant 
combination therapy may be another tool that brings about successful clinical outcomes.  
Where combinations are antagonistic, however, then treatment failure may be likely and 
synergy/combination testing may be able to prevent these combinations from being used 
(Manno et al, 2003). 
Antibiotic resistance is a difficult term to define since it is almost entirely dependent upon 
the dosage that can be tolerated in-vivo without overbearing toxicity (Smith et al, 2003).  
Those organisms with an MIC above this level may be termed as resistant, whereas those 
with an MIC below it may be termed sensitive.   It may often be found that the MIC of one 
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particular infecting organism will also be sufficiently high, that it exceeds that of other 
organisms or strains of the same organism that are present.  The net result of this is that the 
other organisms/strains may be eradicated, adding a selective pressure towards further 
resistance.   Where multiple combination therapy is used, this problem can be prevented by 
effectively taking a multi-pronged approach that prevents the emergence of a single resistant 
strain.  A definition of CF related multiple resistance was made by the CF Foundation 
Microbiology and Infectious Disease Consensus Conference in 1994. It stated that multiple 
resistance was the “resistance of a bacterial organism to all agents in two of the following 
classes of antibiotic: the β- lactams, the aminoglycosides or the quinolones” (Aaron, 2007).  
It should also be noted that of the many studies that have been carried out to test antibiotic 
resistance – both individually and in combinations, many use isolates from different sources 
– for example, some studies select their isolates on the basis of multi-resistance, others on 
invasiveness or other markers.  This can skew results, with the end product being a number 
of studies that are seemingly trying to achieve the same goal but differing in their outcomes 
and opinions (Bonacorsi et al, 1999). 
Susceptibility testing is long established in the microbiology laboratory.  This testing, 
however, is almost exclusively aimed at single antimicrobial agents and is indicative of 
monotherapeutic success.  Where organisms such as Burkholderia cepacia are involved, it is 
common to see pan-resistance – rendering single antibiotic testing methods obsolete (Aaron 
et al, 2005).  Indeed, single antibiotic testing may not be representative in cases of CF as it 
will show that most, if not all, antibiotics are resistant.   Combination testing may be the 
only useful way of demonstrating antimicrobial activity in-vitro and thus informing future 
management of these vulnerable patients (Aaron et al, 2000). Concomitant use of multiple 
antibiotics is common in cases of multiple resistance – especially colonisation by Bcc and 
other colonisers such as P. aeruginosa.  Studies have demonstrated that where the additive 
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or synergistic effects of antimicrobials occur, the clinical outcome may be improved – 
though it is difficult to separate the two effects (Bonacorsi et al, 1999).  
It has been demonstrated in past studies that synergistic combinations of antibiotics can have 
a beneficial effect.  In conditions such as endocarditis (Enterococci) and instances of Gram 
negative sepsis (White et al, 1996) certain groups of antibiotics, such as combinations of β-
lactam and aminoglycosides, have repeatedly been shown to improve outcomes – giving 
enhanced therapy (Eliopoulos & Eliopoulos, 1988; Smith et al, 1999).  
A study carried out in 2006 by Balke et al, whilst not testing in-vivo, found that synergy in-
vitro was not an independent phenomenon.  Strains of Pseudomonas aeruginosa that 
demonstrated synergy between two antimicrobials (in this case between ceftazidime and 
tobramycin), would also correlate with other strains that were found to behave in the same 
way when tested with the same combinations.  In short, the synergy was re-producible with 
unrelated strains (but not necessarily between species - see below).   This may, however, be 
more of a problem with CF isolates of Bcc spp and other non-fermentative multi resistant 
Gram negative bacilli, due to the presence of multiple morphotypes and their proven ability 
to differ in a seemingly random way in their antimicrobial susceptibilities (Foweraker et al, 
2009). 
Whilst the findings of previous work demonstrate that MIC testing in the routine laboratory 
is an excellent predictive indicator of likely clinical outcome in most organisms, there are 
notable exceptions – including many of the organisms seen in CF patients (Smith et al, 
2003).  The relevance of antimicrobial testing in CF patients, therefore, has been questioned 
in a number of studies (Smith et al, 2003; Aaron et al, 2006; Etherington, 2007; Aaron, 
2007, Fowraker et al, 2009; Keays et al, 2009; Fowraker et al, 2010).  It has been 
demonstrated that environmental colonisers such as Pseudomonas and Burkholderia are 
often present in multiple morphotypes – each with a different antibiogram.  It is very 
difficult, therefore, to obtain consistent and repeatable MIC data for these organisms as each 
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subsequent testing may select another colonial variant that, to the microbiologist, visually 
appears to be the same as the rest (Doring et al, 2000; Smith et al, 2003; Fowraker et al, 
2010) giving variable results that may mislead the clinician.   
One of the most recent studies to investigate this variability found that P.aeruginosa was 
represented by a mean four morphotypes per sputum sample – and three antibiograms per 
morphotype.  This huge variability makes CF sensitivity testing very challenging, and the 
interpretation of sensitivity patterns almost impossible (Fowraker et al, 2010).  This 
variability in susceptibility testing along with unpredictable outcomes brings into doubt the 
clinical relevance of such testing in this group of patients.  Whilst a number of different 
methods of testing are recommended (such as combining morphotypes in a single 
susceptibility test, or testing each individually), it was found that no single method was able 
to produce reliable results that correlated directly – resulting in an underestimation of 
bacterial resistance patterns (Fowraker et al, 2010).  A number of studies where testing and 
outcome have been compared have found no correlation – including a study carried out in 
2003 by Smith et al, using Pseudomonas aeruginosa as the model organism.  This was a 
retrospective study using patients from the placebo group of a phase 3 trial of nebulised 
tobramycin.  Clinical outcomes were measured using the FEV1 and spirometry both before 
and after intervention.  Their results found that there was no statistical correlation between 
susceptibility results in-vitro and clinical outcome.     
This was not the first study to draw these conclusions.  An earlier study by Peterson & 
Shanholtzer (1992) also found similar deficiencies in the correlation between in-vitro testing 
and the clinical outcome.  In their study, an animal model was used where a membrane was 
inserted that would restrict the flow of natural immune factors and other potential 
confounders.  This meant that the MBC in-vivo could be tested with some accuracy.  They, 
with a number of other previous studies, found that it was difficult to predict the outcome by 
use of in-vitro testing.  Additionally, they found that different sites and origins of pathogens 
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would also affect the accuracy of this kind of testing – citing an example of a 
Staphylococcus taken from a foreign body in a thigh wound.  It was found that the 
organisms from the foreign body were more resistant than the parent organisms when tested 
in-vivo.  They commented that ultimately, it is difficult to replicate in-vivo the conditions 
that are observed in-vitro.  One of the issues that they highlighted was the variation from 
patient to patient, where any correlation calculated or perceived, would likely differ between 
patients.  Resistance or tolerance of organisms (defined as a bacteriostatic effect where, 
under normal circumstances the effect would have been bactericidal) further confounds the 
picture.  It was found in a study by Goldman & Petersdorf (1979) that simply changing the 
medium in which the organisms are tested can influence the phenotypical expression of 
resistance/tolerance.  In their study, the tolerant organism – Staphylococcus aureus (when 
tested in tripticase soy broth) became sensitive when tested in a different medium (Mueller-
Hinton broth).  This variable expression of resistance can be a major factor when 
considering the correlation of in-vitro testing to in-vivo outcomes (Peterson & Shanholtzer, 
1992).  Studies have been carried out to assess different ways of testing in-vitro that may 
match more closely the in-vivo situation in CF patients.  One such study was carried out by 
Keays et al (2009) where a biofilm model was used.  They found that where patients receive 
antimicrobials to treat exacerbations, it was unlikely that organisms would be eradicated 
completely as antibiotics had been tested upon planktonically grown bacteria.  Where 
antibiotics were tested upon bacteria grown in biofilms, the results of antimicrobial testing 
were notably more positive and where the biofilm model was used to inform clinical 
management of patients, improved outcomes were observed against Pseudomonas 
aeruginosa, but not against Bcc species.  It is clear that more work will be needed to 
investigate this further, but a number of authors are now beginning to agree that something 
has to be done to make testing more representative (Saiman, 2007).   
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Whilst the E-test synergy method has yet to be officially standardised and clinical 
correlation is unclear, it does appear to be a promising method for the routine laboratory 
where single organisms are implicated (Pankey et al, 2005).  There are studies that have 
found in favour of synergy testing with good correlation to clinical outcomes, but equally 
the opposite is also true.  Ultimately, the outcome of synergy or MIC testing can only be 
measured in terms of patient outcomes and successful treatment – though in CF, this is 
somewhat open ended.  To this end, it is well documented that the correlation between such 
testing is unclear – and this is of particular relevance where long term antimicrobial 
chemotherapy (such as in CF cases) is to be considered (Smith et al, 2003).  One of the most 
recent studies where correlations were taken into account was carried out by Foweraker et al 
(2009).  This was a small study using Pseudomonas aeruginosa as their subject organism, 
but demonstrated many of the same issues as found with other CF related pathogens – such 
as polymorphic susceptibilities from apparently pure cultures.  Their study found that 
differing methods of testing actually produced different susceptibilities – further throwing 
doubt upon the usefulness of MIC and combination testing.  Additionally, as they tried to 
correlate response to their testing, they found that no single method was predictive of 
outcome.  It is difficult to assign the appropriate weight to this study, as it was limited in 
size – though thoroughly carried out.  To this end, it was suggested by Smith et al (2003) 
that whilst a correlation is not detected within their own statistical confidence intervals, this 
does not conclusively indicate that it does not exist.  The possibility of better correlations 
may exist where larger numbers are used, though this would be particularly expensive and 
challenging to realise.  This, however, was not the only study to carry out such work; a study 
in 2007 by Etherington et al found that a reduction of susceptibility testing had little bearing 
upon clinical outcomes of IV therapy.  Despite this, however, the authors were unable to 
categorically reject the use of such testing as there were a number of significant areas where 
this may be useful (for example, identifying unusual isolates such as the Bcc species, and the 
identification of multi-resistance for infection control purposes).   
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Clinical failure carries with it a huge risk to the patient.  Many clinicians will be aware that 
such long term treatments will produce resistant bacteria that will make up a percentage of 
any population – and may ultimately be selected for during treatment.  The multiple 
morphotypes that are thus produced – and are commonly seen in CF isolates, may mislead 
the clinician as they will often produce widely differing sensitivity patterns leading to 
uncertain and difficult clinical decisions based on uncertain data.  Many clinicians, 
therefore, will judge clinical failure or success clinically and the results of synergy testing 
overall are only to be used as a guide to the potential of the agent tested (Smith et al, 2003; 
Mariscal et al, 2006).  It can be difficult to judge, however, whether treatment is warranted 
with an antibiotic that has been reported as resistant during susceptibility testing.  Such 
isolates, it has been demonstrated, may still respond clinically (Denton & Kerr, 1998; Aaron, 
2007).    Smith et al (2003) pointed out that there are a number of difficulties that may be 
experienced in assessing whether antibiotics have had the appropriate impact.  It is difficult 
to prospectively carry out such assessments due to the ethical difficulties of withholding or 
using a treatment where susceptibilities suggest otherwise.  The resulting retrospective 
nature of studies, therefore, do not always account fully for confounding factors.  In their 
study, they point out that their only marker of positive/negative outcomes was an increase or 
decrease in pulmonary function.    Inclusion of other clinical factors such as resolution of 
coughs or sputum production would provide further guidance but there are still many factors 
that may be overlooked – such as the timing of treatment (though in the study carried out by 
Smith et al (2003) this was accounted for during their regression analysis), dose regimen and 
other drugs that are being used concurrently.  In their study, Smith et al (2003) found that 
there was no significant trend linking susceptibilities with outcomes (using P. aeruginosa as 
the model organism) though they did stop short at suggesting that no trend existed – only 
that it may not be clinically significant.   
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A double blind, randomised, controlled clinical trial to assess the correlation between 
multiple antibiotic combination testing (MCBT) and clinical outcome, where patients were 
allocated antibiotics either from the more standard single routine testing method, or from 
MCBT was carried out by Aaron et al (2005).  A large number of patients (n = 132) were 
used at the time of exacerbation and a large range of clinical criteria were used to assess 
outcome.  In summary, this very thorough study found that whilst patients certainly did 
improve with antimicrobial therapy, there was no difference associated with treatment that 
was as a result of MCBT.   Whilst MCBT differs slightly in its method of testing (using 
multiple wells and combinations until a successful combination is found that is bactericidal), 
the outcomes can be considered to be very similar – and correlation with clinical outcomes 
apply equally to such testing.   
 Whilst there are a number of studies that suggest no correlation between synergy testing and 
clinical outcome, there are those that do find in favour of such an approach.  In a study 
carried out by Orhan et al (2005), it was found that the synergy results correlated well with 
both treatment regimen/dosage, and clinical outcome.  Petersen et al (2006) suggest that 
despite these problems, where empirical treatment is to be administered, synergy testing 
may at least provide some guidance as to the likely outcome.  At worst, it will prevent the 
clinician from using antagonistic combinations.  This is a position taken by other 
commentators (Mariscal et al, 2006).  Work has demonstrated that combinations are 
anecdotally more likely to deliver improved clinical situations for patients, whilst reducing 
resistance (Saiman, 2007) and some clinicians are very keen to use synergy testing as a 
further tool where there are difficult treatment decisions to be made.  
The clinical relevance of susceptibility testing in CF patients – regardless of method used, 
remains a divisive and unresolved issue and is the subject of much discussion.  
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4.1.1 Previous relevant synergy studies with tigecycline in-vitro 
 
A number of studies have addressed the novel glycycline, tigecycline and its potential to 
exhibit synergy when combined with other antimicrobials.   A review of the literature 
reveals a number of articles citing tigecycline as a potential novel antibiotic agent for use 
against resistant non-fermentative Gram negative bacteria such as Acinetobacter spp (Jones 
et al, 2007), but these are rarely CF isolates and no rigorous testing of MIC has been carried 
out to date in the Bcc or other unusual isolates (Denton & Kerr, 1998; Milatovic, 2003).  A 
large study was carried out and tested tigecycline against a large panel of non-CF organisms 
– including environmental strains of S. maltophilia (Entenza & Moreillon, 2009).  They 
found some synergy (amikacin/tigecycline and colistin/tigecycline), though the net result 
was indifference.  No antagonism was found.   
A feature of many of the studies that, in particular look at the more unusual isolates, is their 
relatively small sample numbers.  This can make it difficult to apply study results to other 
clinical situations.  This is particularly the case in CF which is a very specific disease with 
its own specific clinical problems.  One reason for the low numbers, however, is simply the 
lack of availability of isolates from relevant clinics.  By their very nature, the isolates are 
unusual and, therefore, relatively uncommon.  As such, one must use comparisons with 
some care but some of these studies may be predictive of outcomes in further work as stated 
previously. 
One study in 2009 by Principe et al, used only twenty two isolates of (MDR) Acinetobacter 
baumanii.  They tested levofloxacin, piperacillin-tazobactam, amikacin, imipenem, 
rifampicin, ampicillin-sulbactam and colistin using the checkerboard method rather than the 
solid culture E-test method used in this study.  Some synergy was observed – most notably, 
was that of colistin (8.3%), amikacin (8.3%) and imipenem (8.3%).  
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Demonstrating that these results are likely to be species specific, however, are other studies 
that have found either no synergy or very little synergy when testing with other species.  
One such study (again using relatively low numbers) was carried out by Petersen et al 
(2006).  They found that some synergy between amikacin and imipenem was demonstrated 
against Proteus species.  No synergy was found when tested against Stenotrophomonas 
maltophilia but equally, antagonism, in common with the studies that have been carried out, 
was practically non-existent.  Again, it is difficult to judge the relevance of such a study 
particularly as they used a wide range of organisms but with relatively low numbers of each 
type.  When testing piperacillin/tazobactam in combination with tigecycline, 2/3rds were 
found to show synergy.  The problem here being that there were only three isolates tested in 
this capacity.  Piperacillin was tested alone (without tazobactam) and 3/11 isolates were 
found to demonstrate synergy.  Again, comparing this with the 2/3 isolates tested against 
tigecycline and piperacillin/tazobactam is difficult and any comparison with other studies or 
clinical outcomes must be done with some care. Antimicrobials tested in this capacity 
against S. maltophilia did not demonstrate any synergy (Imipenem, piperacillin – both 0/11 
isolates).  By way of direct comparison, as much as this is possible, with the study by 
Principe et al (2009), colistin (1/9), amikacin (4/9) and imipenem (3/11) were all found to 
demonstrate synergy against Acinetobacter species when in combination with tigecycline.  
This shows some concordance with the previous study, but again backs up the likelyhood 
that synergy is likely to be species specific.  Interestingly, none of the strains in the Petersen 
study showed antagonism – demonstrating only synergy or indifference (Petersen et al, 
2006). S. maltophilia, in recent years, has been the target of a number of studies and is a 
difficult problem due its resistance mechanisms.  Synergy studies have suggested that 
multiple combinations may be more effective than simple pairs.  Additionally, higher 
concentrations have not surprisingly, been found to be more effective.  Colistin is noted to 
be more effective than tobramycin or gentamicin when tested at higher concentrations 
(Gabriel et al, 2004).  The study carried out by Gabriel et al in 2004 demonstrated high 
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levels of synergy between a number of groups of antibiotics – some of which are included in 
this study.  Whilst they did not test tigecycline, doxycycline was used and was noted to be 
effective in combination with ticarcillin clavulanate (49% of strains tested).  It is difficult 
from this study to determine the exact route of synergy as they used not only antibiotics, but 
also β-lactamase inhibitors that would further destroy or inhibit resistance to these 
antibiotics.  It was interesting to note the high levels of resistance that the study found (78% 
multiresistant strains) but also that 91% of the isolates tested demonstrated synergy and 
susceptibility to at least one combination that was tested.  How practical it would be to 
routinely test all of these combinations remains an issue to be resolved (Saiman, 2007). 
A multiple organism study carried out in 2007 by Vouillamoz et al, found that most 
reactions between tigecycline and other antimicrobials demonstrated indifference.   Whilst 
this was a promising result in terms of drug-drug interactions, it did mean that the additive 
or synergistic effect of other antimicrobials may be negligible in-vivo.  Where limited 
amounts of synergy occurred (for example between tigecycline and co-trimoxazole versus 
S.maltophilia), they were found to be of an uncertain and possibly non-specific nature across 
species.  This makes interpretation of such interactions difficult – especially when trying to 
correlate this to clinical outcomes.   
A study by Petersen et al (2006) failed to observe any antagonism where tigecycline was 
tested in combination with other antimicrobials (including some of those tested in this 
study).  Petersen et al (2006) found that synergy occurred when tigecycline was combined 
with minocycline.  Petersen et al (2006) found higher levels of synergy in their panel of 
Gram negative bacteria (for example, amikacin 56%; piperacillin/tazobactam 50%).  Given 
that this panel of bacteria did not include the Bcc species, it is difficult to directly compare 
these results.  They did, however, test S. maltophilia, and it should be noted that no synergy 
to their combinations was observed in this case.  The study was marred a little by low 
numbers, but may demonstrate that where organisms are in possession of multi resistance 
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mechanisms, the effect of synergy may be effectively diluted.  This may explain why 
previous studies have observed these “higher” levels of synergy.  Alternatively, however, 
one cannot discount the effect of low numbers.  In our group of “other” Bcc species, we had 
similarly low numbers which meant that a single organism showing synergy would 
disproportionately skew any results given.   
Aaron et al (1999) carried out a large ranging study against Burkholderia isolates.  
Antibiotics, were tested individually and in combinations – including up to triple 
combinations.  They found that the most effective antimicrobials against Burkholderia were 
ceftazidime, meropenem and high dose tobramycin.  In double combination, the most 
effective pairs were meropenem-minocycline, meropenem–amikacin, meropenem-
ceftazidime, meropenem-tobramycin and tobramycin-ceftazidime.   The antagonistic 
interactions of the antibiotics in this study demonstrated the extent to which this can occur.  
Antagonism where meropenem, ceftazidime and tobramycin had a second antibiotic added 
was fairly widespread – ranging from 65% with ceftazidime to 31% with meropenem or 
tobramycin.  The study did demonstrate, however, that the addition of a third antibiotic 
could negate this antagonistic reaction.  Where triple antibiotics were tested in combination, 
these were often the most effective.  
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4.2 Aim and objectives of the project 
 
4.2.1 The setting 
 
The Leeds Teaching Hospitals NHS Trust runs the second largest CF Centre in the United 
Kingdom – covering a large population and geographical area.  The Centre cares for 
children and adults with CF from a catchment area covering the North, East and West of 
Yorkshire, including ten district general hospitals. The service provided by the CF units are 
fully integrated with other specialist departments such as paediatric intensive care, transplant 
wards and also oncology units. The clinics and wards offer both in-patient and out-patient 
referrals and are among the best equipped in the UK.   
 
It can be very difficult with the unusual isolates found in CF patients, to select an empirical 
therapy.  Courses of antimicrobials are relatively expensive and are prone in some cases, to 
failure. The multiple resistance factors possessed by many of these organisms mean that 
resistance rates are high and susceptibility cannot be reliably predicted.  Combination 
therapy is therefore frequently used, and this study aims to look at tigecycline in 
combination with other agents so that it might inform clinicians in their future selection of 
treatment (Aaron et al, 2000).  Indeed, previous randomised, placebo controlled trials have 
shown that combination therapy is more effective against resistant colonising organisms 
such as Pseudomonas species (Aaron et al, 2000). 
The overall aim of this project was to ascertain the in-vitro activity of tigecycline against 
clinical strains of multi resistant Gram negative bacilli (including B. cepacia complex, 
S.maltophilia and others) isolated from CF patients.   
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4.2.2 Specific objectives 
 
1. To identify, from a 10-year retrospective collection of multi-resistant isolates from CF 
patients, duplicate organisms (and possible epidemiological clusters) using PFGE.  
2. To obtain the MIC of tigecycline and other commonly used antibiotics against a panel of 
clinical strains isolated from CF patients over a 10 year period.   
3. To demonstrate the interaction between tigecycline and other commonly used antibiotics 
that are used to treat CF patients, using an in-vitro synergy model of E-testing and fractional 
inhibitory concentration calculation. 
4. To improve the holistic service given to CF sufferers within the Leeds Teaching 
Hospitals NHS Trust.  This will be a direct result of the fuller understanding of the efficacy 
of tigecycline, both alone and in combination, in the treatment of patients with chronic 
colonization.   
5. To inform our local knowledge of the epidemiological spread of these organisms. 
Resistance patterns, in conjunction with the epidemiological information will further inform 
clinicians and their treatment of CF patients. 
 
These objectives were achieved by the scientific calculation and testing of MIC data, and the 
combination testing of organisms/antibiotics taken from the 10 year collection.  It is difficult 
to judge the clinical outcomes and relevance of such data, due to the poorly understood 
correlations between synergy/MIC testing and clinical outcome.  However, this data should 
give an indication as to the likely clinical success and will provide information that may be 
useful for clinicians that treat CF patients on a daily basis.   
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4.2.3 Ethical approval 
 
Ethical approval was applied for and granted by the Leeds Research Ethics Committee (REC 
reference number: 08/h1307/42).  The full response from the LREC can be obtained in 
Appendix 1. 
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Chapter 5 
5.0 Materials and methods  
 
This study was carried out on isolates gathered over the last ten years.  These were 
principally from patients attending the Regional Paediatric and Adult CF Units in Leeds.  
The isolates were identified in the Microbiology Department of Leeds Teaching Hospitals 
NHS Trust (LTHT), with further characterisation of Burkholderia spp and others being 
carried out at the Centre for Infections, Health Protection Agency, Colindale, London, UK.  
Isolates were identified using a number of techniques including 16s PCR and fatty acid 
analysis.  Laboratory type strains were obtained from EuroCare CF (University of Ghent, 
Belgium) and run as controls.  Following identification and purification, all of the isolates 
were stored at -80
o
C in 15% glycerol broth.  Upon testing, a small number of historical 
isolates were irretrievable and were therefore excluded from the study.  
Table 5.1: Final collection of isolates used in this study 
ISOLATE     NUMBER TESTED 
Burkholderia multivorans 31 
 Burkholderia cenocepacia 16 
 Burkholderia stabilis 
 
2 
 Burkholderia viatnamiensis 1 
 Burkholderia gladioli 
 
1 
 Achromobacter xylosoxidans 20 
 Stenotrophomonas maltophilia 47 
 Chryseomonas indologenes 1 
 Chryseomonas 
meningosepticum 1 
 Delftia acidivorans   2 
 Pandorea apista 
 
1 
 Pandorea sputorum   1 
 Pseudomonas 
stutzeri   2 
 Shewanella putrefaciens 2 
 
  
Total 128   
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When drawing conclusions from this work, it should be noted that over this 10 year period, 
these isolates will have recurred in the same patients as they have become colonised with 
them.  Duplicate isolates from the same patients, therefore, were not included in the study as 
they would yield no further, relevant, information.  Additionally, it is not the policy of the 
LTHT Pathology Department to store duplicate isolates, and so only a prospective study 
could address the extra numbers of organisms that would have been required for these to be 
added.   
All of the strains used in the study had been stored in glycerol broth at -80
o
C.  The isolates 
were sub-cultured onto Columbia blood agar (Oxoid) and incubated at 37
o
C for 24 to 48 h 
(depending upon species).  This allowed us to ascertain the purity of these stored organisms.  
All of the organisms used in this study were then re-stocked in glycerol broth for future use.  
Any organisms that were to be used were re-cultured in the same manner as described 
above.  The final collection of strains is listed in Table 5.1 above.  
5.1 Pulsed field gel electrophoresis  
 
Given the scope of the collection, in that it was obtained in a geographically related 
population, it was prudent to type these strains in order to eliminate any duplicates by way 
of relatedness. Pulsed field gel electrophoresis (PFGE), therefore, was used as it is arguably 
the best method for interpreting a wide array of strain types (Tenover et al, 1995).  There are 
likely to be inaccuracies in any system and with bacteria such as those tested in this study, 
point mutations and insertions are a potential confounding factor – often leading to variable 
results.  Using Tenover’s criteria, however, this system can be reasonably accurate for 
predicting relatedness.   Where greater than ten bands exist on the PFGE fingerprint, the 
PFGE profile is considered to be accurate.  The following criteria proposed by Tenover et al 
(1995) were used: 
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Indistinguishable: Related isolates that are likely to be indistinguishable even when using 
other techniques.  This is where all of the bands correspond with each other with no 
distinguishable difference. 
Closely related:  A closely related isolate will differ by only a single genetic event.  Only 2-
3 band differences would be seen in such circumstances where a point mutation or insertion 
has occurred that will create a new restriction site.  Variations such as this are occasionally 
seen when a single isolate is frequently re-cultured or re-isolated from the same site/patient.   
Possibly related: Where two genetic events have occurred, then a difference of around 4-6 
bands will be seen.  This could be explained by the gain or loss of restriction sites resulting 
from two deletions or insertions.  These strains would be considered likely to be from the 
same lineage but not necessarily epidemiologically linked.   
Unrelated:  A difference of three or more genetic events will render an isolate different by at 
least seven bands.  Using Tenover’s assumption of approximate ten fragment accuracy, this 
would represent less than 50% similarity by fragment presence.  
Given the criteria stated above by Tenover, a bionumerics programme was used to calculate 
“relatedness” and the results are presented in Figures (6.1–6.4) respectively.  These 
comparisons were not made for groups such as the “other CF related Gram negative bacilli” 
(GNB) as these groups contain mixed species for information only and any comparison 
would be meaningless. 
 5.1.1 Method for typing by pulsed field gel electrophoresis  
 
Day 1 
Strains were inoculated into 5 mL of tryptone soya broth and incubated for 6 h at 37°C with 
shaking to attain exponential growth. They were then pelleted by centrifugation at 3,000 x g 
for 10 min, and the supernatant discarded (Columbia blood agar purity plates were cultured 
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at this stage). The cells were then re-suspended and washed in SE buffer (25 mM EDTA [pH 
7.4], 75 mM NaCl) before re-centrifugation.  Where mucoid strains were encountered, the 
process was repeated.  After the addition of 0.3 mL EClysis, the cells were again vortexed 
before the addition of 0.3 mL low melting point agarose.  This was gently mixed using a 
Gilson pipette.  This mixture, whilst still warm, was pipette into plug moulds (10 by 5 by 1.5 
mm), allowing time to set at 4
o
C.  The agarose blocks were then removed to bijoux bottles 
containing 1 mL of 1 mg/mL proteinase K in EClysis and then incubated overnight at 55
o
C.   
Day 2 
Purity plates were checked at this stage – if mixed, the process proceeded no further until 
organisms had been purified.   
EClysis was removed from the bijoux containing the agarose blocks.  It was then replaced 
with 3 mL TE buffer.  The blocks (in bijoux) were then placed onto a roller and washed for 
30 mins.  The buffer was then replaced, and the process repeated for a further four times.  
After this, the bijoux containing agarose blocks and TE buffer, may be stored at 4
o
C until 
required.   
Day 3 
Bijoux containing blocks for testing were removed from refrigeration and were washed 
again with fresh TE buffer (3 mL for 15 min).  A block was then removed and cut to size 
(approx 1 mm width) and placed into an Eppendorf tube (gloves should be worn throughout 
this process).  They were then placed in 750 mL of restriction digest buffer H (50 mM Tris-
HCl, 10 mM MgCl2, 100 mM NaCl, 1 mM dithioerythritol [pH 7.5]) and washed again for 
15 min with rolling.  Fresh H buffer was used to replace the previous buffer, SpeI restriction 
endonuclease (Boehringer, Mannheim, Germany) was added, and plugs then incubated at 37 
°C for 6 h.  SpeI was used as this cuts clearer restriction fragments and is the recommended 
restriction enzyme for Burkholderia species (Anderson et al, 1991; Tenover et al, 1995). 
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Whilst this process is ongoing, a fresh TBE Buffer was prepared.  One g PFGE agarose was 
then added to 100 mL TBE Buffer.  After melting in a microwave (1 min followed by 30 s 
bursts) the resulting mixture was left to cool slightly.  During this phase, the pre-prepared 
blocks were added to a gel comb and the locations recorded.  The PFGE agarose was then 
poured into the gel cassette and left to set for approximately 30 min.  The TBE buffer was 
added to the PFGE tank and cooled to 14
o
C.  
Electrophoresis was performed using the contour-clamped homogeneous electric field DRII 
system (BioRad Laboratories) over 21 h at 14°C with 5 to 35 s of linear ramping at 6 V/cm. 
Lambda ladder was incorporated as a size standard along with a number of laboratory strain 
controls. Electrophoresis products were visualized by ethidium bromide staining, and 
patterns compared by eye and a gel documentation system. Interpretation was based on the 
criteria of Tenover et al (1995).   
5.2 Determination of MIC 
 
Once multiple isolates had been removed, then the remaining collection was subject to MIC 
determination (Pankey & Ashcraft, 2005).  This was carried out by the use of E-testing 
(method in accordance with manufacturer’s guidelines, AB Biodisk, Solna, Sweden).   
MICs were determined on the following antibiotics: aztreonam, amikacin, ceftazidime, 
ciprofloxacin, colisitin, meropenem, minocycline, piperacillin-tazobactam, temocillin, 
tigecycline, tobramycin.  These antimicrobial agents were chosen for their potential 
chemotherapeutic relevance to CF patients.  Other antibiotics noted to be successful against 
the organisms were not necessarily relevant to this study – for example chloramphenicol.  
Whilst useful against S. maltophilia, it is noted that many patients at risk of infection from 
this organism, also have other haematological risk factors and thus would be at risk of 
severe further complications from using this antimicrobial (Denton & Kerr, 1998). 
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5.3 In-vitro E-test synergy testing 
 
Synergy testing was carried out using the method described by Pankey & Ashcraft (2005).  
A combination of two E-test strips was used and the test was performed in duplicate to 
ensure sufficient rigor from which to draw conclusions.   
Briefly, the method used involved fresh cultures of the target organisms.  The organism was 
lawned evenly onto plain Muller Hinton agar (OXOID) and the first strip applied.  The MIC 
of the organism to this particular strip was marked on the agar using a straight wire, and the 
strip was left to incubate at room temperature for 1 h in order to ensure sufficient diffusion 
of the antimicrobial agent.   
After 1 h, the strip was removed and replaced with the second antimicrobial.  The MIC 
(previously determined) of this strip was lined up to match that of the previously applied 
strip.  The rationale behind this being that the resulting ellipse (where indifference is 
observed) should line up precisely at the previously recorded MICs for the target organism.  
Where additive or synergistic results were seen, the ellipse would have moved to a lower 
point of the strip than that previously recorded.  The strips were applied in the reverse order 
during repeat testing to eliminate any experimental bias.   
The net result of this testing method was to determine an in-vitro MIC based upon the use of 
tigecycline in combination with other antibiotic agents.  It identified where synergy occurs 
(increasing its effectiveness), and where antagonism occurs (this will decrease the 
effectiveness of tigecycline in combination with these antimicrobial agents). 
Tigecycline was tested in combination with the following antibiotic agents: aztreonam, 
ceftazidime, ciprofloxacin, colistin, meropem, piperacillin-tazobactam, temocillin 
tobramycin. 
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Minocycline and amikacin were not tested further as minocycline is an analogue of 
tigecycline and would not currently be used combination.  Amikacin has been demonstrated 
in previous studies to be less effective than tobramycin (this was also found during MIC 
testing) and in order to cut down duplication of antibiotic groups, tobramycin was used to 
represent the aminoglycoside group (Bonacorsi et al, 1999).  
The summation fractional inhibitory concentration (FIC) was calculated for each set of 
MICs using the recommended method by the Journal of Antimicrobial Chemotherapy 
(ANON 1999) and other authors (Pankey & Ashcraft 2005, Saiman 2007).   
The calculation of FIC was by the following method:  
FIC of drug a = (MIC drug a in combination)/(MIC drug a alone) 
FIC of drug b = (MIC drug b in combination)/(MIC drug b alone) 
ΣFIC = FIC of drug a + FIC of drug b. 
Synergy was defined by a ΣFIC of ≤ 0.5  
Antagonism was defined by a ΣFIC of > 4.0 
Interactions represented by a ΣFIC of > 0.5 but ≤ 4.0 were to be termed indifferent (Pankey 
& Ashcraft, 2005). 
5.3.1 A brief note on calculation of synergy 
 
An inevitable question will be raised regarding the calculation of synergy, and indeed the 
validity of the calculations.  Whilst it falls outside the scope of this study to devise the 
optimum method of calculation, we did note that this calculation is a seemingly arbitrary 
method of determining synergy. The difficult question in this situation is to ask “what 
actually defines synergy” – a quantitative measurement that to one individual may mean 
something entirely different than that to another. In the case of the calculations used, 
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synergy is loosely defined as a four-fold reduction in the MIC of each agent alone, when 
compared with that in combination (i.e. the combination is more efficacious).  As mentioned 
previously, there are a number of different ways of expressing this data, but ultimately, these 
all stem from the same calculations and use the same cut-off points.    To this end, we did 
attempt to determine the origin of the calculations.  We noted that the trail ended in most 
journal articles, at the Journal of Antimicrobial Chemotherapy (Anon, 1999) where the 
equation was published under an anonymous author as part of their guidelines for 
submission of scholarly articles.  All of the other papers that we reviewed as part of this 
study either independently used the same calculation without reference to previous work, or 
referenced the article above.  Finally, we noted a journal article that compared a number of 
different calculations, (Saiman, 2007) with the result that we deemed that this calculation 
was valid for our purposes.  It should be noted, that in favour of this decision, is the fact that 
all other authors submitting work to respectable journals such as Journal of Antimicrobial 
Chemotherapy, are using the same method.  To this end, we can be reassured that the work 
is standardised and comparable to other work published in this field.   
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Chapter 6 
6.0  Results 
6.1  Typing by pulsed field gel electrophoresis 
 
The pulsed field gel electrophoresis (PFGE) demonstrated that whilst there was some 
clustering of isolates, they were all generally unrelated.  It has been demonstrated in 
multiple studies that whilst these organisms may have been isolated in the same CF clinic, it 
is almost impossible to tie them together epidemiologically and for this reason, no isolates 
were excluded from the study on the basis of the PFGE results alone (Denton & Kerr, 1998; 
Andersen et al, 2007). A small number of isolates were untypeable by PFGE despite 
repeated attempts.  These, therefore, also remained in the study. 
 
Fig 6.1:  Pulsed field gel electrophoresis comparison of B.cenocepacia isolates 
Fig 6.1 shows the PFGE comparison of the Burkholderia cenocepacia isolates (number in 
the right hand columns of each of these figures represent those assigned at their time of 
storage within the laboratory).  This group encompasses the IIIA, IIIB genomovars and, 
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within these, the ET12 epidemic strain (n = 3 (one of which was untypeable by PFGE and 
does not appear in Fig 6.1 above)).  The second group of isolates that show around 90% 
relatedness are notable in that they have an average of 4/5 band differences.  By Tenover’s 
(1995) criteria, 4-6 bands difference suggest possible relatedness.  As with the B.multivorans 
isolates however, there are some subtle differences in MIC for some of these isolates.  
B.cenocepacia numbers “34” and “38” whilst being in the order of 90% relatedness, 
demonstrated significantly differing MICs almost across the board.  As with the 
B.multivorans isolates, it seems prudent to rate these strains as being different from each 
other.  B. cenocepacia numbers “31” and “32”, however, are the most closely related isolates 
in this study with approximately 100% relatedness both by bionumerics calculation, and 
Tenover’s criteria.  It is significant to note also that the MICs of these organisms do not 
appear to differ.  These organisms were tested further as part of the experimental protocol 
(since the relatedness of these isolates is not a foregone conclusion) and minor differences 
were found in the synergy testing.  These isolates, therefore, were retained as it was judged 
that they would not influence, unduly, the final outcome of the trial. 
Fig 6.2 shows the comparison of Burkholderia multivorans isolates.  Using the bionumerics 
programme, it can be seen that the closest related isolates are isolates “52” and “71” at 
approximately 90% relatedness.  By Tenover’s criteria, we would consider these two 
isolates to differ by six bands meaning that, at best, they are “possibly related”.  The next 
nearest pair are around 88% related as calculated by the bionumerics programme.  Again, 
here we see approximately eight bands difference which, by Tenover’s criteria, would make 
these strains “unrelated”.  These results imply, therefore, that only 12.5% of B.multivorans 
isolates tested are potentially related in some way.  Equally, it may be said therefore, that 
87.5% of isolates are clearly unrelated.  Comparison of MIC data shows that isolates 52 and 
71 differ in most of the antibiotics tested, thereby backing up the assumption that these two 
isolates are, in fact, unrelated.  
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Fig 6.2: Pulsed field gel electrophoresis comparison of B.multivorans isolates 
As with previous groups of isolates, the Achromobacter isolates proved to be largely 
unrelated – with the closest of the group being in the order of around 88% similarity.  One 
pair, however, did have identical PFGE profiles.  This pair were not excluded, however, on 
account of having differing MICs to a wide range of antimicrobials.  As with previously 
similar isolates, the full range of synergy testing was also carried out and differences 
between the two isolates were observed (for example, isolate “A9” demonstrated synergy to 
the colistin-tigecycline combination, whereas “A8” demonstrated indifference).   
75 
 
 
Fig 6.3: Pulsed field gel electrophoresis comparison of Achromobacter xylosoxidans 
isolates 
Fig 6.4 shows the PFGE comparison of S. maltophilia strains.  The vast majority of these 
strains are clearly unrelated by PFGE.  The closest pair here being “S32” and “S33”.  As 
with other closely related strains, these two strains demonstrated differing MICs to a range 
of antimicrobials, and for this reason these strains were retained in the study.  The next 
closest group were classified by bionumerics as around 90% related and by Tenover’s 
criteria, these would be classified as “closely related”.  Once again, marked differences in 
MIC were observed during the antimicrobial testing protocol, and these isolates have been 
retained.   
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Fig 6.4:  Pulsed field gel electroporesis comparison of Stenotrophomonas 
maltophilia isolates. 
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6.2 MIC/synergy testing 
 
The results of both MIC and synergy testing can be seen in Tables 6.5 and 6.6 respectively.  
In summary, the most effective antimicrobials observed via MIC testing can be seen in 
Table 6.1 below: 
Table 6.1: Pathogen groups and the most effective antimicrobials in-vitro found from 
our study 
SPECIES GROUP Most effective 2nd most effective
B.cenocepacia Minocyline Ceftazidime, meropenem
B.multivorans Minocyline Ceftazidime 
Other Bcc spp Minocycline, meropenem, ciprofloxacin Piperacillin/tazobactam
A.xylosoxidans Minocycline Tigecycline
S.maltophilia Minocycline  Tigecycline
Other CF related GNBs Minocycline Tigecycline
^The small group of “other” Burkholderia species and “other CF related GNBs” have been included in this section, 
though it is acknowledged that sufficient numbers are not present to reach a conclusive definition of 
sensitivity/resistance.  This group, therefore, appears for illustrative purposes only.   
 
6.2.1 Synergy/antagonism by species/group   
 
This section has been included to show the occurrence of synergy/antagonism/indifference 
across isolate groups.  A brief check of the data will indicate that there are general trends in 
the status of the organism (resistant/sensitive) and the occurrence of synergy (Table 6.2).  
Where organisms were resistant or sensitive to the target antibiotic alone, this was compared 
with the occurrence of synergy/antagonism when these antibiotics were tested in 
combination with tigecycline. It would appear that in most groups, synergy occurs where 
organisms demonstrate resistance to the target antibiotic.  Likewise, it would appear that 
antagonism also occurs primarily in these groups of organisms.  The exception to this, are 
the S. maltophilia and “other Bcc” groups. 
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Table 6.2: The occurrence of synergy and antagonism with respect to original MIC 
data 
ORGANISM GROUP MIC OCCURRENCES OF:  
    RESULT Synergy Antagonism 
B. cenocepacia Resistant 9 0 
    Sensitive^ 0 1 
B. multivorans Resistant 24 9 
    Sensitive^ 8 1 
"other Bcc" Resistant 2 1 
    Sensitive^ 6 0 
S. maltophilia Resistant 19 24 
    Sensitive^ 2 13 
A.xylosoxidans Resistant 9 0 
    Sensitive^ 1 0 
^ Includes sensitive intermediate organisms. 
  
6.2.2 MIC/Synergy testing data 
 
The following figures have been included to show comparative synergy/antagonism and 
indifference of each species against combinations of antibiotics.  Each figure represents one 
of the antibiotics tested in combination, and synergy/antagonism/indifference are expressed 
as a percentage. 
 
Figure 6.5 Percentage synergy/indifference/antagonism of isolates tested with 
colistin and tigecycline in combination. 
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Figure 6.6 Percentage synergy/indifference/antagonism of isolates tested with 
ciprofloxacin and tigecycline in combination. 
 
Figure 6.7 Percentage synergy/indifference/antagonism of isolates tested with 
aztreonam and tigecycline in combination. 
 
Figure 6.8 Percentage synergy/indifference/antagonism of isolates tested with 
Tobramycin and tigecycline in combination. 
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Figure 6.9 Percentage synergy/indifference/antagonism of isolates tested with 
temocillin and tigecycline in combination. 
 
Figure 6.10 Percentage synergy/indifference/antagonism of isolates tested with 
ceftazidime and tigecycline in combination. 
 
Figure 6.11 Percentage synergy/indifference/antagonism of isolates tested with 
piperacillin/tazobactam and tigecycline in combination. 
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6.2.3 Burkholderia cepacia complex 
 
Tigecycline demonstrated poor activity against the Burkholderia cepacia complex isolates, 
with only 13% (B. cenocepacia), 3% (B. multivorans) and 25% (other Bcc spp) being 
sensitive.  A greater proportion of these organisms demonstrated intermediate sensitivity 
(19, 32, 15% respectively), though how this would translate into the clinical setting is 
unclear.  Figs 6.12 – 6.14 show how tigecycline interacted with each individual species of 
Bcc tested in this study.   
 
Figure 6.12: Percentage of B. cenocepacia demonstrating synergy/antagonism or 
indifference when in combination with tigecycline 
 
The range of tigecycline MICs was large, indicating significant heterogeneity in our test 
population and possibly reflecting variability in sensitivity within the Bcc population in 
general. 
In comparison, minocycline - the older analogue of tigecycline, demonstrated greater 
activity against the same isolates with 94% of B. cenocepacia, 91% B. multivorans and 75% 
“other” Bcc spp being sensitive respectively.  It also follows, that intermediate 
resistance/sensitivity was much lower than that of tigecycline.  Both the range of 
minocycline when compared to tigecycline, and the MIC50 and 90 were superior, with 
minocycline being less variable within our test populations than tigecycline – possibly 
indicating greater reliability.   
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Figure 6.13: Percentage of B. multivorans demonstrating synergy/antagonism or 
indifference when in combination with tigecycline 
 
Colistin showed minimum activity against the Burkholderia species with only 3% of 
B.multivorans isolates being sensitive.  Whilst Colistin was relatively inactive against the 
Burkholderia isolates tested, synergistic activity was noted.  In Figures 6.8-6.10 above, it 
can be seen that both synergy and antagonism occurred across the Burkholderia species 
groups tested.  Of note, is the fact that occurrences of antagonism in this combination was 
almost equal in proportion to the occurrence of synergy.   
Between 50 and 70% of isolates demonstrated indifference leaving rather a confused and 
variable pattern for colistin in combination with tigecycline.  The activity of ciprofloxacin 
was variable against all isolates in this study.  75% of B. cenocepacia species were resistant 
along with 68% of B. multivorans.  75% of “other Burkholderia spp” were sensitive to 
ciprofloxacin, but the low numbers in these particular isolates as previously stated, preclude 
any real comparison of this pattern with other Burkholderia cepacia complex species tested 
here. 
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Figure 6.14: Percentage of Bcc “other” strains demonstrating synergy/antagonism or 
indifference when in combination with tigecycline 
 
In combination with tigecycline, ciprofloxacin was observed to produce the variable results 
that typified these investigations.  Some synergy was observed with B. multivorans, and the 
group of “other” Bcc isolates.  Low levels of antagonism were observed, though this 
seemingly correlated with those isolates that had demonstrated synergy.  The vast majority 
of the isolates tested, however, were indifferent to the combination. 
Aztreonam showed variable activity against the Burkholderia species.  It was most active 
against B. multivorans isolates (19% sensitive, 35% intermediate), with poorer activity 
against the B. cenocepacia isolates (6% sensitive, 19% intermediate).  Both sets of isolates 
showed a large range, further indicating variation in susceptibility throughout the groups. 
In combination with tigecycline, aztreonam demonstrated low levels of synergy across the 
board, with antagonism only occurring at low levels when challenged with S. maltophilia 
and small numbers of the other CF related GNBs (P. sputorum).  Of particular note was the 
small number of other Bcc species that demonstrated 25% synergy though the low numbers 
in this group may have exaggerated this result. 
The aminoglycosides tested in this study showed variable and rather low activity across the 
spectrum of isolates with large ranges in all species.  Tobramycin was marginally less 
effective overall than amikacin, though direct comparison is difficult as amikacin has an 
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intermediate range that was frequently observed.  Using the MIC50 data, it is possible to see 
that tobramycin had the lower MICs throughout the Burkholderia species with 13, 10 and 
25% sensitivity to B. cenocepacia, multivorans and “others” respectively.  In comparison, 
amikacin was sensitive to only 6, 3 and 25%, but intermediate to 6, 10 and 25% 
respectively.  The lower MICs observed with tobramycin suggest that it is more effective in-
vitro, though the intermediate range of amikacin may make up for this difference somewhat.  
Amikacin, in particular, was less effective than tobramycin, particularly with respect to the 
Burkholderia species demonstrating a mean sensitivity of 11% across the isolates. 
Tobramycin demonstrated marginally more activity against the Burkholderia species with an 
average of 16% sensitivity.   
Where tobramycin was combined with tigecycline, low levels of antagonism were recorded 
– notably against the B. multivorans species (3%).  
Against B. cenocepacia, B. multivorans and “others”, temocillin demonstrated 31, 48 and 
25% sensitivity respectively.  With a low MIC50 and shorter ranges than most of the other 
antimicrobials tested in this study, it appears that temocillin is a promising antimicrobial 
when used against the Burkholderia isolates in-vitro.   
Temocillin, demonstrated some activity against the Bcc isolates (31% sensitive to 
B.cenocepacia, 48% B. multivorans). Sensitivity against the Burkholderia species averaged 
around 35% compared to 54% sensitivity of the same isolates tested against ceftazidime – 
another β-lactam antibiotic. This situation was not improved by combining temocillin with 
tigecycline – with the majority of isolates being indifferent to the combination.     
Ceftazidime was relatively effective against all of the species tested in this study.  It was 
particularly effective against B. multivorans where 74% susceptibility was observed.  With 
low MIC50 observations, it appears that ceftazidime is a powerful antimicrobial where 
around 50% susceptibility across the range of species tested was observed.  Of the β-lactam 
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antibiotics tested, ceftazidime, was the only cephalosporin antibiotic tested in this study and 
was the most effective.  It has long been documented to be active against Pseudomonas spp 
and in this study its effectiveness whilst variable against both Bcc and other GNBs from CF 
patients, was generally good.  The Burkholderia species averaged around 60% sensitivity 
across the range.  As with many of the antibiotics tested, the testing range was large (1-256) 
but most of the islolates tested fell within the lower MIC bracket. 
In combination with tigecycline, ceftazidime demonstrated good activity with an average of 
21% synergy demonstrated across the Burkholderia species.  No antagonism was noted. 
Piperacillin in combination with tazobactam (PTA) was another anti-pseudomonal penicillin 
and was found to be more effective than temocillin in-vitro.  Against the Burkholderia 
species, the two antibiotics are broadly comparable, with PTA being slightly more active 
(for example, 58% sensitivity against B. multivorans versus 48% sensitivity where 
temocillin was used). 
As with many of the other combinations of antibiotic/isolate, tobramycin ciprofloxacin and 
meropenem demonstrated variable amounts of synergy.  This was only observed in the 
B.multivorans and “other” isolates, though they may have been exaggerated in some cases 
due to small numbers of “other” isolates.  Against the B. multivorans isolates, however, 
meropenem did demonstrate significant levels of synergy that may be useful.   
6.2.4 Stenotrophomonas maltophilia isolates 
 
Tigecycline showed promising activity against S. maltophilia isolates, with 77% sensitivity 
and 11% intermediate sensitivity/resistance.  This was in direct contrast with the results 
previously described in the Bcc species.  When compared with minocycline, however, there 
remains a significant difference.  Minocycline exhibited 96% sensitivity with 2% of isolates 
tested being intermediate.  In addition to this, tigecycline once again showed greater 
variation though how significant this difference is, where sensitive isolates predominate, is 
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unclear.  The overall results of testing of S.maltophilia against tigecycline in combination 
with other antimicrobials can be seen below in Fig 6.15. 
 
  Figure 6.15: Percentage of S. maltophilia strains demonstrating synergy/antagonism 
or indifference when in combination with tigecycline 
 
The most effective antibiotics against S. maltophilia in-vitro from this study were 
minocycline (96% sensitivity) and tigecycline (77% sensitivity).  Conversely, the least 
effective were aztreonam (2% sensitivity) and temocillin (temocillin exhibited no activity 
against S. maltophilia).  Whilst temocillin did exhibit some limited synergy, it was 
outweighed by antagonistic interactions (not noted in other species).  The largest single 
group of isolates in this study comprised of the S. maltophilia isolates.  It was in this group 
where the most antagonism was noted – across almost the entire spectrum of antimicrobials 
that were tested in combination.  As with the pattern observed with colistin with other 
isolate groups, the antagonism in the S. maltophilia group appears to match almost exactly 
the synergy as it occurs.  The only antibiotic in this group where antagonism was mutually 
exclusive, was tobramycin.  This was the only group in which these elevated levels of 
antagonism were noted.  In other groups as noted, antagonism was almost entirely absent 
and promising levels of synergy were observed.   
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6.2.5 Achromobacter xylosoxidans 
 
The activity of tigecycline against this group of organisms was promising, with 85% of 
isolates being sensitive to this antibiotic.  Unlike other groups of organisms, this was 
comparable to minocycline where 80% of isolates were sensitive.  The main difference 
between the two antibiotics was in the intermediate range where tigecycline showed 10% 
and mincycline 20% respectively.  Only 5% of isolates were resistant to tigecycline whereas 
none were resistant to minocycline.  The results of testing can be seen in Fig 6.16 where 
A.xylosoxidans was tested against tigecycline in combination with other antimicrobials. 
 
Figure 6.16: Percentage of A. xylosoxidans demonstrating synergy/antagonism or 
indifference when in combination with tigecycline 
 
Tigecycline, minocycline and piperacillin/tazobactam were the most successful antibiotics 
in-vitro against this group of organisms, with temocillin and aztreonam being virtually 
inactive.  Most of the other antibiotics tested showed significantly reduced activity.   
Unfortunately, despite observing synergy in other species tested in this study, very little 
synergy was observed in the A .xylosoxidans group.  Previous patterns have indicated that 
synergy occurs where organisms would otherwise have been resistant.  This does not appear 
to have been the case here.   
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The only synergy observed within this group occurred with colistin (40%), aztreonam (5%) 
and piperacillin/tazobactam (5%).  The only group of isolates where no antagonism was 
observed was the A. xylosoxidans group.  At 40% synergy, the significance of colistin 
cannot be easily overlooked.  Unfortunately, though the lack of antagonism was 
encouraging, the levels of synergy with other combinations were either completely absent, 
or very low and it would appear that only colistin in this group generated reliable and 
significant levels.   
6.2.6 Other Gram negative bacilli (GNB) clinical strains 
 
The group of “other GNB clinical stains” was a rather mixed group and was included in this 
study largely for illustrative purposes.  It was recognised that insufficient numbers from 
which to draw firm conclusions, existed – but that the study may benefit from this additional 
information in the wider context of CF colonisation/infection.   
Table 6.3: Summary of “Other” GNB clinical trains and their response to each 
antibiotic tested. 
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Of particular note in this group were the Pandorea isolates – apista and sputorum.  These 
produced almost completely polarised result in that the P. apista group demonstrated 
marked synergy when tested against combinations.  P. sputorum, however, demonstrated a 
concerning amount of antagonism.  Similarly discrepant results were observed with the 
Pseudomonas stuzeri isolates tested – with one isolate demonstrating synergy almost across 
the entire range of antimicrobials and the other showing complete indifference.  A summary 
of these results can be seen in Table 6.3 
6.2.7 Additive effects. 
 
The decision was made in this study to describe non-synergistic and non-antagonistic 
interactions as “indifferent”.  It should be noted, however, that a 4th option does exist but 
that it may be viewed with some subjectivity (Balke et al, 2006).  It was also noted that a 
number of authors do not use the term in their research findings – presumably for the same 
reasons (Pankey & Ashcraft, 2005; Smith et al, 2006; Aaron, 2007).  Where the term is 
used, it is acknowledged that it may be viewed differently by different authors (Saiman, 
2007).  For completeness, it was decided to include this data as an addendum so that it may 
be used as deemed appropriate by the reader and we draw attention to the discussion where 
further mention of this data is made. 
Table 6.4:  Additive strains as a percentage of the total percentage of indifferent 
strains. 
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B.cenocepacia 94 6 68 19 100 6 100 6 87 29 81 16 94 6 100 6
B.multivorans 87 22 78 0 84 12 80 0 81 16 81 32 87 15 97 33
"other Bcc spp " 75 33 50 0 75 0 75 0 50 0 75 0 75 0 100 25
S.maltophilia 90 0.6 74 0.4 77 0.4 80 0.6 83 0 96 0.6 88 1 90 14
A.xylosoxidans 100 0.5 60 0 100 0.5 100 0.5 95 0.1 100 0.5 95 0 100 2
"other GNBs" 90 11 70 0 90 0 70 0 60 0 70 14 70 0 90 0
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Table 6.5: The minimum inhibitory concentrations (mg/L) of eleven tested antibiotics for each species/genus group. Proportion susceptible (S), intermediate (I) or 
resistant (R) in relation to defined breakpoints.  
       
TGC MIN AMI TOB AZT CAZ MER  PTA TEM COL   CIP    
 
Burkholderia cenocepacia (16)   Range 1-64 0.25-8 4-256 4-256 1-256 1-256 0.5-32 0.5-256 4-64 32-256 0.5-32   
     MIC50      32   2   256     32   256    4     2   32   32    256     32 
     MIC90      64   4   256     64   256    64   32   256   64    256     32 
%S    13   94      6     13    6    56   56    38   31    0          6 
     %I    19   6      6      0    19    0   25    0   0    0     19 
     %R    68   0    88     87    75    44   19    62   69    100     75 
 
Burkholderia multivorans (31)   Range 1-256 0.5-16 4-256 0.25-1024  1-256 0.5-256 0.5-32 0.12-256 2-1024   0.25-256 0.25-32    
     MIC50    4   1   256     32   4    2    2     2   8    256    2 
     MIC90   64   4   256    512  256    64   32    256   32   256    32 
     %S      3   91      3     10    19    74   48      58   48     3    13 
     %I    32    6    10       0    35    0   19      0   0     0    19 
     %R    65    3    87     90    46    26   33      42   52     97    68 
 
Other Burkholderia cepacia complex species (4) Range 1-16 0.25-16 4-256   1-64 1-256 1-256 1-32     0.016-256 0.5-64   256 0.125-4 
     MIC50   2 0.25    16     8      2    2    1      8   64   256   0.25 
     MIC90   12  2  256     64    64    4   32  256   64   256    4 
     %S   25  75    25     25    25    50   75    60   25   0    75 
     %I   50  0    25     0    25    0   0    0   0   0    0 
     %R   25  25    50     75    50    50   25    40   75   100    25 
 
Achromobacter xylosoxidans (20)  Range 0.12-8 0.25-8 0.5-256 0.25-1024 32-256 2-256 0.06-32 0.5-256 64-1024 0.12-256 0.03-32 
     MIC50     0.5    2  256        8  256      8 0.125      1  1024      4      4 
     MIC90     2    8  256  1024  256  256   32    64  1024  256    32 
%S   85   80    10     15   0    60   65    85   0    40      10 
%I   10   20    0     0   0    0   10    0   0    0    15 
%R     5   0    90     85  100    40   25    15   100    60    75 
 
Stenotrophomonas maltophilia (47)  Range 0.12-4  0.12-64 4-256    0.12-1024 1-256 0.25-256 0.25-32 4-256 32-1024  0.06-256 0.25-32  
     MIC50     1     0.5  256     32  256    16   32  256    512    2      4 
     MIC90     4     2  256 1024  256  256   32  256  1024  256    32 
     %S   77    96    9    26      2    47   21    26    0    51    13 
     %I   11     2    15    0      9    0     2    0    0    0      9  
     %R   12     2    76    74    89    53   77    74    100    49    78 
 
Other CF-associated Gram negative bacteria^ (10) Range 0.12-16 0.125-16 1-256 0.12-1024 1-256 0.12-256 0.06-32 0.01-256 2-1024 0.06-256 0.01-16 
     MIC50     0.5     0.5  256    32  256      8   32    8    1024  256      0.25   
     MIC90       2     2  256 1024  256  256   32  256    1024  256      8 
     %S   80   100    30     20    10    60   40    60      30    50    60 
     %I   10     0    10     0    20    0   0    0      0    0    20 
     %R   10     0    60     80    70    40   60    40      70    50    10 
 
TGC: tigecycline; MIN: minocycline; AMI: amikacin; TOB: tobramycin; AZT: aztreonam; CAZ; ceftazidime; MER: meropenem; PTA: piperacillin-tazobactam; TEM: temocillin; COL: colistin; CIP: ciprofloxacin.  
^ Delftia acidovorans (2), Pseudomonas stutzeri (2), Shewanella putrefaciens (2), Chryseomonas indologenes, Chryseomonas meningosepticum,  Pandoraea sputorum, Pandorea apista. 
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Table 6.6:. Tigecycline in combination with other antimicrobial agents: percentage of isolates demonstrating synergy (SYN), antagonism (ANT), or indifference (IND) for 
each species/genus group. 
 
TOB AZT CAZ MER  PTA TEM COL   CIP    
 
Burkholderia cenocepacia (16)   %SYN    0     6   19   0   13   0   19   0 
      %ANT    0     0   0   6   0   0   13       0 
      %IND 100     94   81   94   87  100   68   100 
 
Burkholderia multivorans (31)   %SYN   13   13   19   23   19      3     3   10    
      %ANT     3      0     0     0     0      0   19   10 
      %IND   84   87    81   77   81    97    78   80 
 
Other Burkholderia cepacia complex species (4)  %SYN   25   25   25   25   50 0   25            25 
      %ANT   0   0   0   0   0 0   25   0 
      %IND   75   75   75   75   50 100   50   75 
 
Achromobacter xylosoxidans (20)   %SYN   0     5   0    0     5   0   40   0 
%ANT   0     0   0    0     0   0   0   0 
%IND 100   95 100   100   95 100   60 100  
 
Stenotrophomonas maltophilia (47)   %SYN   0      6     2     6     6     4     9   11 
      %ANT   23     6     2     4   11     6   17     9 
      %IND   77   88   96   90   83   90   74   80 
 
Other CF-associated Gram negative bacteria^ (10) %SYN   10   20   20   10   30  0   20   20 
      %ANT   0   10   10   0   10  10   10            10 
      %IND   90   70   70   90   60  90    70   70 
 
TOB: tobramycin; AZT: aztreonam; CAZ; ceftazidime; MER: meropenem; PTA: piperacillin-tazobactam; TEM: temocillin; COL: colistin; CIP: ciprofloxacin.  
^ Delftia acidovorans (2), Pseudomonas stutzeri (2), Shewanella putrefaciens (2), Chryseomonas indologenes, Chryseomonas meningosepticum, Pandoraea apista 
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Chapter 7 
7.0 Discussion 
 
7.1 PFGE and epidemiology 
 
One of the aims of this study was to ascertain the epidemiological spread of the isolates that 
have been obtained in the Leeds Cystic Fibrosis Centre over the last ten years.  This was 
primarily to enable the exclusion of duplicate isolates for MIC/synergy testing, though the 
PFGE work does tentatively draw some epidemiological conclusions.  The long-term 
colonisation of patients with Bcc and other organisms has serious implications for infection 
control within the Leeds CF unit, but also within the CF community (Govan et al, 2007).  As 
has been mentioned previously, the stigma attached to carriage of Bcc organisms is such that 
the psychological effect upon patients can be pronounced (McDowell et al, 2004).   
Notwithstanding potential duplicate isolates and the small number that were unrecoverable 
from storage, B. multivorans was the predominant organism in the LTHT historical 
collection.  It is difficult with small numbers and a historical collection to draw firm 
conclusions, though as stated in the introduction, this may indicate that 
colonisation/infection of the patients in this study was sporadic and may have originated 
from environmental sources rather than patient to patient spread (McDowel et al, 2004). 
There have been a number of studies that have found centre specific predominance of Bcc 
strains that differ from environmental strains.  The findings of this study, however, do not 
appear to support this work and it has been noted that in some units, there can be a large 
spread of genetically differing species with not all isolates necessarily carrying specific 
markers of transmissibility (Mahenthiralingam et al, 1996, Mahenthiralingam et al, 2002).  
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Some historical work has found similar results where a small number of isolates did not 
cluster when examined (Steinbach et al, 1994), though in most studies, patient to patient 
transmission within CF units has been found (Speert et al, 2002).  This indicates that, whilst 
patient to patient spread is important, it does not necessarily follow that all patients within a 
CF unit will harbour the same strains of Bcc, and that this may be dependent upon the origin 
of the strains and the predominance of specific types – such as B. multivorans.  It has also 
been suggested that despite segregation in CF units, patients will still be sporadically 
colonised by Bcc organisms from the environments in which they live (McDowell et al, 
2004).  The findings in this study may also indicate that the infection control policies of the 
LTHT have been relatively successful over the last ten years.  Had this not been the case, 
this study may have found more pronounced clustering of isolates as similar strains are 
detected in multiple patients.  Furthermore, given the findings of previous work and the 
patient to patient transmission data presented; it may seem reasonable to tentatively 
postulate that patients within the LTHT CF unit have likely acquired their strains from the 
environment and that nosocomial spread has been minimal (Speert et al, 2002, 
Mahanthiralingam et al, 2002, McDowel et al, 2004).  This, therefore, would represent 
promising data in terms of the practices of the LTHT CF unit.   
As the major route of transmission for organisms such as S. maltophilia and A. xylosoxidans 
may be environmental, it is difficult to accurately quantify the effect that infection control 
measures and isolation may have had with regard to these organisms.  The evidence from 
PFGE typing, however, is that the isolates in the LTHT CF unit appear to be, for the most 
part, unique – suggesting that acquisition was either from multiple external/environmental 
sources, or that the LTHT CF unit infection control measures may have had some beneficial 
outcomes where nosocomial spread was possible (Denton et al, 1998).  Our work on these 
organisms has shown some agreement with previous studies in this area – suggesting that 
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our collection of isolates is not unique in their diverse nature.  Large studies by Valdezate et 
al (2004) and Denton et al (1998) demonstrated that in a single, large CF unit, there was 
very little relationship between isolates.  This has been matched by our findings, and 
confirms to some degree the hypothesis that these organisms are also acquired from the 
environment and not necessarily from other patients.    
The continuous monitoring of microbiological colonisation of patients within the LTHT has 
clearly paid dividends in terms of proactively seeking to identify those patients who are, 
unfortunately, harbouring pathogenic species such as Bcc and then putting into place 
protective measures to prevent the further spread of these organisms.   
Epidemiology aside, the main reason for testing isolates by PFGE, was to eliminate 
duplicate isolates.  The benefit of this is to achieve a data set that is representative not only 
of the LTHT CF unit, but that potentially gives an indication of national trends.  Had we 
included large numbers of repeat isolates or duplicates that have come from multiple 
patients (as part of an outbreak, or nosocomial spread within the CF unit), then the data 
would have been skewed to benefit/disadvantage individual antibiotics.  Our collection, 
therefore, gives a cross sectional, representative sample of organisms isolated from CF 
patients in the LTHT CF unit without prejudice to age, gender or other demographics.  
Where similarities were observed, we investigated further to ensure that the isolates were 
phenotypically different – as can be seen in the examples provided in the next section.  No 
complete and convincing duplicates were found in this study. 
7.1.1 Heterogeneity/variability of strains and testing 
 
MIC testing gave an overall picture of the performance of each individual antimicrobial 
against each group of isolates, thereby providing a baseline upon which to extrapolate the 
results of synergy testing.  This information was also useful as a likely indicator of clinical 
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efficacy amongst those patients regularly seen in the LTHT CF unit.  The clinical relevance 
of this data is discussed later, but a number of patterns emerged that may potentially inform 
the clinician about the likely outcomes of antimicrobial chemotherapy.  Combining the MIC 
data with that gained from the PFGE investigations gave an interesting picture of the 
diversity of the organisms found in the LTHT CF unit and may shed some further light not 
only on the likely epidemiology described earlier, but also on future patterns that may 
develop as a result of the relative genetic promiscuity of these organisms, and the testing 
issues that may arise as a result of this.  It is these issues of heterogeneity that are discussed 
here. 
Since differences in susceptibility between organisms are quite normal – especially in CF 
patients, a small number of “closely” related strains are illustrated here to demonstrate the 
variability that can be observed when conducting MIC testing (Doring et al, 2000; Fowraker 
et al, 2010).  One example of the polymorphisms exhibited by CF isolates is demonstrated 
by the three ET12 epidemic strains of B. cenocepacia that were investigated in this study.  
Not surprisingly, there was some clustering of these organisms, though by Tenover’s criteria 
(1995), it would appear that these are likely to be different strains.  We know from past 
work, however, that the ET12 lineage, whilst widespread in hospitals, is part of a small 
group of strains that have rarely been seen in other environments (Holden et al, 2009).  
Whilst these strains may genuinely differ (indicating that they are unique in origin), it may 
be that other factors such as insertions and other random genetic events may have had an 
influence.  The genomes of a number of ET12 isolates have been sequenced in recent years, 
and the variable expression of virulence (including differences in antimicrobial 
susceptibility) investigated.  It was found that the ET12 strains differed from others by up to 
21% indicating that genetic transfer plays a major part in their virulence and adaptability to 
the host environment.  It is also likely that this plasticity may have an influence where the 
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strains are typed by PFGE (Holden et al, 2009).  We found that our three isolates differed in 
their susceptibility to tobramycin (three differences), ceftazidime (one difference) and 
temocillin (one difference).  These differences are difficult to explain without sequencing 
the genomes of the respective isolates.  However, previous work by Holden et al (2009) 
suggests that ET12 strains possess multiple resistance genes encoding efflux pumps, 
siderophores (that, when activated help to protect against the reactive oxygen radicals 
encountered during treatment) and β-lactamases.  In their study, it was noted that the 
expression of these genes was variable, and could be influenced by the medium within 
which the bacteria grow (in their case, CF sputum).  Up to eight drug efflux pumps were 
detected by Holden et al (2009), and it may be reasonable to hypothesise that some of these 
may have been present in some of the isolates investigated in this study.  Since both 
ceftazidime and temocillin are β-lactam antibiotics, it is likely that they, too, may have been 
susceptible to upregulated β-lactamase and penicillin binding protein expression.  Again, it 
is difficult without sequencing, to state unequivocally which mechanisms may be 
responsible, but a number have been noted to be present – including a highly conserved 
metallo-β lactamase of uncertain significance (it is not known at present whether this is a 
functionally active domain).  The variable expression of these resistance markers means that 
there are a large number of combinations possible from even small numbers of isolates – 
leading to significant heterogeneity in both scientific end points (such as MICs), and clinical 
outcomes.  This effect upon the heterogeneity of clinical outcomes has been demonstrated in 
a number of studies and appears to be a likely confounder in any treatment prediction that 
results from this type of testing (Speert et al, 2002; Fowraker et al, 2010). 
Another aspect that fell outside the remit of this study, relates to the current and past 
treatment of patients.  It has been demonstrated that some antibiotic resistance mechanisms 
are potentially treatment induced (for example the ceo efflux pump – which is activated 
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when the patient is treated with chloramphenicol, trimethoprim or ciprofloxacin).  Where 
inducible effects occur – relating to antimicrobial therapy, growth environment and genetic 
events, these will increase the heterogeneity of the test population.   
Finally, the additional effect of heterogeneous populations is something with which any CF 
microbiologist has to grapple.  As mentioned previously, it is well reported that testing can 
demonstrate, even from single colonies, multiple morphotypes that will differ in their 
susceptibility.  Up to three morphotypes were found in a number of studies (Aaron et al 
2007; Fowraker et al, 2010) when testing P. aeruginosa, and this effect is common 
throughout CF isolates (Denton & Kerr, 1998).  Test populations, therefore, may produce 
variable results.  It is possible that duplicate isolates may be tested resulting in apparently 
completely different MIC data.   As stated previously, this variation is not limited to the Bcc 
species and P. aeruginosa.  Small colony variants (SCV) of S. maltophilia have been noted, 
and these are difficult to culture using standard methods (Anderson et al, 2007).  At present, 
it is difficult to quantify the effect that they may have on testing due to their unique growth 
characteristics.  We cannot, therefore, rule out the possibility that these organisms are 
present in our, or any test population or their influence upon the results.  These SCVs have 
been found in numerous pathogenic organisms, and whilst there is currently no data relating 
to the other species tested in this study (Bcc spp/A. xylosoxidans), this may be an area for 
further investigation and may additionally confound susceptibility testing.   
The historical lineage of many CF related organisms, is environmental.  S. maltophilia, for 
example, has been found in many habitats including plants, water, soil sediments and 
organic residues.  It is thought that this diversity of habitats may be one of the factors in the 
metabolic diversity of the organism – thereby assisting the heterogeneity of both testing, and 
outcome with these organisms.  Other differences in susceptibility – both to single and 
multiple antibiotic combinations may be due to differences in resistance mechanisms both 
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acquired and innate.  One example of this is the multi-drug efflux pump “sme” – this is a 
pump that in combination with its outer membrane protein (OMP), energy dependent 
transporter and membrane fusion protein, is capable of pumping antibiotics from the 
bacterium S. maltophilia.  Notably, however, this pump is not associated with the multi-
resistance phenotype.   Conversely, other isolates that have been studied have been found to 
have completely different pump mechanisms such as the similarly named “smeDEF” pump 
(Alonso & Martinez, 2000) – which is associated with multi-resistant phenotypes.  When 
sequence analysis was carried out on these two pumps they were noted to be quite different 
– indicating that whilst S. maltophilia may be widespread within a CF unit, the 
susceptibilities can vary considerably due to the differing mechanisms of resistance that may 
be present.   
In all of the organisms tested here, there is the issue of biofilm and differential growth 
curves.  Studies have noted that bacteria exhibit differing levels of resistance depending 
upon their growth stage – with resistance increasing markedly during the exponential growth 
phase and topping out at the stationary phase during which bacteria are located in the 
biofilm (Desai et al, 1998).  As stated later in the discussion of limitations and further work, 
it is difficult to propose a way of including this data – and indeed detecting the growth phase 
of the organism concerned and would likely be prohibitive.  We did time the application of 
organisms into growth media as accurately as possible, though it is difficult to know where 
the organisms originated from in the patient in terms of growth phase or biofilm location, 
and there may have been some experimental variability that could influence these factors.  It 
should be noted that in a clinical environment, organisms are less likely to be uniform in 
their growth phases, though this has been controlled as much as practicable within this 
study. 
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7.2 MIC/synergy testing 
 
The MIC ranges found with most of the test antibiotics were very wide – except for a limited 
number of agents such as meropenem.  This may be due to a number of possibilities – 
chiefly the presence of resistant mutant strains among the test population.  Additionally, the 
effect of bacterial heterogeneity as previously discussed cannot be discounted.  The larger 
ranges observed with older and more established antimicrobials are not surprising, as the use 
of these antimicrobials may have induced resistance over time. 
7.2.1  The tetracyclines 
 
Tigecycline was considerably less effective in-vitro than its legacy minocycline derivative 
against the Bcc species, though it was far more effective against S. maltophilia and 
A.xylosoxidans isolates.  Thirteen percent of B. cenocepacia isolates were sensitive to 
tigecycline compared to 94% sensitivity to minocycline.  Similar results were observed 
when B. multivorans was tested.  It is difficult to qualify these differences in susceptibility – 
particularly as the antibiotics are similar in overall structure.  One can only postulate that 
there may be subtle differences in the uptake of tigecycline by the Bcc species and that this 
is sufficient to make a significant difference.  Other resistance mechanisms such as efflux 
pumps have yet to be characterised, though it is likely that these are present as they have 
been observed in other similar species and are noted to have homologues.   
It should be noted that the data relating to both minocycline and tigecycline can be skewed 
somewhat as BSAC/CLSI guidelines are updated and amended.  In the latest version that we 
used for this study (2010), an intermediate range was given.  There is some evidence to 
suggest that where organisms are classed as resistant to antimicrobials in-vitro, then 
organisms in-vivo may still respond – possibly due to host factors working in combination 
100 
 
with antimicrobial therapy (Aaron et al, 2006).  It may be that these intermediate organisms 
may be susceptible in some of these cases, though this falls outside the remit of this study.  
Intermediate sensitivity/resistance is largely subjective and depends upon the set of 
guidelines used. It should be noted that where Bcc appeared to be resistant to tigecycline 
(compared with minocycline), 19% of B. cenocepacia and 32% B. multivorans had 
intermediate sensitivity/resistance to tigecycline respectively.  Whilst the difference between 
sensitivity and resistance to tigecycline and minocycline is substantial, this may bridge that 
gap.  It does, however, suggest that minocycline would be the more useful antimicrobial 
agent for use in patients colonised with Bcc organisms.   
More promisingly, tigecycline was comparable to minocycline against all of the other 
species tested in this study in that around 80% sensitivity was observed, though whether it 
would be a better choice clinically is another issue that would have to be investigated 
further.  Tetracycline efflux pumps have been noted in past work, but it is stated in a number 
of articles that these are not effective against tigecycline – indeed it is noted that this is one 
of the selling points of this antimicrobial (Greer, 2006).  Likewise, tigecycline is noted to be 
“resistant” to ribosomal protection mechanisms.  It is difficult, therefore, to predict 
accurately why tigecycline is both relatively inactive against the whole spectrum of Bcc 
species, but also why it is less active than its legacy derivative; minocycline.  A number of 
possibilities exist but are as yet unproven as work has not yet been carried out.  Differences 
in the uptake of tigecycline when compared with minocycline may mean that the antibiotic 
is reduced in its effectiveness due to a lack of penetration.  Additionally, it is possible that 
there are, as yet, undetected efflux pump mechanisms or changes to the outer membrane 
proteins that are able to work in combination with this reduced uptake.  Interestingly, though 
we did not test minocycline further, a study by Petersen (2009) found synergy between 
tigecycline and minocycline, though the mechanisms for this are not understood.  Where 
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synergy occurs with tigecycline, it is possible that the cascading effect of the second 
antimicrobial may break down or inhibit the appropriate mechanisms, allowing tigecycline 
to both penetrate and be effective.  Assuming, however, that the latter mechanisms are 
responsible for synergy, this does not fully explain why it is such an ephemeral and 
hetrogenenous phenomenon.  As yet, there is little data relating to tigecycline and 
minocycline although a study carried out by in the United States in 2000 found that 
minocycline was active against S. maltophilia and Bcc species and our data shows 
concordance with this work (Kurlandksy & Fader, 2000).  Other work has found that 
doxycycline and the tetracyclines in general are effective in-vitro against S. maltophilia and 
A. xylosoxidans and our work agreed with these observations (Vartivarian et al, 1994; San 
Gabriel et al, 2007).  One issue with these antibiotics however, is that they are bacteriostatic 
and the resulting likelihood of resistance is higher as they are likely to leave small sub-
populations uninhibited.  Using the tetracyclines in combination with bactericidal antibiotics 
may solve this problem though it has been suggested that any treatment should be at, or near 
the highest doses tolerable to mitigate the potential effects of developing resistance 
(Vartivarian et al, 1994). 
The Bcc isolates in general showed great variability in both MIC, and synergy/antagonism 
across the spectrum of isolates and antimicrobials tested.  The most successful antibiotics in 
combination with tigecycline appeared to be ceftazidime, piperacillin/tazobactam and 
aztreonam – though, there are a number of problems that may prevent these combinations 
from being used clinically.  Ceftazidime has a history of being less effective in-vivo, whilst 
aztreonam simply was not effective alone – and its resulting combination MIC would not 
necessarily translate to a successful clinical outcome as a result.  Piperacillin/tazobactam 
remains a good performer, though its use in combination with tigecycline would have to be 
monitored until further data is available.   
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Whilst a number of antimicrobials were effective against the S. maltophilia isolates, 
combination testing highlighted a number of serious issues.  Antagonism was widespread 
and in most cases outnumbered the instances of synergy.  This would suggest that the use of 
any combination should be after rigorous testing in order to avoid clinical failure.  The poor 
synergy observed in these isolates would indicate that combinations that include tigecycline 
and one other antibiotic may not be effective.  Further work may indicate that triple 
combinations can overcome these issues. 
40% of A. xylosoxidans isolates were sensitive to colistin – 40% of the isolates were found 
to be synergistic.  Unfortunately the two effects are, for the most part, mutually exclusive.  
The usefulness of combination therapy using tigecycline must be questioned when treating 
patients with these organisms.  The lack of synergy was disappointing, as many of the 
antibiotics tested were, in fact, quite efficacious.  It does, however, raise the question of 
whether synergy testing is absolutely necessary against this particular group of organisms, 
when antibiotics are effective in-vitro by themselves.  Combination testing may help to 
further our knowledge of other combinations (not necessarily including tigecycline) and 
could help to reduce the development of resistance over time.   
7.2.2 Tobramycin 
 
The lack of sensitivity of the Bcc species to tobramycin was concerning.  Since nebulised 
tobramycin is in common use with CF patients, it is disappointing to find that 75% of the 
organisms tested were resistant.  This may represent increasing levels of resistance over time 
resulting from the long term use of nebulisers - a similar situation was observed with all 
groups of organisms tested.  This would represent an area where future expansion of this a 
study would be useful as it is difficult to make any conclusions in respect of this without 
further information.  To confirm developing resistance, a time linear testing method would 
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be required.  This brings up the issue of non-duplicate isolates.  Since it is presumed (after 
PFGE testing) that all or most of our isolates are possible environmental organisms and that 
they are unique, then the effects of aggressive antimicrobial therapy may not, in fact, have 
influenced the susceptibility of these isolates.  Further work is warranted.  It may also be 
noted that testing concentrations where disc tests and other methods are used, do not 
necessarily reflect those that are achieved therapeutically.  Aaron et al (1999) tested 
tobramycin at much higher concentrations that would be more representative of those 
achieved through nebulisation (they cannot be achieved intravenously).  It has also been 
found that some bacteria – notably Bcc species are far more resistant to tobramycin in 
biofilms when compared to other common CF bacteria such as P. aeruginosa.  This is true 
even when the bacteria are harvested and dispersed before culture (Desai et al, 1998). It is 
difficult, therefore, to determine how effective our MIC/synergy testing of these antibiotics 
would translate where we have determined an antibiotic to have an MIC that would be 
classed as a resistant organism, and it may indicate that current BSAC and CLSI guidelines 
are inadequate for specific groups of patients and antibiotic/bacterial combinations.  As 
stated previously, the rather open ended objectives of treatment in CF patients make the 
view of “sensitive” and “resistant” somewhat subjective.  The epidemiological data, 
suggesting that isolates are environmentally acquired indicates that any resistance 
mechanisms to aminoglycosides must be either very widespread or chromosomally mediated 
– such as active efflux pumps as seen in Pseudomonads, and the presence of 
phosphorylating enzymes.  Low levels of synergy were observed with the combination of 
tobramycin and tigecycline.  These low levels of synergy may be of some benefit where the 
patient is empirically treated with tobramycin and then tigecycline is added.  However, the 
low levels of synergy may also indicate that the clinical benefit is, at best tenuous. 
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Very little synergy with tigecycline was noted except in the case of B. multivorans isolates, 
though this was only in the order of 13%.  More concerning, were the higher levels of 
antagonism that were observed with S. maltophilia isolates.  Other than colistin which 
demonstrated the highest overall levels of antagonism, tobramycin demonstrated 23% 
antagonism against S. maltophilia isolates and 3% against B. multivorans.  It would appear 
from the data, that tobramycin is unlikely to be of realistic use in combination with 
tigecycline, or that testing before use would be warranted to prevent adverse reactions and 
clinical failure. 
7.2.3 Colistin 
 
Of all the antibiotics tested, colistin demonstrated the most synergy – particularly against 
A.xylosoxidans isolates where 40% synergy was observed.  Indeed, colistin/tigecycline was 
one of the most synergistic combinations across the whole spectrum of isolates.  This 
presents an interesting issue of how useful this combination is likely to be in the clinical 
situation.  Colistin is available in nebulised form, and has previously been shown to be more 
effective at the higher concentrations achievable by nebulisation – even when resistance is 
indicated (Gabriel et al, 2004).  Tigecycline, however, is not available via this route and 
would have to be administered parenterally.  It remains to be seen how this differential 
administration would affect the synergistic interactions of the drugs and unfortunately this 
falls outside the remit of this study.  We did not take into account these higher 
concentrations though, as previously noted, most synergy was detected in isolates that would 
otherwise be resistant or borderline resistant.  It may be possible that we did not detect 
synergy in low or high MIC organisms at the limits of the spectrum due to limitations of the 
E-testing method – see later in this chapter for discussion of these issues.   
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Unfortunately, despite colistin/tigecycline being one of the most successful combinations in 
terms of observed synergy, the combination also yielded significant antagonism – the most 
observed in any combinations used in this study.  It is difficult to predict why this has 
occurred as the action of colistin to damage the membrane of the cell in the catastrophic way 
observed, would potentially allow tigecycline to penetrate better than if it was administered 
alone.  Further work would be needed to ascertain these mechanisms, though it is possible 
that the two antibiotics simply react under specific circumstances and in the presence of 
cellular or host factors.   
7.2.4 Ciprofloxacin 
 
Ciprofloxacin was variable against the isolates in this study, and was not particularly 
effective against the Bcc.  There is suggestion that this antibiotic may be useful in a 
nebulised form, though this is not currently available.  When tested in combination with 
tigecycline, ciprofloxacin showed mainly indifference with some low level synergy.  In 
previous work, ciprofloxacin has been found to be less effective against the Bcc than in 
others.  In combination, however, it has been demonstrated to significantly enhance the 
killing power of combination with meropenem, piperacillin/tazobactam and imipenem.  It 
did not, however, assist other β-lactamase agents (Bonacorsi et al, 1999).  Ciprofloxacin 
showed a wide range of MICs against the B. multivorans isolates, suggesting the possibility 
of mutants within the population, though the range was very narrow when tested against 
B.cenocepacia isolates and this has been previously documented in P. aeruginosa (Gold et 
al, 1983).  It was suggested by Bonacorsi et al that this is possible in the Bcc species as the 
migration of insertion sequences within the chromosome can alter the expression of 
chromosomal resistance genes (Bonacorsi et al, 1999).   Work has historically found steadily 
increasing resistance of A. xylosoxidans to ciprofloxacin – and that this has increased with 
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exposure (isolates identified as “older” were found to be more resistant).  This resistance 
was in accordance with our findings and suggests that ciprofloxacin may not be appropriate 
for treatment of these organisms (Vartivarian et al, 1994).  Additionally, there was no 
synergy noted when ciprofloxacin was used in combination with tigecycline against 
A.xylosoxidans, indicating that the additional killing effect observed with other 
antimicrobials is not effective in this case.   
Ciprofloxacin was variably active against the S. maltophilia isolates as previously described 
(Denton & Kerr, 1998) and some synergy was observed.  As with colistin and tobramycin, 
however, the occurrences of synergy appear to be matched to an extent by the appearance of 
antagonism in other isolates.  Given that the killing effect of ciprofloxacin in combination 
has not been observed with any of the organisms used in this study, and that antagonism is 
common, it would seem prudent to not use this combination in the clinical environment – at 
least until isolates have been tested and antagonism is ruled out.   
7.2.5 The β-lactam/carbapenem group: ceftazidime, 
piperacillin/tazobactam, temocillin and meropenem 
 
Of the β-lactam antibiotics tested, ceftazidime was the most active against all of the 
organisms tested, with an average of around 50% susceptibility.  It is well documented that 
the organisms tested in this study possess numerous β-lactamase enzymes and other 
resistance mechanisms, and it has also been shown in past studies that even where results are 
promising in-vitro, this does not necessarily translate to the clinical situation (Govan & 
Deretic, 1996).  The risk of using ceftazidime in-vivo is that the likelihood of 
cephalosporinases, β-lactamases, drug-efflux and reduced porin channel access being 
possessed by the target organisms tested here, is high.  However, this may be addressed to 
some extent by using ceftazidime in combination.  It remains to be seen what the optimal 
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combination for this antimicrobial would be, but with good activity against around 50% of 
all isolates tested and with a relatively low MIC 50, it would, in-vitro, indicate that the 
combination of ceftazidime and tigecycline could show some promise.  Except for 
A.xylosoxidans where no synergy was observed, and S. maltophilia where only 2% synergy 
was observed, the ceftazidime-tigecycline combination averaged around 20% synergy.  If 
this combination was further combined with a β-lactamase inhibitor, one may imagine that 
the combination may be more potent.  The caveat regarding inhibitors, however, must be 
that S. maltophilia has been demonstrated to possess both L1 metallo and L2 serine-β-
lactamases.  These are able to overcome both β-lactam antibiotic, and the β-lactamase 
inhibitor combinations.  The fact that synergy was observed in these combinations (minus 
the inhibitor) suggests that the combination of tigecycline-ceftazidime may be able to 
somehow bypass these mechanisms, though as can be seen by the low levels of synergy, this 
may be purely sporadic and incidental.  Where we did test an antibiotic-antibiotic-inhibitor 
combination (tigecycline-piperacillin-tazobactam) we found very little difference in 
performance.  It is unfortunate, that with such good and promising in-vitro results, previous 
studies and clinical work have found that despite this, there is a lack of clinical efficacy of 
this antibiotic (Gold et al, 1983; Desai et al, 1998), though this may be related to the 
bacterial presence of a biofilm.  These biofilms have been found to significantly raise the 
MIC of both piperacillin/tazobactam and meropenem in the Bcc species and it is conceivable 
that this may have some influence upon the efficacy of ceftazidime and ultimately, the 
potential use of ceftazidime in combination with tigecycline (Caraher et al, 2007).  Further 
work to ascertain the efficacy of the combination of ceftazidime and tigecycline may be 
indicated for this promising combination.  Our results match those of earlier studies, where 
the most effective β-lactam antibiotics against the Bcc organisms were found to be 
ceftazidime, meropenem and temocillin (Bonacorsi et al, 1999). 
108 
 
Comparatively, the antibiotic/inhibitor combination of piperacillin-tazobactam-tigecycline 
does not appear to have fared much better than the tigecycline-ceftazidime combination.  
Piperacillin-tazobactam-tigecycline gave very similar results to ceftazidime and its 
effectiveness when not in combination was broadly similar – though slightly less effective 
against S. maltophilia suggesting that the β-lactamases in this case may not have been 
bypassed/inhibited.  It may be possible to argue on this basis, that the inhibitor may play no 
part in synergistic interactions though further study would have to be carried out to ascertain 
this.  More concerning, was the 11% antagonism seen when the combination was used 
against S. maltophilia.  Historically, antibiotics such as aztreonam have been tested in 
combination with an inhibitor against A. xylosoxidans (Vartivarian et al, 1994).  It was noted 
that only a 2:1 ratio of inhibitor-antibiotic would be effective in-vitro – the issue being that 
serum levels of the inhibitor drop rapidly allowing the antibiotic to be inactivated.  This may 
limit such options and it is unclear how this would be useful clinically. 
There is some evidence to suggest that antibiotics such as temocillin may still bring about a 
positive outcome, despite appearing to be resistant in-vitro.  A study was carried out in 1992 
by Taylor et al where clinical improvement was observed in patients that were colonised 
with isolates previously established as being resistant.  This suggests that higher therapeutic 
doses may be beneficial.  However, in our study, we found that temocillin was not effective 
in-vitro against A. xyolosoxidans or S. maltophilia isolates.  Activity against the Bcc species 
in general was more promising, though only in the order of around 30% sensitivity.  This 
loosely agrees with previous work by Lekkas et al (2006) though their work measured 
outcomes where temocillin was used.  Unfortunately they were unable to categorically state 
that temocillin was individually beneficial, as their patients also received (as is standard 
practice) an aminoglycoside.     
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Unfortunately, synergy was rarely observed when tigecycline was tested in combination 
with temocillin.  Had synergy been common, it may have been possible that this would 
further enhance clinical outcomes where resistance has been detected.  With the combination 
of higher dosing, and a synergistic effect, the resistance mechanisms could potentially have 
been overwhelmed.  Unfortunately, in the case of temocillin, it was more common – though 
by no means predominant, to observe antagonism when the combination was tested against 
S.maltophilia and other multi resistant GNBs.  It would seem prudent therefore, in this case, 
to avoid using temocillin in combination with tigecycline.  Curiously, our results do not 
match some previous work carried out in 1999 by Bonacorsi et al, where temocillin was 
found to be the most active β-lactam agent.  It is difficult to explain this seemingly different 
picture of resistance, other than to suggest that the populations tested differ geographically 
(their study was carried out in France), and may therefore, have acquired differing resistance 
factors.    
Meropenem as a β-lactamase stable carbapenem had mixed results demonstrating around 
50% sensitivity to all of the organisms tested except, as expected, for S. maltophilia.  In 
combination with tigecycline, meropenem demonstrated 23% synergy (B. multivorans), 
though the pattern for all other organisms was predominantly indifference.  These data 
match previous work, and we note that in other studies, the MIC range was relatively 
narrow.  It was suggested previously (in 1999 by Bonacorsi et al) that this may have been 
due to the recent introduction of the drug, though the situation some 11 years later appears to 
be similar and this may be promising for the long term use of meropenem against the Bcc 
and other species tested here (excepting S. maltophilia).  Meropenem demonstrated good 
levels of synergy against the B. multivorans (23%) though no synergy was observed with 
B.cenocepacia – there being only antagonistic activity (6%) other than indifference.  Once 
again, and following the pattern of otherwise resistant antibiotics, there was some low level 
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synergy observed when the combination of meropenem/tigecycline was tested against 
S.maltophilia.  Given the overall lack of activity of meropenem against S.maltophilia, 
however, it seems likely that this combination would not be clinically useful.  Likewise, any 
decision to treat with the combination against Burkholderia species would have to be 
carefully considered due to the antagonism noted with B. cenocepacia.  We cannot say from 
this study whether this is species specific, or merely an anomaly of testing with these two 
different sets of isolates.   
 
7.2.6 Aztreonam 
 
Aztreonam is noted to have variable activity against the Bcc species and little activity 
against S. maltophilia and A. xylosoxidans - including in combination with β-lactamase 
inhibitors (Vartivarian et al, 1994; Denton 2008).  Our findings in this study appear to agree 
with these observations, though the susceptibilities of the Bcc species tested here were 
somewhat disappointing A study in 2009 by Poirel et al, found that B. multivorans harbours 
a chromosomally active Class A β-lactamase (PenB).  This is induced via a LysR-type 
transcriptional regulator similar to that found in Proteus vulgaris and a number of other 
organisms, though the trigger is unclear.  The narrow spectrum of activity of this enzyme 
includes aztreonam.  Once again, whilst it is difficult without additional data to hypothesise 
a reason for differential expression of such resistance mechanisms or, in fact, their presence 
in the organisms tested here; it may be likely that such mechanisms may be responsible for 
the differing antimicrobial susceptibilities.  Notably, however, and in line with other 
antibiotics tested in the study, we found that synergy was present when aztreonam was 
tested in combination.  This synergy was observed across the entire spectrum of species 
groups, though as stated elsewhere in this study, it is difficult to accurately predict whether 
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the combination of two poorly active antibiotics would add up to a more positive clinical 
outcome than the use of a single or groups of far more effective agents.   
7.3 Mechanisms of synergy 
 
It is difficult to account for the sporadic nature of synergy or antagonism.  Indeed, where 
previous work has been carried out to determine synergy, antagonism or additive effects, 
there is very little information relating to the mechanisms behind these interactions.  Many 
authors point out the clinical benefits or otherwise of the interactions, but do not suggest the 
basis/origin of the interactions.  It is clear that fuller understanding of this is needed before a 
true picture emerges that can be reliably used in a clinical setting.   Some combinations are 
known to act in a positive way (such as penicillins and amino-glycosides) and the 
mechanism is largely understood.  One can only postulate that, as with the previous 
example, one of the antimicrobials is able to prepare conditions that are conducive to the 
next antimicrobial agent.  Combinations where macrolide antibiotics (not tested here) have 
been included, for example, have been demonstrated to reduce biofilm/alginate production 
in CF isolates (Saiman et al, 2002).  This is an example where the antibiotic used in 
combination is not necessarily acting upon the target organism, but may be simply making 
the environment around the organism more conducive to the bactericidal or bacteriostatic 
effects of the antibiotic given/tested in combination.   
In terms of both the usefulness of synergy testing and therapy, and the scientific basis for 
carrying out these tests, it is interesting to note previous findings when P. aeruginosa was 
tested against combinations.  It was found by Saiman et al (2002) that CF strains responded 
better to combination therapy than their non-CF equivalents.  Equally, non-mucoid strains 
did not respond as effectively as the mucoid strains.  This suggests that synergy testing may 
have some measurable, and tacit, benefit in those cases, and that the mechanisms of synergy 
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may not be straightforward.  The possibility that synergistic combinations may act upon 
other bacterial/host factors in addition to the published bactericidal/bacteriostatic effects 
cannot be ruled out and would be an interesting area for further study. 
Further supporting the idea of a cascading “open door” interaction, are other studies using 
non-antibiotic substances that considerably increase the efficacy of antibiotics when given in 
combination.  One such study used membrane-active peptides (MEPs) that are capable of 
disrupting, with catastrophic effect the bacterial membrane, in combination with a number 
of commonly used antibiotics to test their effect against S. maltophilia.  Given that the 
impermeability of S. maltophilia (and, indeed, other CF organisms) acts as a major innate 
resistance mechanism, it is thought that these MEPs are able to penetrate the cell and disrupt 
to an extent the peptidoglycan by the induction of bacterial hydrolases.  This renders the 
bacterial membrane more porous and promotes synergy with some antibiotics (Giacometti et 
al, 2000).  Once again, this demonstrates where a substance may be used to simply “open 
the door” prior to the bactericidal work of the active antimicrobial where this would not 
have been possible with only one antimicrobial alone.  It must be stated, however, that the 
combination given above, was active only for a limited group of antibiotics – namely 
clarithromycin, β-lactams and polymixin B.   
Despite the lack of an inhibitor, ceftazidime in this study was relatively successful when 
paired with tigecycline.  Given the completely different mechanisms of action of these 
antibiotics, it may be possible that a cascading effect may have occurred.  Poor permeability 
is a noted resistance mechanism in most CF related organisms – and particularly where the 
Bcc species are concerned.  The presence of ceftazidime, as an antibiotic that damages the 
cell membrane, may be a factor in the further success of tigecycline.  Given that tigecycline 
does not appear to be as efficacious when compared with minocycline – and this may be due 
to a difference in cellular penetration, it may be possible that the disruption of the cell 
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membrane may be sufficient to allow the further penetration of tigecycline – resulting in a 
synergistic effect.  Furthermore, since synergy appears to be a phenomenon that is related to 
resistance (most occurrences of synergy were noted in otherwise resistant antibiotics), it is 
possible that the ceftazidime does not actually kill the cell, but simply acts as a conduit 
through which tigecycline can penetrate and disrupt the cellular protein production.   This, 
of course, is speculation, and it is perhaps equally possible that the activity of tigecycline is 
sufficient upon the bacterial cell to disrupt the chromosomal β-lactamases – thus allowing 
ceftazidime to act more fully upon the cellular membrane structure.   
It is clear from previous work that the mechanisms of synergy are poorly understood.  Many 
clinicians, in fact, may see them as almost irrelevant so long as the outcome correlates 
successfully with the results of testing.  A fuller understanding of these mechanisms, 
however, would allow this correlation to be understood further and it seems that further 
work is warranted in this subject.   
The outcome of this study is difficult to judge objectively, as the measurement of outcomes 
may take a number of different forms.  Highest on the list, of course, remains the clinical 
improvement of patients’ health and wellbeing – especially those that are unfortunate 
enough to harbour resistant strains (McDowell et al, 2004).  This study does not have a 
clinical remit and can only, therefore, act as a predictive indicator of success or failure.  
Only further trials in-vivo can accurately ascertain the relevance of the work carried out 
here. 
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Chapter 8 
8.0  Relevance and application to practice 
 
8.1 Clinical relevance of synergy testing and the application to practice 
of this study. 
 
Previous work on synergy and combination antibiotic therapy has not always targeted the 
same organisms that were used in this study.  The combinations used in this study are to a 
greater extent, unique at the time of writing.  Interestingly, however, where data has been 
published we note that most studies have found similar levels of resistance in-vitro when 
carrying out MIC testing with the organisms used here.  Likewise, we have also encountered 
similar levels of synergy, antagonism and indifference that, whilst sporadic and of a low 
level nature, is encouraging for further investigation (Saiman, 2002).   
It is clear from the data that synergy does occur – albeit in a seemingly random and sporadic 
pattern.  The data presented here, however, show that in most cases, synergy has occurred 
where the organism would have been otherwise resistant to the test antibiotic when tested 
individually.  This poses an interesting question of whether this information is clinically 
useful/relevant.  Where an organism was sensitive, then synergy may be somewhat less 
useful, since the antibiotic being tested would likely have yielded a positive clinical outcome 
anyway – with some exceptions noted earlier.  It may be useful, in the reduction of 
resistance, and it could be argued that any improvement in MIC as a result of synergy could 
be beneficial.  Where the organism was not susceptible in-vitro, however, it may be that a 
synergistic interaction would be sufficient to make the difference between a positive or 
negative clinical outcome – either by being sufficiently effecaceous in combination to kill 
the organism, or by rendering it vulnerable to host factors by damaging it. There are, of 
course, other issues that confound the results.  CF isolates – especially Bcc organisms, 
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unlike Pseudomonads and other colonising organisms possess multiple resistance 
mechanisms that may not be overcome by simple combinations (hence there are now trials 
being carried out using triple combinations).  One example of this would be where an 
aminoglycoside is used in combination with a β-lactam antibiotic.  Under normal 
circumstances this combination is noted to produce a synergistic effect.  With the Bcc 
organisms however, the presence of both chromosomally encoded β-lactamases, altered 
penicillin binding proteins, intrinsic resistance to aminoglycosides and other mechanisms 
such as antibiotic efflux pumps (effective against trimethoprim and ciprofloxacin), makes 
combination therapy an unpredictable and subjective method of treatment.  Randomised 
control trials have found that triple combinations are generally beneficial in CF patients, 
though antagonism is common.  This demonstrates a case for good quality synergy testing 
before treatment is commenced (Aaron et al, 2000).  In Aaron et al (2000) the best 
bactericidal activity against B.cepacia was achieved using inhaled tobramycin, meropenem 
and a third antibiotic (ceftazidime, chloramphenicol, trimethoprim/sulfamethoxasole, 
aztreonam or amikacin).  This suggests that where patients are stable, multiple combination 
testing can give an indication of likely therapeutic success in the event of an excacerbation.  
The benefit being that time is saved, and the patient will benefit from rapid targeted therapy 
(Aaron et al, 2000).   
Where organisms are found to be resistant in-vitro, there is often still a positive response in-
vivo when the patient receives antimicrobial chemotherapy.  Likewise, antibiotics such as 
tobramycin and colistin have been demonstrated to be more useful in high doses (the most 
effective being colistin) – and in nebulised form, it is possible to reach these concentrations 
at the site of action.  Without further clinical trials, it is difficult to predict the activity of 
tigecycline in-vivo, either alone or in combination when at higher concentrations for a 
number of reasons.  Tigecycline is not currently available in a nebulised form and may only 
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be administered as an IV antibiotic meaning that the sites of administration will differ. The 
variable routes of administration along with variability in the organisms found in CF patients 
mean that the results of testing are difficult to predict with any accuracy.  It is likely that this 
variation would carry over to the clinical treatment/response and would have an impact upon 
outcomes. It may not be possible to reach the concentrations required at the target site 
without administering higher doses, possibly over different timescales – indicating a higher 
cost in clinical contact.  Issues of toxicity fall outside the remit of this study and would have 
to be investigated further.  It should be noted, however, that this study has demonstrated that 
many isolates show intermediate sensitivity (or resistance) and that this can be viewed as a 
subjective end point of MIC testing.  Where this occurs, there is a possibility of the 
antibiotic being successful in treatment of colonised patients – particularly those that are 
colonised with Bcc species.  Likewise, given that we have demonstrated some synergy with 
other commonly used antimicrobials, it may be possible that some increased effectiveness 
will be seen when these combinations are attempted in-vivo.  The real issue with these 
assumptions, however, is that the “hit rate” is relatively low.  We were not able to 
demonstrate synergy across the whole spectrum of organisms, antimicrobials or, in fact, 
sensitivity in many cases.  If the clinician were to rely upon the synergistic effects of 
antimicrobial combinations as tested here for empirical treatment, then failure is a 
significant possibility.  As synergy was found to be in the order of 20% or less across the 
board, then we can assume that only a small percentage of these patient isolates will actually 
respond in-vivo.  This makes the synergy testing versus clinical outcome link potentially 
tenuous.  Conversely, when previous work is taken into account, we find that many studies 
that look at the potential clinical correlation between synergy testing and outcome do not 
take note of the small number of patients who have failed previous empirical treatments – 
and it is possible that this small subset of patients may benefit from such therapy.  The end 
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point of treatment in CF as mentioned previously is not complete eradication.  This would 
be physically impossible with current medicine.  Reductions in colonisation with a 
commensurate improvement in symptoms is one of the primary goals.  One aspect that many 
researchers do not appear to take into account is this slightly more limited – though just as 
important role.  It doesn’t stop there, however.  Antibiotic treatment can have many benefits 
– they challenge or stress the bacterial cell sufficiently to alter its behaviour and this can be 
observed where multiple phenotypes are expressed.  The reduction of biofilms, for example, 
may be a useful product of antimicrobial chemotherapy with the resulting drop in 
pathogenicity/virulence of the target organisms.  It is in these specific areas that antibiotics 
may be useful – regardless of sensitivity results.   
Given the nebulous occurrence of synergy and antagonism in all of the antibiotics tested in 
this study, combined with the doubt about the clinical uses of this data, one must pose the 
question about routine laboratory testing for synergy and its validity/usefulness.  Many 
researchers appear to have taken a purely research/laboratory view of antimicrobial testing.  
Models such as the biofilm method used by Keays et al (2009) or, indeed the synergy model 
used in this study (Pankey & Ashcraft, 2005) may not lend themselves to the routine 
laboratory where thousands of CF related specimens are received every year.  To carry out a 
simple disc test using any one of the currently available methods (modified Stoke’s, BSAC), 
takes a very short period of time, and is relatively inexpensive.  Most laboratories use this 
type of testing as a routine method, and though it does not give precise MIC data, it is 
predictive of outcomes.  MIC testing is expensive and more time consuming than standard 
disc diffusion methods.  Additionally, this expense is multiplied where numerous antibiotics 
are to be tested – either individually or in combination.  To test in combination, as seen in 
the method section, one is required to test all of the antibiotics individually first – at 
considerable expense (over 24 h), followed by combination testing.  The total time from a 
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fresh, pure culture, to a completed result is around 24 h for MIC testing and 48 h for a 
synergy test.  It must also be taken into account that these organisms often do not oblige by 
growing in pure cultures, so additional time must be taken to purify organisms, thereby 
ensuring valid results.  The technical time required of scientists in the laboratory is also 
greatly enhanced where synergy testing is used – taking up to 1.5 h to set up a small number 
of synergy tests.  This is due to the long incubation required for diffusion.  It is, therefore, 
unlikely that this type of testing will ever be considered for routine use within the 
laboratory.  Newer suggested methods of testing may be more representative of the in-vivo 
response, but would also be more difficult to introduce into the routine laboratory.  In the 
LTHT, specimens received number in the thousands, and it would be very difficult to 
conduct biofilm testing on each of these.  Additionally, where multiple morphotypes are 
observed, this would considerably increase the cost and workload per patient.  It remains to 
be seen how such methods could be introduced in a practical and inexpensive way (Keays et 
al, 2009). 
Synergy testing is expensive and time consuming.  A number of laboratories have been set 
up around the world (UK, USA, Canada, Australia and Europe) and the cost of testing single 
isolates can be as high as $300 (Aaron, 2007).   
Many authors have questioned the clinical relevance of synergy and MIC testing and clearly 
have some distrust/doubts about how results of this should be employed in clinical practice.  
This study, unfortunately, has probably added little to this ongoing debate.  It is possible to 
view the situation from two distinct positions.  The first is that MIC/synergy testing is a 
complete waste of time and resources.  The tests may be seen as being carried out in near 
“perfect” conditions, on a solid media with pure organisms and at concentrations that do not 
necessarily represent those found in-vivo.  There are no host factors, the environment is 
carefully controlled and any effects are timed carefully.  Compared to the human 
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environment where host factors abound, temperature and pH may vary considerably, and 
other drug-drug interactions make treatment unpredictable, the situation may be seen as 
quite different.  Adding to this are the complications of multiple morphotypes, biofilm 
production, differential growth phases and the protective element that they provide.  From 
this view, and it is quite understandable, clinicians may decide that empirical treatment can 
only be guided by clinical response and prior experience.  Indeed, there are a great many 
previous studies that have found no correlation between testing, and clinical outcome (Smith 
et al, 2003; Aaron et al, 2006; Aaron, 2007; Etherington, 2007; Fowraker et al, 2009; 
Fowraker et al, 2010).   
The other viewpoint contends that MIC and synergy testing may actually be a useful tool 
where used properly – and it is this appropriate use that is advocated here.  As with any 
scientific methodology that informs clinical treatment, the response of the patient is the end 
point and the raison d’etre behind all of the work – including this study.  If the data are used 
appropriately, with the previously mentioned limitations taken into account, then we believe 
that MIC and synergy testing may be a useful, and perhaps powerful tool to guide empirical 
treatment of this unfortunate group of patients.  Where an organism (including multiple 
morphotypes) has been identified and tested, then it should be remembered that this is the 
same causative/colonising organism possessed by the patient.  Some of its response, 
therefore, will be representative of the likely response in-vivo.  Where options are limited by 
resistant organisms, multiple morphotypes and phenotypical expression, there are only two 
avenues of action.  Empirical therapy guided by experience, and evidence based targeted 
therapy.  Despite obvious limitations of MIC/synergy testing, it stands to reason that this 
must still offer a more accurate view of likely outcome than simple guesswork – though 
experienced clinicians may be able to predict the likely response for fast treatment.   
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The position taken by this study – based upon the evidence gathered here, is that on the 
whole, synergy testing is not useful.  This is because it is time consuming, expensive, and in 
most cases – as seen here, will not yield any useful information.  The vast majority of 
antibiotic combinations that are tested result in indifference.  There are situations, however, 
where a patient suffering from an exacerbation or significant morbidity may benefit from the 
small changes in efficacy that synergistic combinations may provide.  As stated earlier in 
this study, there have been noted benefits of combinations in particularly sick patients – but 
these could not be correlated with testing.  This does not mean that there is no correlation.  
In those vulnerable, perhaps, last chance patients then synergy may be warranted.  Given the 
heterogeneous nature of both the organisms, and the occurance of synergy/antagonism, it is 
essential that combinations should be trialled in-vitro first, to prevent clinical failure.   
Where CF patients have undergone lung transplantation, their risk of death within 1 year of 
this procedure has been noted to increase by up to six times.  Any reduction in colonisation 
has to have significant benefits for these risk groups and cannot be underestimated 
(Alexander et al, 2008).  Further benefits of the successful reduction in numbers of patients 
colonised with B.cenocepacia and, indeed Bcc generally, include the not inconsiderable 
improvement in psycho-social status of patients that attend the CF centre.  It is clear that the 
isolation of patients that harbour these strains can have a dramatic effect upon their social 
lives and the way in which they are accepted by other CF patients that may attend the same 
unit or other CF related events.  The reduction in the prevalence of Bcc strains in particular, 
will reduce this level of segregation for patients and improve their psycho-social wellbeing.  
More difficult to measure, are the spin-off benefits of this – such as the improvement in 
health that is often observed in “happy” patients (Speert et al, 2002; McDowell et al, 2004).  
A further benefit of such improvements can be seen in the microbiological monitoring that is 
required.  Isolates such as the Bcc species require complex identification at specialist 
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reference centres.  A general reduction in the isolation of these organisms from patients 
attending the CF unit may have a commensurate reduction in spending as a result of this 
drop in identification referrals in some units, though the LTHT currently does not pay for 
these.  Normal microbiological monitoring, however, is unlikely to change as a result of this, 
as it is important to maintain a clear picture of each patient’s colonisation status (McDowell 
et al, 2004).  Additionally, it should be noted that the isolation procedures of any CF unit 
will not mitigate against the sporadic spread of Bcc from environmental sources – meaning 
that expenditure on screening remains prudent (McDowell et al, 2004). 
We have demonstrated in this study that tigecycline has disappointing activity against the 
Bcc organisms.  Equally, we have demonstrated that other antimicrobials are still effective – 
and that there are still many options with each of the species tested.  We have demonstrated 
that synergy does exist, it does occur with most of the groups tested, and that multiple 
combination therapy can have beneficial effects – though it should be used carefully, and 
after thorough testing and review of individual cases.  It may be that synergistic 
combinations of antibiotics will be the way forward as options are limited by further 
resistant phenotypes.  Only further, thorough, study will provide the full answer as to the 
correlation between testing and outcome.  
8.2 Limitations of this study and suggestions for further work 
 
As with many studies carried out in the pursuit of novel treatment strategies for patients with 
difficult conditions, there are a number of limitations and confounding factors that can affect 
the outcome of such work.  This is particularly true for CF patients and their associated 
isolates and antibiotics.  It is appreciated that the list of limitations given here is somewhat 
long and may cast some doubt upon the likely success, or impact of this study, though these 
confounders are quite normal and common in a CF study of this size.  Many of the issues 
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highlighted fall outside the remit of a simple in-vitro investigation such as this one, and 
require huge budgets, ethical approval, willing patients and time to complete – often making 
them impractical on a modest budget.  Any such approach would have to include multiple 
centres – both in the laboratory and clinical environment.     
One issue that remains unresolved by this study is that of clinical efficacy of the antibiotics 
tested – both alone and in combination.  Whilst we can postulate based upon in-vitro data, it 
is difficult to fully understand the in-vivo relationships between bacterium, host and 
antimicrobial.  Tigecycline is clearly less effective – particularly where Bcc species are to be 
the target organisms, though it could be that in-vivo, the effect of host factors, biofilm 
growth and antibiotic may change this relationship sufficiently that this balance is redressed.  
A study by Keays et al (2009) took a slightly different approach to susceptibility testing – 
and this may further develop the methods used in this study.  They chose to use a biofilm 
model, citing the build up of biofilm in CF patients as a potential confounding factor.  Their 
model was used to test susceptibilities of the bacteria that are tied up in a biofilm and, 
therefore, likely to be exhibiting altered phenotypical expression – resulting in differing 
antibiotic susceptibilities.  They had found that antibiotics had previously been prescribed 
based upon culture results from planktonically grown bacteria.  Unfortunately, isolates 
grown as planktonic cultures were found to be far more susceptible (60%) to previously 
prescribed antibiotics than the same organisms grown in a biofilm model (22%).  How this 
correlates to clinical outcomes, however, remains to be seen.  In the study, they used 
multiple parameters to calculate clinical outcomes, and though this study largely stands by 
itself in its methods, it may inform future work and, indeed, be more representative of the 
situation found in CF patients in-vivo.  Another aspect of growth in biofilms that is often not 
taken into account, is the growth phase of the organism at the time of testing.  How this 
information could be introduced into testing is difficult to imagine, but a study by Desai et al 
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(1998) demonstrated that this can make a significant difference to the results of 
susceptibility testing.  Biofilm susceptibility testing appears to be one way that susceptibility 
may be ascertained, though this is, as yet, a new idea and has not been thoroughly correlated 
with clinical outcomes or more standardised methods (Caraher et al, 2007; Keays et al, 
2009). 
One important aspect of susceptibility testing in CF patients that may be overlooked, is that 
it does not often correlate to a specific end point (Foweraker et al, 2009).  Where antibiotics 
may be used in a case of bactaeremia, for example, the end point is the eradication of the 
target organism.  This can be measured with some accuracy.  In CF patients, however, the 
aim is for a reduction in bacterial colonisation and the resulting improvement of pulmonary 
symptoms.  Eradication is not only unlikely, it is virtually impossible to clear the lower 
respiratory tract of organisms.  It is reasonable to assume, therefore, that such open ended 
susceptibility testing may not correlate accurately with outcomes.  There are also many ways 
in which these improvements can be measured – from improvements in forced expiratory 
volumes, to the wellbeing of the patient.  Further work to take into account these factors in 
combination with multiple antibiotic treatments correlated with MIC/synergy testing would 
possibly answer some of the questions relating to clinical efficacy and outcome.  It seems 
likely, however, that where studies take into account multiple factors, they will likely arrive 
at different conclusions based upon the factors chosen (Foweraker et al, 2009).  Clinical 
outcome is difficult to measure, and to include this in any study of this type would 
substantially increase the difficulty by the addition of a number of confounding factors that 
would have to be carefully controlled such as environmental factors, host factors, concurrent 
treatments etc. 
Possible reasons that combination testing may not yield a definite clinical benefit when 
compared to single antibiotic testing are unclear.  Other authors have investigated this 
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phenomenon, and numerous comments have been made all of which may be relevant to this 
study (Aaron et al, 2005).  As with many other studies carried out, we were unable to 
account for “unknown” confounders.  An example of this can be seen where apparent 
synergy occurs but where this is not translated into clinical benefit in a controlled trial.  The 
possibility that some antimicrobials (Aaron et al (2005) use the example of azithromycin)) 
may have other effects that are of more benefit in improving clinical outcome (such as the 
reduction of inflammation) – whereas the enhanced bactericidal effect produced by 
synergistic interactions may make little difference against a large and variable population of 
resistant organisms. 
Given the differences in expression of antibiotic susceptibility of organisms investigated in 
this study, it may have been prudent to log concurrent antibiotic treatment of patients from 
whom the isolates were obtained.  Having demonstrated links between previous treatment 
and the expression of resistance (Drevinek et al, 2008), it would follow that a prospective 
study may shed further light onto the clinical relevance, impact and after effects of treatment 
with the antimicrobials available.  Unfortunately, prospective studies to assess the 
correlation between antimicrobial sensitivities and clinical response are difficult to carry out 
due to the ethical dilemma of treating/not treating where susceptibilities suggest otherwise.  
We maintain, therefore, that only retrospective data can be used and may be flawed by other 
confounding factors that are not recorded concurrently.   For future work, a retrospective 
study taking into account all of the above may yield more accurate and clinically relevant 
data.  This would be time consuming and even in a busy CF unit, reliable data utilising 
sufficient numbers of isolates and patients would take some considerable time to collate. 
 Detection of higher levels of synergy may not be possible due to limitations in the E-test.  
Because there is a lower limit to the E-test antibiotic strip, low MIC organisms may grow 
close to, or even exceed these limits – giving no discernable ellipse difference.  Where 
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synergy occurs at or around this point, we would simply not detect it.  Likewise, at high 
MIC values we would have similar problems – and this may skew data relating to high 
concentration antibiotics where they are administered by nebulisation.  In addition to this, 
we did not grow or detect SCVs of any organism type – possibly due to the reliance on a 
solid culture medium.  In mitigation of this, the final MIC/synergy test results would be a 
composite of any isolate plus its SCV and so we consider the MIC/synergy results to be 
accurate. 
One potential problem with antimicrobial therapy for CF patients is the relative promiscuity 
of the organisms with which they are colonised.  Previous studies have demonstrated that 
where an exacerbation occurs, treatment is likely to be given.  In most clinical situations, 
this will be informed by previous microbiological results.  Where there has been any delay 
in real time between testing and the exacerbation (a 23% difference in susceptibility was 
found in a study conducted by Aaron et al (2005) where treatment was given 3 months after 
the last susceptibility test), there is the strong likelihood that antimicrobial susceptibilities 
may have evolved and that previously efficacious antibiotics may be rendered useless.   
There are currently no published MIC values against the Bcc species and other organisms in 
this study – particularly in relation to the tetracycline class of antimicrobials.  The result is 
that we have extrapolated data from the nearest and most similar organisms – in most cases 
P.aeruginosa.  Until guidelines are published, we can only speculate about any error that 
arises as a result of these assumptions, and at present, the data can only be taken at face 
value.  Of note, is that other authors who publish similar data have access to the same 
BSAC/CLSI data that was used here, and so we can say with some confidence that our data 
is standardised with any concurrent works.   
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In calculating synergy, we described our data as “synergistic”, “antagonistic” or 
“indifferent”.  It was noted that previous studies have also used the term “additive” where a 
small proportion of those results falling between Synergistic and antagonistic could be 
described to represent the sum of the two susceptibilities (Saiman et al, 2001).  It was 
decided for the benefit of this study to ignore this term, since it is not only difficult to 
accurately ascribe an additive vs synergistic effect (where summative results occur, we 
cannot say exactly how this has occurred), but may be clinically irrelevant.  If two 
antibiotics are found to inhibit growth, and they show “indifference” when paired together, 
then clinically, it may be assumed that no antagonism will occur.  The likely result, therefore 
would be either additive or, indeed, indifferent where the combination is used.  In the 
interest of brevity, therefore, and to avoid producing misleading results in what is already a 
difficult clinically quantifiable situation, the term “additive” was omitted from this study.  
For completeness, however, it should be noted that an additive effect would generally be 
considered to include those organisms with a summation FIC of 0.5 - < 1.0 (Saiman et al, 
2001).   
It has been demonstrated that environmental colonisers such as Pseudomonas and 
Burkholderia are often present in multiple morphotypes – each with a different bacterial 
sensitivity.  It can be very difficult, therefore, to obtain consistent and repeatable MIC data 
for these organisms as each subsequent testing may select another colonial variant that, to 
the microbiologist, appears to be the same as the rest (Doring et al, 2000).   
Given that minocycine is the legacy analogue of tigecycline and was shown, overall, to be 
more effective in-vitro than tigecycline, it may have proved beneficial to attempt synergy 
testing with this antimicrobial.   
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Chapter 9 
9.0 Final Reflections 
 
I write this, a short piece of reflection, as the project nears its conclusion after several years 
with the benefit of hindsight and humility.  It is easy, within the scientific profession of 
microbiology – and I would imagine other professions, to become somewhat closeted – not 
just in our own specialities, but to a degree within our own world and self importance.  
Viewing the NHS and the world through the eyes of a microbiologist is comforting in its 
familiarity.  This project has challenged this familiarity in a number of ways – few of which 
I expected.  Of course, all soldiers like to play the part of generals; nurses second guess 
doctors, and scientists claim to know the secrets of life, the universe and everything.  How 
humbling, therefore, to work outside our own normal remit – inductively learning and 
updating the process of research. 
9.1 Personal development and learning 
 
In a moment, perhaps a year or so ago, I understood how the astronauts of the Apollo 
mission must have felt as they viewed the blue orb of Earth from afar – tiny in our almost 
infinite universe.  It was this moment in which the true extent and reach of projects such as 
this became apparent.  The realisation that the science, whilst important, plays but a small 
part in the whole clinical process was something of a revelation.  I’ve always been aware of 
the wider implications of the biomedical profession – one must always bear in mind that a 
life and its welfare is the end point of anything that we do on a day to day basis.  Mistakes 
can sometimes be costly.  Working against this, however, is the day to day routine.  Tests 
arrive in the laboratory.  We perform them, and then release the results – where some distant 
and anonymous clinician interprets them and treats the patient.  We exist in this comfortable 
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world from day to day – and only occasionally step out into the wider world of clinical 
medicine.  It would be true to say, without being disparaging of the diagnostic scientist that 
there is very little reflection on or in action during these processes (Schon, 1987).  
This project has been my journey into that wider world.  Ironically, it has been a journey 
into a small part of the wider world – being specialised to such a degree in CF medicine. 
I think it is fair to say that my own learning style throughout this project has been somewhat 
inductive.  I was given the idea and brief by Dr Miles Denton – a consultant clinician and 
specialist in CF medicine.  We had some idea of the likely outcome – previous work had 
been carried out on these organisms, though it was limited.  My own position was largely 
technically based – culturing bacteria and interpreting sensitivity patterns.  Looking into the 
wider field of clinical medicine took some adjustment – not only in my own knowledge and 
scope of practice, but also in interpretation of the science.   Much of the process during this 
project – particularly during the first 3rd was somewhat inductive and reflects the “self 
directed learning” style suggested by Gerald Grow (1996).  This was not what I had at first 
anticipated, but with the benefit of some hindsight, I believe that the project is richer in its 
content, and I feel that I have more ownership than if the whole project had been dictated.  
Dr Miles Denton was very supportive of this method of study and has been a constant source 
of contact where questions arose.  It is this support that ensures success as suggested by 
Daloz (1986) in a model where mentorship must match the challenge.  Where the challenge 
is high and mentorship is low – so failure is likely.    
The work that I carried out for this study was practically based – well within my own 
comfort zone.  The difference on this occasion was the reflection on action that was 
required.  Not only did I have to look at the work that I was carrying out – was it done 
accurately/correctly and was it appropriate, but also how did it fit with the literature and 
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current thinking in CF medicine.  This kind of reflection suggested by Schon (1987) is one 
that research scientists likely perform without being aware.  For the diagnostic scientist, 
however, where results are produced, released and the next test arrives, it is more unusual.  
It took me some considerable time to change from an almost “concrete” style of reflection 
upon action to a more “formal style” (Dembo, 1994) where every action carried out had to 
be analysed and put into context with the wider field of clinical medicine.  With a more 
“formal” style, it was possible to find the meaning of the work that was being carried out.    
In Fig 9.1, my own learning style during this project is represented.  It appears somewhat 
complex, but for the user – me, it is remarkably simple:  the usual reflection takes place – 
looking at an event, that has just occurred about which I am not content (or, in fact, it may 
be a positive event which I choose to look back on and learn what I did right).  My feelings 
are explored – was it painful, embarrassing, should I feel contented/proud of the 
achievement, followed by a rational look at my own position - did I perform the task 
accurately, and at what level?  Am I competent or proficient – do I work according to the 
standard operating procedure, or am I able to use my own clinical judgement?  Here, there is 
the option of mentoring – someone to tell you at what stage you appear to be.    It is or at 
least should be, however, a two way process (Johns, 2000).  At some stage, you have to look 
forward – what am I going to do next to solve the problem or build upon a success?  Again, 
in the right situation, a mentor can help, if appropriate.  This reflection continues with 
constant reference to a fixed point – where am I now, at what stage in my research and 
competence (this can be illustrated by the ladder of competence suggested by Dreyfus & 
Dreyfus (1986).  This project has been pieced together – rather in the style favoured by 
Teekman (2000) where any piece of work, event or thought process can be broken into 
discrete portions.  There were a number of distinct portions to this project – each with their 
own challenges and response – and each in-turn requiring a different, reflective approach.   
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Fig 9.1: The reflective process of this project. 
These ultimately have combined to produce the final thesis presented here.  I think that this 
was a necessary process.  The large size of this document along with the complexity of 
balancing work and play, have made it very difficult to see the project as a whole – 
particularly during the writing phase.  By breaking down the project, it has been possible to 
give each section the attention that it was due – in the hope that the whole thing would fit 
together well.  It was this final stage that was the most difficult and having asked a number 
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of completely neutral people to read the document, could I be assured that it works as I 
hoped.   
My time at during this project fulfilled several criteria that are set down by Carper (1978) 
when several patterns of “knowing” were identified.   
Empirical knowledge - was the first of these fundamental criteria to be addressed.  I was able 
to increase my theoretical and technical knowledge about CF.   
Personal Knowledge - learning about oneself and how to interact with other professionals or 
patients.  Each of the parts of this project involved interactions with different groups.  And 
each part as it became complete, gave me further confidence and knowledge to move onto 
the next.  
Aesthetic knowledge - a subjective and tacit knowledge gained through experience does not 
come quickly and I think it would be safe to suggest that I still have much to learn.  In a 
profession such as the biomedical sciences, tacit knowledge is less appropriate although is 
still used by the proficient professional (Dreyfus & Dreyfus, 1986).  Scientific fact is the 
main driving force behind decisions that are made – and this fits nicely with the latest 
evidence based practice campaign of the NHS (Todd et al, 2004).  Because we do not deal 
directly with patients and make judgements based upon feelings, it has taken time to gain 
this kind of knowledge.    
I think that the process of reflection during this project has been complex and multi-faceted.    
Learning wasn’t the only issue, and neither was my own technical expertise as a scientist.  
The fear of failure and the desire to be a better professional was, perhaps, the overriding 
motivation during this project – and at times the only thing that stopped me from failure.  
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It is, perhaps, poignant that one should write a reflective piece about this large academic 
project.  I think that with a busy life encompassing both a new baby, and demanding job 
along with steadily advancing years, this is likely to be my last substantial academic piece of 
work.  It has in some ways been a cathartic experience – highlighting new areas of 
deficiency and putting to rest others.  I sincerely hope that whilst the clinical benefit of this 
project was, perhaps minimal; it may somewhere fit into the larger jigsaw and ultimately 
benefit those unfortunate sufferers of CF.   
9.2  Publication and dissemination 
 
One unfortunate part of this project – and no doubt a similar issue to all such research 
ventures was its end point.  Such ventures hinge upon results, and as such this can often 
determine whether it is viewed in a positive or negative light.   
Tigecycline is, of course, not just an antibiotic.  It is a commercial product, and as such it 
exists in the commercial world to be sold and to make profit.  Having gained an unrestricted 
research grant from Wyeth Pharmaceuticals for this project, it was natural that they would 
wish to publicise the work that was carried out.  I had some initial misgivings about this – 
wondering if the company would wish to put its own version of events forward, but these 
were soon alleviated when we had no such restrictions either suggested or imposed.  To this 
end, I accompanied a group of sales representatives to the European Conference of 
Microbiological and Infectious Diseases (ECCMID) where we presented a poster that was 
prepared by Dr Miles Denton (project supervisor) along with an abstract (Appendix 2).  In 
addition to this, a presentation was made at a CF conference in Brest, France by Dr Denton. 
Whilst this met with some success, as we were able to point out the relative benefits and 
limitations of tigecycline against specific organisms, we were unable to proceed further with 
publication.  The reasons given for this were numerous – some due to technicalities in the 
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way in which we had prepared the data though ultimately, it was felt by both the Journal of 
Antimicrobial Chemotherapy and Journal of Cystic Fibrosis that our data did not have a 
sufficiently positive clinical impact to warrant further publication.  Whilst I do not agree on 
this point – contending that we have demonstrated not only where testing is not appropriate, 
but also where it is, perhaps, entirely appropriate - this was a major blow.   
It was noted by Boyd & Fales (1983) that negative experiences are one of the strongest 
driving forces behind reflection and change – and this was true to an extent in the way that 
this project was carried out.  From this point, we were able to identify not only where the 
strengths of the project were, but also its weaknesses.  The main problem was that 
correlation of our results into clinical success is very difficult to achieve with CF patients.  I 
believe that this has become an important factor in our research and that any future attempt 
at publication would have to cover this subject in some depth.  In the meantime, this 
research thesis highlights many of these issues and is likely to be of use in the LTHT and 
hopefully, as other researchers pick up the loose ends, in the wider field of CF medicine.  
My feeling, based upon experience within the LTHT and other microbiology departments, is 
that this work will not be wasted by the limited exposure it has received.  Ultimately, it is 
likely that other projects, perhaps on a smaller scale, will incorporate these findings and 
expand upon them. 
Unfortunately, it has been said in the past that “science does not exist until it is published” 
(Garcia, 2004).  We must, though, at this stage take comfort in the positive effect that was 
gained through the poster presentation and literature produced by Wyeth pharmaceuticals.  
Publication and dissemination has occurred for this project – just not as widely as we would 
have hoped.  Though the clinicians in the LTHT CF unit, the findings of this project will 
find an audience and may, indirectly or otherwise, have some benefit howsoever it occurs.  
My feeling, is that publication will occur eventually, but that there may be some challenge in 
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persuading non-CF clinicians and researchers of the value of this work since they mainly 
work in finite end points – eradication of infection and curing patients.  It is an unfortunate 
aspect of CF medicine that we can say both as researchers, scientists or clinicians that this is 
not currently possible with available medicine.  For my part, I hope that this work benefits 
patients in the LTHT, and through the steady dissemination however it occurs, a wider 
population of CF sufferers.   
  
135 
 
10.0 References 
 
Aaron, S. D. (2007). Antibiotic synergy testing should not be routine for patients with cystic 
fibrosis who are infected with multi-resistant bacterial organisms.  Paediatric Respiratory 
Reviews, 8, 256-261. 
Aaron, S. D., Ferris, W., Henry, D. A., Speert, D. P., & Macdonald, N. E. (2000). 
Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected 
with Burkholderia cepacia. American Journal of Respiratory Critical Care Medicine,161, 
1206-12. 
Aaron, S. D., Vandemheen, K. L., Ferris, W., Fergusson, D., Tullis, E., Haase, D., 
Berthiaume, Y., Brown, N., Wilcox, P., Yozghatlian, V., Bye, P., Bell, S., Chan, F., 
Rose, B., Jeanneret, A., Stephenson, A., Noseworthy, M., Freitag, A., Paterson, N., 
Doucette, S., Harbour, C., Ruel, M., & MacDonld, N. (2005). Combination antibiotic 
susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant 
bacteria: a randomised, double-blind, controlled clinical trial.  The Lancet, 366, 463-471. 
Alonso, A., & Martinez, J. L. (1997). Multiple antibiotic resistance in Stenotrophomonas 
maltophilia.  Antimicrobial Agents and Chemotherapy, 41, 1140-1142. 
Alexander, B. C., Petzold, E. W., Reller, L. B., Palmer, S. M., Davis, R. D., Woods, C. 
W., & LiPuma, J. J. (2008). Survival after lung transplantation of cystic fibrosis patients 
infected with Burkholderia cepacia complex.  American Journal of Transplantation, 179, 
1025-1030. 
136 
 
Alonso, A., & Martinez, J. L. (2000). Cloning and characterisation of SmeDEF, a novel 
multidrug efflux pump from Stenotrophomonas maltophilia.  Antimicrobial Agents and 
Chemotherapy, 44(11), 3079-3086. 
Anderson, D. H. (1938). Cystic fibrosis of the pancreas and its relation to celiac disease. 
American Journal of Diseases of Children, 56, 344-399. 
Anderson, D. J., Kuhns, J. S., Vasil, M. L., Grding, D. N., & Janoff, E. N. (1991). DNA 
fingerprinting by pulsed field gel electrophoresis and ribotyping to distinguish Pseudomonas 
cepacia isolates from a nosocomial outbreak.  Journal of Clinical Microbiology, 29, 648-
649. 
Anderson, S. W., Stapp, J. R., Burns, J. L., & Qin, X. (2007). Characterization of small 
colony variant Stenotrophomonas maltophilia isolated from the sputum specimens of five 
patients with cystic fibrosis.  Journal of Clinical Microbiology, 45(2), 529-535. 
Anonymous (2005) Instructions to authors.  Antimicrobial Agents and Chemotherapy, 49, 
1-20. 
Baldwin, A., Mahenthiralingam, E., Drevinek, P., Pope, C., Waine, D. J., Henry, D. A., 
Speert, D. P., Carter, P., Vandamme, P., LiPuma, J. J., & Dowson, C. G. (2008). 
Elucidating global epidemiology of Burkholderia multivorans in cases of cystic fibrosis by 
multilocus sequence typing.  Journal of Clinical Microbiology, 46(1), 290-295. 
Balke, B., Hoagardgt, M., Schmoldt, S., Hoy, L., Weissbrodt, H., & Haussler, S. (2006). 
Evaluation of the E-test for the assessment of synergy of antibiotic combinations against 
multi-resistant Pseudomonas aeruginosa isolates from cystic fibrosis patients.  European 
Journal of Clinical Microbiology and Infectious Diseases, 25(1), 25-30. 
137 
 
Belkin, R. A., Henig, N. R., Singer, L. G., Chaparro, C., Rubenstein, R. C., Xie, S. X., 
Yee, J. Y., Kotloff, R. M., Lipson, D. A., & Bunin, G. R. (2006). Risk factors for death of 
patients with cystic fibrosis awaiting lung transplantation.  American Journal of Respiratory 
and Critical Care Medicine, 173, 659-666. 
Berg, G., Roskott, N., & Smalla, K. (1999). Genotypic and phenotypic relationships 
between clinical and environmental isolates of Stenotrophomonas maltophilia.  Journal of 
Clinical Microbiology, 37(11), 3594-3600. 
Bernhardt, S. A., Spiker, T., Coffery, T., & LiPuma, J. J. (2003). Burkholderia cepacia 
complex in cystic fibrosis: frequency of strain replacement during chronic infection.  
Clinical Infection and Disease, 37, 780-785.  
Biddick, R., Spilker, T., Martin, A., & LiPuma, J. J. (2003). Evidence of transmission of 
Burkholderia cepacia, Burkholderia multivorans and Burkholderia dolosa among persons 
with cystic fibrosis.  FEMS Microbiology Letters, 228, 57-62. 
Blazevic, D. J. (1976). Current taxonomy and identification of non-fermentative Gram-
negative bacilli.  Human Pathology, 7, 265-275. 
Boyd, E. M., & Fales, A. W. (1983). Reflective learning: Key to learning from experience.  
Journal of Humanistic Psychology, 23(2), 99-117. 
Brown, P., Butler, S., Nelson, J., Doherty, C., Govan, J., & Greening, A. (1993). 
Pseudomonas cepacia in adult cystic fibrosis: accelerated decline in lung function and 
increased mortality.  Thorax, 48, 425-426. 
Burkholder, W. H. (1950). Sour skin, a bacterial rot of onion bulbs. Phyto-pathology, 40, 
115-117. 
138 
 
Bonacorsi, S., Fitoussi, F., Lhopital, S., & Bingen, E. (1999). Comparative in-vitro 
activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination 
with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from 
patients with cystic fibrosis.  Antimicrobial Agents and Chemotherapy, 43(2), 213-217. 
Bonapace, C. R. R., White, R. L., Friedrich, L. V., & Bosso, J. A. (2000). Evaluation of 
antibiotic synergy against Acinetobacter baumannii: a comparison with E-test, time kill and 
checkerboard methods.  Diagnostic Microbiology and Infectious Disease, 38, 43-50. 
Boyd, E. & Fales, A. (1983). Reflective learning: Key to learning from experience. Journal 
of Humanistic Psychology, 23, 99-117. 
Caraher, E., Reynolds, G., Murphy, P., McClean, S., & Callaghan, M. (2007). 
Comparison of antibiotic susceptibility of Burkholderia cepacia complex organisms when 
grown planktonically or as biofilm in vitro.  European Journal of Clinical Microbiology and 
Infectious Diseases, 26(3), 213-216. 
Carper, B (1978).  Fundimental patterns of knowing in nursing.  Advances in nursing 
science, 1 (1), 13-23 
Ciofu O, Jensen T, Pressler T, Krogh Johansen H, Koch C, Hùiby N. (1996) 
Meropenem in cystic fibrosis patients infected with resistant Pseudomonas aeruginosa or 
Burkholderia cepacia with hypersensitivity to Beta lactam antibiotics.  Clinical 
Microbiology Infections, 2, 91-98 
Craig, C. R., Stitzel R. E. (2007) Modern Pharmacology.  Lippincott Williams & Wilkins. 
Daloz, L.A. (1986). Effective Teaching and Mentoring.  London: Jossey-Bass. 
David, E., Geller, M. D., & Rubin, B. K. (2009). Respiratory care and cystic fibrosis.  
Respiratory Care, 54(6), 796-800. 
139 
 
De Baets F, Schelstraete P, Van Daele S, Vaneechoutte M. (2007). Achromobacter 
xylosoxidans in cystic fibrosis: prevalence and clinical relevance. Journal of Cystic Fibrosis 
2007; 6: 75-78 
De Ley, J., Kersters, K., Khan-Matsubara, J., & Shewan, J. M. (1970). Comparative D-
gluconate metabolism and DNA base composition in Achromobacter and Alcaligenes.  
Journal of Microbiology and Serology, 36, 193-207. 
Denton, M., & Kerr, K. G. (1998). Microbiological and clinical aspects of infection 
associated with Stenotrophomonas maltophilia.  Clinical Microbiology Reviews, 11(1), 57-
80. 
Denton, M., Todd, N. J., Kerr, K. G., Hawkey, P. M., & Littlewood, J. M. (1998). 
Molecular epidemiology of Stenotrophomonas maltophilia isolated from clinical specimens 
from patients with cystic fibrosis and associated environmental samples.  Journal of Clinical 
Microbiology, 36(7), 1953-8. 
Dembo, M. H. (1994). Applying educational phsychology (5
th
 Ed.).  New York: Longman. 
Desai, M., Buhler, T., Weller, P. H., & Brown, M. R. W. (1998). Increasing resistance of 
planktonic and biofilm cultures of Burkholderia cepacia to ciprofloxacin and ceftazidime 
during exponential growth.  Journal of Antimicrobial Chemotherapy, 42, 153-160. 
Dodge, J. A., Lewis, P. A., Stanton, M., & Wilsher, J. (2007). Cystic fibrosis mortality 
and survival in the UK: 1947-2003. European Respiratory Journal, 29, 522-26. 
Doring, G., Conway, S. P., Heijerman, H. G. M., Hodson, M. E., Hoiby, N., Smyth, A., 
& Touw, D. J. (2000). Antibiotic therapy against Pseudomonas aeruginosa in cystic 
fibrosis: a European consensus.  European Respiratory Journal, 16, 749-767.  
140 
 
Drevinek P, Holden MT, Ge Z, Jones AM, Ketchell I, Gill RT, Mahenthiralingam E. 
(2008). Gene expression changes linked to antimicrobial resistance, oxidative stress, iron 
depletion and retained motility are observed when Burkholderia cenocepacia grows in cystic 
fibrosis sputum. BMC Infectious Diseases. 19;8:121. 
Dreyfus, H. L., & Dreyfus, S. E. (1986). Mind over machine.  New York: Free Press. 
Eliopoulos, G. M., & Eliopoulos, C. T. (1988). Antibiotic combinations: should they be 
tested? Clinical Microbiology Reviews, 1, 139-156. 
Entenza, J. M., & Moreillon, P. (2009). Tigecycline in combination with other 
antimicrobials: a review of in-vitro animal and case report studies.  International Journal of 
Antimicrobial Agents, 34(8), 8.e1-8.e9. 
Etherington, C., Hall, M., Conway, S., Peckham, D., & Denton, M. (2007). Clinical 
impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa 
infections in cystic fibrosis.  Journal of Antimicrobial Chemotherapy, 61, 425-427. 
France, M. W., Dodd, M. E., Govan, J. R., Doherty, C. J., Webb, A. K., & Jones, A. M. 
(2008). The changing epidemiology of Burkholderia species infection at an adult cystic 
fibrosis centre.  Journal of Cystic Fibrosis, 7(5), 368-372. 
Frederiksen, B., Koch, C., & Hoiby, N. (1999). Changing epidemiology of Pseudomonas 
aeruginosa infection in Danish cystic fibrosis patients (1974-1995).  Paediatric 
Pulmonology, 8, 59-66. 
Foweraker, J. E., Laughton, C. R., Brown, D. F., & Bilton, D. (2009). Comparison of 
methods to test antibiotic combinations against heterogeneous populations of multiresistant 
Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis.  
Antimicrobial Agents and Chemotherapy, 53(11), 4809-4815. 
141 
 
Foweraker, J. E., Laughton, C. R., Brown, D. F. J., & Bilton, D. (2010). Phenotypic 
variability of Pseudomonas aeruginosa in sputa from patients with acute infective 
exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility 
testing.  Journal of Antimicrobial Chemotherapy, 55, 921-927. 
Gabriel, P. S., Zhou, J. Z., Tabibi, S., Chen Y., Trauzzi M., Saiman, L. (2004) 
Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates 
from patients with cystic fibrosis.  Antimicrobial Agents and Chemotherapy. 48 (1), 168-171 
Garcia, A. M. (2004). Sixth version of the “uniform requirements for manuscripts 
submitted to Biomedical Journals”: lots of ethics, some new recommendations for 
manuscript preparation.  Journal of Epidemiology and Community Health, 58, 731-733. 
Geller, D. E. (2009). Aerosol antibiotics in Cystic Fibrosis.  Respiratory Care, 54(5), 658-
669. 
Giacometti, A., Cirioni, O., Del Prete, M. S., Barchiesi, F., Fortuna, M., Drenaggi, D., 
& Scalise, G. (2000). In-vitro activities of membrane active peptides alone and in 
combination with clinically used antimicrobial agents against Stenotrophomonas 
maltophilia.  Antimicrobial Agents and Chemotherapy, 44(6), 1716-1719. 
Gold, R., Jin, E., Levinson, H., Isles, A., & Fleming, P. C. (1983). Ceftazidime alone and 
in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe 
respiratory infections caused by Pseudomonas cepacia.  Journal of Antimicrobial 
Chemotherapy, 12(supplement A), 331-336. 
Goldman, M. J., Anderson, G. M., Stolzenberg, E. D., Kari, U. P., Zasloff, M., & 
Wilson, J. M. (1997).  Human beta-defensin 1 is a salt sensitive antibiotic in lung that is 
inactivated in cystic fibrosis, Cell, 88, 553-560. 
142 
 
Goldman, P. L., & Petersdorf, R. G. (1979). Significance of methicillin tolerance in 
experimental Staphylococcal endocarditis.  Antimicrobial Agents and Chemotherapy, 15, 
802-806.  
Govan, J. R., Brown, P. H., Maddison, J., Doherty, C. J., Nelson, J. W., Dodd, M., 
Greening, A. P., & Webb, A. K. (1993). Evidence for transmission of Pseudomonas 
cepacia by social contact in cystic fibrosis. The Lancet, 342, 15-19. 
Govan, J. R., & Deretic, V. (1996). Microbial pathogenesis in cystic fibrosis: mucoid 
Pseudomonas aeruginosa and Burkholderia cepacia.  Microbiological Reviews, 60, (3), 
539-574. 
Greer, N. D. (2006). Tigecycline (Tygacil): the first in the glycycline class of antibiotics.  
Pharmacology notes: Baylor University Medical Center Proceedings, 19, 155-161.  
Grow, G. O. (1996). Teaching learners to be self-directed.  Adult Education Quarterly, 
41(3), 125-149. 
Hawkey, P. M., Birkenhead, D., Kerr, K. G., Newton, K. E., & Hyde, W. A. (1993). 
Effect of divalent cations in bacteriological media in the susceptibility of Xanthomonas 
maltophilia to imipenem with special reference to zinc ions.  Journal of Antimicrobial 
Chemotherapy, 31, 47-55. 
Hirotoshi, M., Grubb, B. R., Tarran, R., Randell, S. H., Gatzy, J. T., Davis, C. W., & 
Boucher, R. C. (1998). Evidence for pericilliary liquid layer depletion, not abnormal ion 
composition, in the pathogenesis of cystic fibrosis airways disease.  Cell, 95, 1005-1015. 
Hutchinson, G. R., Parker, S., Pryor, J. A., Duncan-Skingle, F., Hoffman, P. N., 
Hodson, M. E., Kaufmann, M. E., & Pitt, T. L. (1996). Home-use nebulizers: a potential 
143 
 
primary source of Burkholderia cepacia and other colistin resistant Gram-negative bacteria 
in patients with cystic fibrosis.  Journal of Clinical Microbiology, 34(3), 584-587. 
Holden, M. T., Seth-Smith, H. M, Crossman, L. C, Sebaihia, M, Bentley, S. D, 
Cerdeño-Tárraga, A. M, Thomson, N. R, Bason, N, Quail, M. A, Sharp, S, Cherevach, 
I, Churcher, C, Goodhead, I, Hauser, H, Holroyd, N, Mungall, K, Scott, P, Walker, D, 
White, B, Rose, H, Iversen, P, Mil-Homens, D, Rocha, E. P., Fialho, A. M, Baldwin, A, 
Dowson, C, Barrell, B. G, Govan, J. R, Vandamme, P, Hart, C. A, Mahenthiralingam 
E, Parkhill, J. (2009) The genome of Burkholderia cenocepacia J2315, an epidemic 
pathogen of cystic fibrosis patients.  Journal of Bacteriology. 191(1):261-77 
Igra-Siegman, Y., Chmel, H., & Cobbs, C. (1980). Clinical and laboratory characteristics 
of Achromobacter xylosoxidans infection.  Journal of Clinical Microbiology, 11(2), 141-
145. 
Inglis, T. J. I., Rodrigues, F., Rigby, P., Norton, R., & Currie, B. J. (2004). Comparison 
of the susceptibilities of Burkholderia pseudomallei to meropenem and ceftazidime by 
conventional and intracellular methods.  Antimicrobial Agents and Chemotherapy, 48(8), 
2999-3005. 
Isles, A., Maclusky, I., Corey, M., Gold, R., Prober, C., Fleming, P., & Levison, H. 
(1984). Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. Journal of 
Pediatrics, 104, 206-210. 
Jakobi, M., Winkelmann, G., Kaiser, D., Kempter, C., Jung, G., Berg, G., & Bahl, H. 
(1996). Maltophilin: a new antifungal compound produced by Stenotrophomonas 
maltophilia R3089.  Journal of Antibiotics, 49, 1101-1104. 
144 
 
Johns, C. (2000). Becoming a reflective practitioner – a holistic approach to clinical 
nursing, practice development and clinical supervision.  Oxford: Blackwell Science. 
Jones, R. N., M. J. Ferraro, L. B. Reller, P. C. Schreckenberger, J. M. Swenson, and H. 
S. Sader. (2007). Multicenter studies of tigecycline disk diffusion susceptibility results for 
Acinetobacter spp. Journal of Clinical Microbiology. 45:227-230. 
Joris, B., Galleni, M., Frere, M., & Labia, R. (1994). Analysis of the pen A gene of 
Pseudomonas cepacia 249.  Antimicrobial Agents and Chemotherapy, 38, 407-408 (letter). 
Kasbekar, N. (2006). "Tigecycline: a new glycylcycline antimicrobial agent.". American 
Journal Health Sysemst and Pharmacology 63 (13): 1235–43. 
Keays T., Ferris W., Vandemheen K. L., Chan F., Yeung S. W., Mah T. F., Ramotar 
K., Saginur R., & Aaron S. (2009). A retrospective analysis of biofilm antibiotic 
susceptibility testing:  A better predictor of clinical response in cystic fibrosis exacerbations.  
Journal of Cystic Fibrosis, 8, 122-127. 
Kurlandsky L. E., & Fader R. C. (2000). In-vitro activity of minocycline against 
respiratory pathogens from patients with cystic fibrosis.  Pediatric Pulmonology 29, 210-
212. 
Lekkas A., Gyi K. M., & Hodson M. E. (2006). Temocillin in the treatment of 
Burkholderia cepacia infection in cystic fibrosis.  Journal of Cystic Fibrosis, 5, 121-124. 
Li, J., Nation R. L., Milne R. W., Turnidge J. D., & Coulthard K. (2005). Evaluation of 
colistin as an agent against multi-resistant Gram negative bacteria.  International Journal of 
Antimicrobial Agents. 25, 11-25. 
145 
 
LiPuma J. J. (2005) Update on the Burkholderia cepacia complex.  Current Opinion in 
Pulmonary Medicine, 11 (6) 528-533 
LiPuma J. J., Dasen S. E., Nielson D. W., Stern R. C., & Stull T. L. (1990). Person-to-
person transmission of Pseudomonas cepacia between patients with cystic fibrosis.  The 
Lancet, 336, 1094-1096. 
LiPUma J. .J, Fisher M. C., Dasen S. E., Mortensen J. E., & Stull T. L. (1991). Ribotype 
stability of serial pulmonary isolates of Pseudomonas capacia.  Journal of Infectious 
Diseases, 164, 133-136. 
Liou T. G., Adler F. R., Cahill B. C., Fitzsimmons S. C., Huang D., & Hibbs J. R. 
(2005). Use of lung transplantation survival models to refine patient selection in cystic 
fibrosis.  American Journal of Respiratory and Critical Care Medicine, 171, 1053-1059. 
Livermore D. M. (2005). Tigecycline: what is it, and where should it be used? Journal of 
Antimicrobial Chemotherapy, 56, 611-614. 
Livermore, D. M., Tulkens, P. M. (2009). "Temocillin revived". Journal of Antimicrobial 
Chemotherapy 63 (2): 243–5. 
Lyczak J. B., Cannon C. L., & Pier G. B. (2002). Lung infections associated with cystic 
fibrosis. Clinical Microbiology Reviews, 15, 194-222. 
Mahenthiralingam E, Baldwin A, Vandamme P.(2002). Burkholderia cepacia complex 
infection in patients with cystic fibrosis. Journal of Medical Microbiology; 51: 533-538 
Mahenthiralingam E., Campbell M. E., Henry D. A., & Speert D. P. (1996). 
Epidemiology of Bukholderia cepacia Infection in patients with cystic fibrosis: Analysis by 
146 
 
randomly amplified polymorphic DNA fingerprinting.  Journal of Clinical Microbiology, 
39(12), 2914-2920. 
Mahenthiralingam E., Simpson D. A., & Speert D. P. (1997). Identification and 
characterisation of a novel DNA marker associated with epidemic Burkholderia cepacia 
strains recovered from patients with cystic fibrosis.  Journal of Clinical Microbiology 35(4), 
808-816. 
Mall M., Grubb B. R., Harkema J. R., O’Neal W. K., & Boucher R. C. (2004). 
Increased airway epithelial Na absorption produces cystic fibrosis like lung disease in mice.  
Nature Medicine 10, 487-493. 
Manno G., Ugolotti E., Belli M. L., Fenu, M.L., Romano, L., & Cruciani M. (2003). Use 
of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia 
cepacia complex from patients with cystic fibrosis.  European Journal of Clinical 
Microbiology and Infectious Diseases, 22(1), 28-34. 
Mariscal D., Bosque M., Pomares X., Ferreros P., Garcia I,. Monton C., & Gallego M. 
(2006). Combination bactericidal antibiotic testing to multi-resistant strains of Pseudomonas 
aeruginosa, cepacia and Stenotrophomonas maltophilia isolated from patients with cystic 
fibrosis (CF).  Chest 130(4), 139(supplement). 
McDowell A., Mahenthiralingam E., Dunbar K. E. A., Moore J. E., Crowe M., & 
Elborn J. S. (2004). Epidemiology of Burkholderia cepacia complex species recovered 
from cystic fibrosis patients: issues related to patient segregation.  Journal of Medical 
Microbiology, 53, 663-668. 
147 
 
Milatovic, D., Schmitz, F. J., Verhoef, J., Fluit A. C. (2003). Activities of the 
glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial 
isolates. Antimicrobial Agents and Chemotherapy. 47:400–404. 
Millar, F. A., Symmonds, F. J., Hodson, M. E. (2009).  Trends in pathogens colonising the 
respiratory tract of adult patients with cystic fibrosis, 1985–2005.  Journal of Cystic 
Fibrosis. 8 (6): 386-391 
Moellering R. C. (1979). Antimicrobial synergism – an elusive concept.  Journal of 
Infectious Disease, 140, 639-641. 
Moore H. B., & Pickett M. J. (1960). Organisms resembling Alcaligenes faecalis.  
Canadian Journal of Microbiology, 6, 43-52. 
O’Riordan S. M., Robinson P. D., Donaghue K. C., & Moran A. M. (2008). 
Management of cystic fibrosis related diabetes.  Pediatric Diabetes, 9, 338-344. 
O’Sullivan B., & Freedman S. (2009). Cystic Fibrosis. The Lancet, 373, 1891-1904, 
Orhan G., Bayram A,. Zer Y., & Balci I. (2005). Synergy tests by E-test and checkerboard 
methods of antimicrobial combinations against Brucella melitensis.  Journal of Clinical 
Microbiology, 43(1), 140-143. 
Palleroni N. J., & Bradbury J. F. (1993). Stenotrophomonas, a new bacterial genus for 
Xanthomonas maltophilia (Hugh 1980) Swings et al 1983.  International Journal of 
Systematic Bacteriology, 43, 606-609.  
Papapetropolou M., Rodopolou G., Gionnoulaki E., & Stergiopoulos P. (1994). Effect of 
temperature on antimicrobial susceptibilities of Pseudomonas species isolated from drinking 
water.  Journal of Chemotherapy, 6, 404-407.  
148 
 
Pankey G., Ashcraft D., & Patel N. (2005). In-vitro synergy of daptomycin plus rifampin 
against Enterococcus faecium resistant to both linezolid and vancomycin.  Antimicrobial 
Agents and Chemotherapy, 49(12), 5166-5168. 
Pankey, G., & Ashcraft D. (2005). In Vitro Synergy of Ciprofloxacin and Gatifloxacin 
against Ciprofloxacin-Resistant Pseudomonas aeruginosa. Antimicrobial Agents and 
Chemotherapy, 49, (7), 2959–2964 
Payne D. J., Bateson J. H., Gasson B. C., Proctor D., Khushi T., Farmer T. H., Tolson 
D. A., Bell D., Skett P. W., Marshall A. C., Reid R., Ghosez L., Combret Y., & 
Barchand-Brynaert J. (1997). Inhibition of metallo-beta lactamases by a series of 
mercaptoacetic acid thiol ester derivatives.  Antimicrobial Agents and Chemotherapy, 41, 
135-140. 
Petersen P. J., Labthavikul P., Jones C. H., & Bradford P. A. (2006).  In vitro 
antibacterial activities of tigecycline in combination with other antimicrobial agents 
determined by chequerboard and time kill kinetic analysis.  Journal of Antimicrobial 
Chemotherapy, 57, 573-576. 
Peterson L. R., & Shanholtzer C. J. (1992). Tests for bactericidal effects of antimicrobial 
agents: technical performance and clinical relevance.  Clinical Microbiology Reviews, 5(4), 
420-432. 
Poirel L., Rodriguez-Martinez J. M., Plesiat P., & Nordmann P. (2009). Naturally 
occurring class A β-lactamases from the Burkholderia cepacia complex.  Antimicrobial 
Agents and Chemotherapy, 53(3), 876-882. 
149 
 
Principe L., D’Arezzo S., Capone A., Petrosillo N., & Visca P. (2009). In vitro activity of 
tigecycline in combination with various antimicrobials against multidrug resistant 
Acinetobacter baumannii.  Annals of Clinical Microbiology and Antimicrobials, 8(18), 18. 
 
Randell S. H., & Boucher R. C. (2006). Effective mucus clearance is essential for 
respiratory health.  American Journal of Respiratory Cell and Molecular Biology, 35, 20-28. 
H. P. Rang, M. M. Dale., & J. M. Ritter (Eds.). (1995). Pharmacology (3rd Ed.). pp 718-
743. London: Churchill Livingstone. 
Ratjen, F. A. (2009). Cystic Fibrosis: Pathogenesis and Future Treatment Strategies.  
Respiratory Care, 54(5), 595-605. 
Reik R., Spilker T., & LiPuma J. (2005). Distribution of Burkholderia cepacia complex 
species among isolates recovered from persons with or without cystic fibrosis.  Journal of 
Clinical Microbiology, 43(6), 2926-2928. 
Report of the UK cystic fibrosis trust infection control group, Cystic Fibrosis Trust. 
(2004). The Burkholderia Cepacia complex – Suggestions for prevention and infection 
control.   
http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/C_Burkholderia_cepacia_Sep_
2004.pdf (accessed 15/9/10) 
Rogers G. B., Carroll M. P., Serisier D. J., Hockey P. M., Jones G., & Bruce K. D. 
(2004). Characterization of bacterial community diversity in cystic fibrosis lung infections 
by use of 16s ribosomal DNA terminal restriction fragment length polymporhism profiling.  
Journal of Clinical Microbiology, 42, 5176-5183. 
150 
 
Rogers G. B., Carroll M. P., Serisier D. J., Hockey P. M., Kehagia V., Jones G. R., & 
Bruce K. D. (2005). Bacterial activity in cystic fibrosis lung infections.  Respiratory 
Research, 6, 49-60. 
Ronne Hansen C, Pressler T, Hoiby N, Gormsen, N. (2006). Chronic infection with 
Achromobacter xylosoxidans in cystic fibrosis patients: a retrospective case-control study. 
Journal of Cystic Fibrosis 5: 245-251 
Sachet D.L. , Rosenberg W. M. C., Muir-Gray J. A., Haynes R. B., & Richardson S. 
(1996). Evidence Based Practice – what it is and what it isn’t. British Medical Journal, 312, 
71-72. 
Saiman L. (2007). Clinical utility of synergy testing for multidrug-resistant Pseudomonas 
aeruginosa isolated from patients with cystic fibrosis “the motion for”.  Paediatric 
Respiratory Reviews, 8, 249-255. 
Saiman L., & Siegel J. (2004). Infection control in cystic fibrosis.  Clinical Microbiology 
Reveiws, 17(1), 57-71. 
Saiman L., Chen Y., Tabibi S., San Gabriel P., Zhou J., Liu Z., Lai L., & Whittier S. 
(2001). Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated 
from patients with cystic fibrosis.  Journal of Clinical Microbiology, 39(11), 3942-3945. 
Saiman L., Chen Y., San Gabriel P., & Knirsch, C. (2002). Synergistic activities of 
macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, 
Stenotrophomonas maltophilia, and Alcaligines xylosoxidans isolated from patients with 
Cystic Fibrosis.  Antimicrobial Agents and Chemotherapy, 46(4), 1105-1107. 
151 
 
San Gabriel P., Zhou J., Tabibi S., Chen Y., Trauzzi M., & Saiman L. (2004). 
Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates 
from patients with cystic fibrosis.  Antimicrobial Agents and Chemotherapy, 48(1), 168-171. 
Schon, D. (1987). Educating the reflective practitioner.  San Francisco: Jossey-Bass. 
Sharma G. D., Tosi M. F., Stern R. C., & Davis P. B. (1995). Progression of pulmonary 
disease after disappearance of Pseudomonas in cystic fibrosis.  American Journal of 
Respiratory and Critical Care Medicine, 152, 169-173. 
Shawar, R. M., MacLeod, D. L., Garber, R. L., Burns, J. L., Stapp, J. R., Clausen, C. 
R., Tanaka, S. K. (1999) Activities of tobramycin and six other antibiotics against 
Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrobial Agents 
and Chemotherapy; 43: 2877-2880. 
Siebor, E. (2006). VEB-1 in Achromobacter xylosoxidans form cystic fibrosis patient, 
France.  Emerging Infectious Diseases, 12(11), 1737-1739.  
Smith A. L., Doershuk C., Goldman D., Gore E., Hilman B., Marks M., Moss R., 
Ramsey B., Redding G., Rubio T., Williams-Warren J,. Wilmott R., & Wilson H. D. 
(1999). Comparison of beta-lactam alone versus beta-lactam and an aminoglycoside for 
pulmonary exacerbation in cystic fibrosis.  Journal of Paediatrics, 134, 413-421. 
Smith A. L., Standley B., Mayer-Hamblett N., Ramsey B., & Burns J. L. (2003). 
Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to 
parenteral antibiotic administration: lack of association in cystic fibrosis.  Chest, 123, 1495-
1502. 
152 
 
Spear J. B., Fuhrer J., & Kirby B. D. (1987). Achromobacter xylosoxidans (Alcaligenes 
xylosoxidans subsp. xylosoxidans) bacteremia associated with a well-water source: Case 
report and review of the literature.  Journal of Clinical Microbiology, 26(3), 598-599. 
Speert D. P., Henry D., Vandamme P., Corey M., & Mahenthiralingam E. (2002). 
Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada.  
Emerging Infectious Diseases, 8(2), 181-187. 
Steinbach, S., Sun, L., Jiang, R. Z., Flume, P., Gilligan, P., Egan, T. M., Goldstein, R. 
(1994) Transmissibility of Pseudomonas cepacia infection in clinic patients and 
lungtransplant recipients with cystic fibrosis. New England Journal of Medicine. 331: 981-
987. 
Tarran R., Grubb B. R., Parsons D., Picher M., Hirsh A. J., Davis C. W., & Boucher R. 
C. (2001). The CF Salt Controversy: In vivo observations and therapeutic approaches.  
Molecular Cell, 8, 149-158. 
Taylor R., Gaya H., & Hodson M. (1992). Temocillin and cystic fibrosis: outcome of 
intravenous administration in patients with Pseudomonas cepacia.  Journal of Antimicrobial 
Chemotherapy, 29, 341-344. 
Teekman B. (2000). Exploring reflective thinking in nursing practice.  Journal of Advanced 
Nursing, 31(5), 1125-1135. 
Tenover F. C., Arbeit R. D., Goering R. V., Mickelsen P. A., Murray B. E., Persing D. 
H., & Swaminathan B. (1995). Interpreting chromosomal DNA restriction patterns 
produced by pulsed field gel electrophoresis: Criteria for bacterial strain typing.  Journal of 
Clinical Microbiology, 33(9), 2233-2239. 
153 
 
Tilton R. C., Steingrimsson O., & Ryan R. W. (1978). Susceptibilities of Pseudomonas 
species to tetracycline, minocycline, gentamicin and tobramycin.  American Journal of 
Clinical Pathology, 69, 410-413. 
Todd A., Palfreyman S., & Burke L. (2004). Evidence Based Practice is a time of 
opportunity for nusing.  British Journal of Nursing, 13(4), 211-216. 
Tyler S. D., Strathdee C. A., Rozee K. R., & Johnson W. M. (1995). Oligonucleotide 
primers designed to differentiate pathogenic Pseudomonads on the basis of sequencing of 
genes coding for 16S-22S rRNA internal transcribed spacers.  Clinical and Diagnostic 
Laboratory Immunology, 2, 448-453 
Valerius N. H., Koch C., & Hoiby N. (1991). Prevention of chronic Pseudomonas 
aeruginosa colonisation in cystic fibrosis by early treatment.  The Lancet; 338, 725-672. 
Valdezate S., Vindel A., Martin-Davila P., Del Saz B.S., Baquero F., & Canton R. 
(2004). High genetic diversity among Stenotrophomonas maltophilia strains despite their 
originating at a single hospital.  Journal of Clinical Microbiology, 42(2), 693-699. 
Vanlaere E., LiPuma J. J., Baldwin A., Henry D., De Brandt E., Mahenthiralingam E., 
Speert D., Dowson D., & Vandamme P. (2008). Burkholderia latens sp. nov., 
Burkholderia diffusa sp. nov., Burkholderia arboris sp. nov., Burkholderia seminalis sp. 
nov. and Burkholderia metallica sp. nov., novel species within the Burkholderia cepacia 
complex.  Journal of Systemic and Evolutionary Microbiology, 58, 1580-1590. 
Vanlaere E., Baldwin A., Gevers D., Henry D., De Brandt E., LiPuma J. J., 
Mehanthiralingham E., Speert D. P., Dowson C., & Vandamme P. (2009). Taxon K, a 
complex within the Burkholderia cepacia complex, comprises at least two novel species, 
154 
 
Burkholderia contaminans sp. nov. and Burkholderia lata sp. nov.  Journal of Systemic and 
Evolutionary Microbiology, 59, 102-111. 
Vartivarian S., Anaissie E., Bodey G., Sprigg H., & Rolston K. (1994). A changing 
pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications 
for therapy.  Antimicrobial Agents and Chemotherapy, 38(3), 624-627. 
Walters S., & Mehta A. (2007). Epidemiology of cystic fibrosis. In M. Hodson, D. M. 
Geddes, & A. Bush (Eds.).  Cystic fibrosis, 3
rd
 edition (pp21-45). London: Edward Arnold 
Ltd. 
Wheat P. F., Winstanley T. G., & Spencer R. C. (1985). Effect of temperature on 
antimicrobial susceptibilities of Pseudomonas maltophilia.  Journal of Clinical Pathology, 
38, 1055-1058. 
White R. L., Burgess D. S., Manduru M., & Bosso J. A. (1996). Comparison of three 
different in vitro methods of detecting synergy: Time Kill, Checkerboard, and E-test.  
Antimicrobial Agents and Chemotherapy, 40(8), 1914-1918. 
Wine J. J. (1999). The genesis of cystic fibrosis lung disease.  Journal of Clinical 
Investigation, 103, 309-312. 
Worlitzsch D., Tarran R., Ulrich M., Schwab U., Cekici A., Meyer K. C., Birrer P., 
Bellon G., Berger J., Weiss T., Botzenhart K., Yankaskas J. R., Randell S., Boucher R. 
C., Döring G. (2002). Effects of reduced mucus oxygen concentration in airway 
Pseudomonas infections of cystic fibrosis patients.  Journal of Clinical Investigation, 
109(3), 317-325. 
Yabuuchi E., & Ohyama A. (1971). Achromobacter xylosoxidans n.sp. from human ear 
discharge.  Japanese Journal of Microbiology, 15, 477-481. 
155 
 
Yao J. D., Louie M., Louie L., Goodfellow J., & Simor A. E. (1995). Comparison of E-
test and agar dilution for antimicrobial susceptibility testing of Stenotrophomonas 
(Xanthomonas) maltophilia.  Journal of Clinical Microbiology, 33, 1428-1430. 
Yi H., Srivivasan S., & Kim M. K. (2010). Stenotrophomonas panacihumi sp.nov., isolated 
from soil of a ginseng field. Journal of Microbiology, 48(1), 30-35. 
Zhang L., Li X., & Poole K. (2001). Fluoroquinolone susceptibilities of efflux-mediated 
multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and 
Burkholderia cepacia.  Journal of Antimicrobial Chemotherapy, 48, 549-552. 
 
  
156 
 
Appendix 1 
 
Below is the response from the Leeds Research Ethics Committee that was received prior to 
starting practical work on this project.   
 
Leeds (West) Research Ethics Committee 
A/B Floor, Old Site 
Leeds General Infirmary 
Great George Street 
Leeds 
LS1 3EX 
 
Telephone: 0113 3923181  
Facsimile: 0113 392 2863 
19 March 2008 
 
Dr Miles Denton 
Consultant Microbiologist 
Leeds Teaching Hospitals Trust 
Department of Microbiology 
Leeds General Infirmary 
Leeds 
LS1 3EX 
UK 
Dear Dr Denton 
Full title of study: IN VITRO SUSCEPTIBILITY TESTING OF BURKHOLDERIA CEPACIA COMPLEX AND OTHER 
MULTI-RESISTANT NON-FERMENTATIVE GRAM NEGATIVE BACILLI (GNBs) ISOLATED FROM 
PEOPLE WITH CYSTIC FIBROSIS 
REC reference number: 08/H1307/42 
The Research Ethics Committee reviewed the above application at the meeting held on 14 March 2008.  
Ethical opinion 
The members of the Committee present gave a favourable ethical opinion of the above research on the basis described in the application 
form, protocol and supporting documentation. 
Ethical review of research sites 
The Committee agreed that all sites in this study should be exempt from site-specific assessment (SSA).  There is no need to submit the 
Site-Specific Information Form to any Research Ethics Committee.  The favourable opinion for the study applies to all sites involved in the 
research.  
157 
 
 
Conditions of approval 
The favourable opinion is given provided that you comply with the conditions set out in the attached document.  You are advised to 
study the conditions carefully. 
Approved documents 
The documents reviewed and approved at the meeting were: 
 
Document    Version    Date      
Application  1       
Investigator CV  J Kenning       
Investigator CV  G Mills       
Investigator CV  M Denton       
Protocol  1       
 
R&D approval 
You should arrange for the R&D office at all relevant NHS care organisations to be notified that the research will be taking place, and 
provide a copy of the REC application, the protocol and this letter. 
All researchers and research collaborators who will be participating in the research at a NHS site must obtain final approval from the R&D 
office before commencing any research procedures. 
Membership of the Committee 
The members of the Ethics Committee who were present at the meeting are listed on the attached sheet. 
Statement of compliance  
The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees (July 2001) and 
complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK. 
After ethical review 
Now that you have completed the application process please visit the National Research Ethics Website > After Review  
Here you will find links to the following 
a)   Providing feedback. You are invited to give your view of the service that you have received from the National Research Ethics Service 
on the application procedure. If you wish to make your views known please use the feedback form available on the website. 
b)   Progress Reports. Please refer to the attached Standard conditions of approval by Research Ethics Committees. 
c)   Safety Reports. Please refer to the attached Standard conditions of approval by Research Ethics Committees. 
d)   Amendments. Please refer to the attached Standard conditions of approval by Research Ethics Committees. 
e)   End of Study/Project. Please refer to the attached Standard conditions of approval by Research Ethics Committees. 
We would also like to inform you that we consult regularly with stakeholders to improve our service. If you would like to join our 
Reference Group please email referencegroup@nationalres.org.uk . 
08/H1307/42                                    Please quote this number on all correspondence 
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With the Committee’s best wishes for the success of this project 
Yours sincerely 
 
Laura Sawiuk 
REC Co-ordinator 
On Behalf of 
Dr Michael Rivlin 
Vice Chair 
Email: laura.sawiuk@leedsth.nhs.uk 
 
Enclosures: List of names and professions of members who were present at the meeting and those who 
submitted written comments 
Standard approval conditions  
 
 
Copy to: Dr Derek Norfolk, Leeds Teaching Hospitals NHS Trust 
 
 
Leeds (West) Research Ethics Committee 
Attendance at Committee meeting on 14 March 2008 
Committee Members:  
Name   Profession   Present    Notes      
Miss Petra Bijsterveld  BHF Research Nurse  Yes      
Professor Howard Bird  Consultant Rheumatologist  Yes      
Dr Michael  Blackburn  Consultant Paediatric Cardiologist  Yes      
Mrs Rhona Bratt  Lay Member  Yes      
Mrs Sheila E. Fisher  Senior Lecturer / Hon Consultant 
in Oral & Maxillofacial Surgery  
Yes      
Dr Stella Kwan  Senior Lecturer in Dental Public 
Health  
Yes      
Mr Peter Margerison  Lay Member  Yes      
Miss Eve Miles  Lay Member  Yes      
Dr Wendy Neil  Consultant Psychiatrist  No      
Dr Vera Neumann  Consultant in Rehabilitation 
Medicine  
Yes      
Dr Michael Rivlin  Lay Member, Medical Ethics 
Lecturer  
Yes      
Mr Andrew Scally  Statistician  No      
Dr Ken Shenderey  General Practitioner  Yes      
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Mr  Jon Silcock  Lecturer in Pharmacy  No      
Revd. Chris Swift  Lay Member, Chaplain  Yes      
Mr Daniel Williams  Lay + Member  Yes      
 Also in attendance:  
Name   Position (or reason for attending)     
Miss Laura Sawiuk  REC Co-ordinator    
 Written comments received from:  
Name   Position     
Mr Andrew Scally  Statistician    
Mr  Jon Silcock  Lecturer in Pharmacy    
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Appendix 2 
 
Below is the abstract and draft of the journal article prepared with Dr Denton for publication 
and presentation both in the Journal of Antimicrobial Chemotherapy, and Journal of Cystic 
Fibrosis.  This abstract was also presented with a poster at the ECCMID conference in 
Helsinki. 
The in vitro activity of tigecycline and other antimicrobial agents against Burkholderia cepacia 
complex and other cystic fibrosis-associated Gram negative bacteria. 
John Kenning1, Steven Conway2 and Miles Denton1* 
1Department of Microbiology, Leeds General Infirmary, Great George Street, Leeds, LS1 3EX, United Kingdom 
2Regional Adult and Paediatric Cystic Fibrosis Centres, St James’s University Hospital, Leeds, LS9 7TF, United Kingdom  
*Corresponding author 
Dr Miles Denton 
Department of Microbiology 
Leeds General Infirmary 
Great George Street 
Leeds 
LS1 3EX 
E-mail: miles.denton@leedsth.nhs.uk 
Tel: + 44 113 392 2922 
Fax: + 44 113 392 2696 
Summary 
Background: Options for treating Burkholderia cepacia complex (Bcc) and other multi-resistant Gram negative bacilli isolated from 
people with CF are limited. We assessed the in vitro activity of tigecycline and eleven other antimicrobial agents against a collection of 
these organisms 
Methods: The collection comprised of 148 isolates of CF-associated Gram negative bacilli (36 Burkholderia multivorans, 20 Burkholderia 
cenocepacia, 7 other members of the Bcc, 48 Stenotrophomonas maltophilia, 20 Achromobacter xylosoxidans, 17 other miscellaneous CF-
associated Gram negative bacilli). Minimum inhibitory concentrations of tigecycline and eleven other antimicrobials for each isolate were 
determined using Etest. Synergy between tigecycline and each of eight other antimicrobials was determined using an Etest overlay method. 
Results: Tigecycline showed poor in vitro activity versus all members of the Bcc, with only 10% and 3% of B. cenocepacia and B. 
multivorans susceptible, respectively. Conversely minocycline showed good activity against these species, with 85% and 92% of isolates 
being susceptible. Tigecycline showed good activity against A. xyloxidans and S. maltophilia with 85% and 77% of isolates being 
susceptible, respectively. Tigecycline in combination with other agents mostly resulted in indifference. 
Conclusions: Although the in vitro activity of tigecycline against many of these difficult to treat species appeared variable it remains 
unclear how these results correlate with clinical outcomes. Further clinical studies are warranted. 
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Introduction 
Cystic fibrosis (CF) is a serious genetically inherited disease affecting around 1 in 2000 live births particularly those of Caucasian 
background. People with CF are prone to recurrent respiratory tract infections, most commonly with Pseudomonas aeruginosa. However 
other multi-resistant Gram negative non-fermentative bacteria are frequently isolated from people with CF, including Burkholderia 
cepacia complex (Bcc), Stenotrophomonas maltophilia and others.1 Some members of the Bcc, most commonly Burkholderia cenocepacia 
IIIA are a major cause of rapid deterioration, sepsis and death (“cepacia syndrome”) in CF.2  
Therapy for many of these multi-resistant Gram negative non-fermentative bacteria is compromised by resistance to many of the 
available antibiotics.3 Current options are therefore limited and are further compromised by frequent allergies to antibiotics, particularly 
beta-lactams and concerns regarding toxicity. 
Minocycline (a tetracycline) has been shown to have useful activity against many of the multi-resistant GNBs isolated from people with 
CF.4,5  However it is only available orally, which may not be appropriate in all clinical cases. If tigecycline, a novel injectable glycylcycline 
antibiotic derived from minocycline, was shown to have reliable activity against these difficult CF-associated pathogens it would enhance 
the options available for treatment. This study assesses the in vitro activity of tigecycline and other commonly used antibiotics against 
Bcc and other CF-associated Gram negative bacteria.  
Methods 
Isolate collection 
The following collection of isolates was used in the study: 36 Burkholderia multivorans (33 clinical, 3 laboratory type strains); 20 B. 
cenocepacia (16 clinical, 4 laboratory type strains); seven other Bcc members comprising Burkholderia cepacia (1 type strain), 
Burkholderia stabilis (1 type, 1 clinical), Burkholderia vietnamiensis (1 type, 1 clinical) and Burkholderia pyrrocinia (1 type); 20 
Achromobacter xylosoxidans (all clinical); 48 S. maltophilia (47 clinical, 1 type); 17 other assorted CF-associated Gram-negative bacilli, 
including Burkholderia gladioli, Pandoraea species and Ralstonia species (9 clinical, 8 type). All clinical isolates had been collected from 
patients attending the Regional Paediatric and Adult CF Units in Leeds and identified using conventional laboratory methods. 
Identification of all members of the Bcc and other isolates had been confirmed using molecular methods after submission to a reference 
laboratory (Centre for Infections, Health Protection Agency, Colindale, London, UK). Type strains had been provided by EuroCare CF 
(University of Ghent, Belgium). Isolates had been stored in 15% glycerol broth at -70oC until required. 
Genotyping 
All isolates were subjected to pulsed field gel electrophoresis (PFGE) to identify multiple isolates of the same strain. The method used 
was identical to one previously published with a single modification that SpeI was used in place of XbaI as the restriction endonuclease.6 
Determination of minimum inhibitory concentrations (MICs) using Etest 
The MIC of eleven agents (aztreonam, amikacin, ceftazidime, ciprofloxacin, colistin, meropenem, minocycline, piperacillin-tazobactam, 
temocillin, tigecycline, tobramycin) was determined using Etest (AB Biodisk, Solna, Sweden). Etests were performed on Mueller-Hinton II 
agar (MHA) plates according to the manufacturer’s instructions. Plates were incubated overnight in air at 37oC, except isolates of S. 
maltophilia, which were incubated at 30oC. Each isolate was tested in duplicate. MICs in between twofold dilutions were rounded up to the 
next twofold dilution for purposes of comparison. None of the tested isolates have species-specific breakpoints available in recognised 
guidelines for the agents tested. Isolates were called susceptible, intermediate or resistant on the basis of British Society for Antimicrobial 
Chemotherapy (BSAC) breakpoints used for P. aeruginosa, except for tigecycline and temocillin (published BSAC breakpoints for 
Enterobacteriaceae were used), and minocycline (the Clinical and Laboratory Standards Institute breakpoint for non-Enterobactericeae was 
used). 
Synergy testing using Etest 
Synergy testing between tigecycline in combination with one of eight other agents (aztreonam, ceftazidime, ciprofloxacin, colistin, 
meropenem, piperacilllin-tazobactam, temocillin, tobramycin) was performed in duplicate, with the summation fractional inhibitory 
concentration (FIC) calculated for each set of MICs, using the Etest method reported by Pankey and Ashcraft.7 The inoculum and streaked 
MHA plates for each isolate were prepared the same as for Etest MICs. An Etest strip of drug a was applied to a MHA plate and then 
removed after 1h at room temperature. Using an Etest applicator, a strip for drug b was placed over the area of the previously removed 
drug a strip. The resulting combination ellipses were read after a further 20 h of incubation at 35°C, except for S. maltophilia, which was 
incubated at 30oC. 
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The effect of tigecycline in combination was assessed by calculating the FIC for each antibiotic in each combination. The following 
formulae were used to calculate the ∑FIC: 
 
FIC of drug a = (MIC of drug a in combination)/(MIC of drug a alone) 
FIC of drug b = (MIC of drug b in combination)/(MIC of drug b alone) 
∑FIC = FIC of drug a + FIC of drug b. 
Synergy was defined by a ∑FIC of < 0.5. Antagonism was defined by a ∑FIC of 
> 4. Interactions represented by a ∑FIC of > 0.5 but < 4 were termed indifferent. 
Results and discussion 
The results of MIC determination and synergy testing are shown in tables 1 and 2 respectively. Tigecycline was poorly active against the 
Bcc, with only 10%, 3% and 14% of B. cenocepacia, B. multivorans and other Bcc isolates being susceptible, respectively. By comparison 
the activity of minocycline was much greater, with 85%, 92% and 86% of isolates being susceptible. The beta-lactams ceftazidime and 
meropenem were more active than tigecycline against the Bcc, with 60% and 50% of B. cenocepacia and 58% and 39% of B. multivorans 
being susceptible, respectively. Temocillin was active against 40% of B. cenocepacia and 44% of B. multivorans isolates 
The activity of tigecycline against A. xylosoxidans and S. maltophilia was much more reliable, with 85% and 77% of isolates being 
susceptible. Minocycline activity was similar, with 80% and 96% susceptibility for the same isolates. Piperacillin-tazobactam was the only 
beta-lactam with comparable activity versus A. xylosoxidans with 85% susceptibility. The most active beta-lactam against S. maltophilia 
was ceftazidime but only 48% of isolates appeared susceptible.  
As expected, colistin had no activity against the Bcc. Activity against A. xylosoxidans and S. maltophilia was moderate. The activity of 
ciprofloxacin against B. cenocepacia, B. multivorans, A. xylosoxidans and S. maltophilia was poor throughout. Aminoglycosides also 
demonstrated poor activity against all species groups. 
The combination of tigecycline with other agents usually resulted in indifference against tested isolates. Antagonism was rarely 
encountered, except when used in combination with colistin. Conversely the most synergistic combination was tigecycline with colistin 
against A. xylosoxidans, with synergy demonstrated against 40% of isolates.   
The activity of tigecycline against tested isolates was therefore variable and largely showed indifference in combination with other 
agents. However, the correlation between in vitro susceptibility test results and clinical outcomes for these species is unknown. Species-
specific breakpoints are not available at present and therefore definitions of susceptible and resistant remain arbitrary. This is further 
complicated in the setting of CF where infection with organisms such as the Bcc are often chronic rather than acute. Correlation between 
in vitro susceptibility testing results and clinical outcomes in chronic P. aeruginosa infections in CF is well recognised as poor and patients 
frequently respond to therapy even when their isolates are reported as resistant to the agents used.8 Clinical data regarding the 
therapeutic utility of tigecycline or minocycline in treating Bcc, A. xylosoxidans or S. maltophilia infection in CF is currently lacking and 
needs further study. This is particularly important as therapeutic options are often limited by drug allergy, particularly to beta-lactams, 
and toxicity concerns, most commonly with aminoglycosides. 
The optimum method of susceptibility testing of these isolates from people with CF has been a subject of much debate. Although 
selection of treatment regimens based on the results of in vitro synergy testing has been advocated, a double-blind randomised 
controlled trial failed to demonstrate any benefit for regimens showing synergy in vitro in comparison to those that do not.9 More 
recently, novel approaches to susceptibility testing, such biofilm and stationary-phase models,10 have been reported but none as yet 
have been shown to be more predictive of clinical outcomes in comparison to traditional susceptibility testing methods. 
The observation that tigecycline appears significantly less active in vitro than minocycline against members of the Bcc is interesting and 
warrants further investigation. Possible explanations are that tigecycline uptake into Bcc cells is via different channels to that of 
minocycline, that Bcc possesses as yet unknown efflux mechanisms that preferentially work against tigecycline compared to minocycline, 
or that technical variables (e.g. cationic content of media) during in vitro testing are exerting an influence. 
Genotyping by PFGE revealed that little clustering of isolates for most species (data not shown). This was not surprising as 
epidemiological studies of B. multivorans, A. xylosoxidans and S. maltophilia in CF have consistently found most patients have unique 
strains, suggesting independent acquisition from presumed environmental sources. Several (JOHN – need to see PFGE gel to get exact 
numbers) of the B. cenocepacia isolates clustered with the ET-12 epidemic strain. However, susceptibility of these isolates to tigecycline 
and other agents was variable, suggesting differential expression of resistance. This is also worthy of further investigation. 
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In summary, the in vitro activity of tigecycline against Bcc was poor but promising against A. xylosoxidans and S. maltophilia. Further 
clinical studies are required to ascertain how these in vitro findings correlate with clinical outcomes when used to treat people with CF. 
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